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Malaria is a devastating disease killing over 400,000 people every year, mainly children 
under the age of 5. The Plasmodium parasite responsible for this disease exhibits a 
complex life cycle with many stages; one of these essential stages is the liver stage, 
during which the sporozoite form of the parasite traverses the liver sinusoidal barrier 
through Kupffer cells (KCs), liver-resident macrophages, before invading hepatocytes. 
The liver stage has been less well-studied compared to other stages of the parasite’s life 
cycle due to the inherent difficulties of working in this life stage. Inexpensive and easy-
to-use in vitro models for the human parasites at this stage do not exist, and despite the 
advanced work with murine parasites, gaps in knowledge remain. Herein, we report on 
the use of in vitro models to answer fundamental questions regarding parasite traversal 
of KCs and invasion of hepatocytes. Using mass spectrometry, cytokine array analysis, 
and cell wounding assays with primary rat KCs and P. berghei, we addressed basic 
questions of surrounding the use of an immortalized rat KC system as a substitute for 
primary cells and, importantly, the cellular and immunological response of KCs to 
sporozoites. We found that while immortalized KCs and primary KCs exhibit comparable 
protein expression profiles under naïve conditions, they behave very differently following 
immune activation. We also found that KCs mount an immune response upon sporozoite 
interaction by releasing a diverse, non-specific, and short-lived cytokine repertoire. 
Importantly, contrary to the established dogma, KCs are not significantly injured or killed 
during this interaction. Using an hepatocarcinoma cell line and P. falciparum, we also 
developed a model for in vitro hepatocyte invasion to understand what makes a 
hepatocyte susceptible to invasion. Using our knowledge of in vivo liver biology, we 
created a system that achieves >2% P. falciparum invasion. We used proteomics and 
RNA-seq to profile comprehensively the hepatocyte clone we developed to understand 
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“invasion-susceptibility,” identifying glypican-3 as a novel receptor for sporozoite 
invasion. Through our studies, we filled key gaps in the current knowledge of 






Dr. Rhoel R. D. Dinglasan, PhD, MPH 
Emerging Pathogens Institute, University of Florida 
Formerly Cellular and Molecular Medicine, Johns Hopkins School of Medicine & 
Molecular Microbiology & Immunology, Johns Hopkins Bloomberg School of Public 
Health 
 
Dr. Alan L. Scott, PhD 




Preface (or Acknowledgements) 
Completing a PhD is no simple task. It is a focused, concentrated effort that takes many 
years and many people to achieve. For that reason, I would like to highlight the many 
people who have made this thesis and my PhD possible. 
 
To all my teachers throughout grade school and high school: Thank you for teaching me 
the basic skills and lessons that form the foundation of all of my knowledge. Thank you 
for taking the time to invest in students like me and our futures. Dr. Ross, thank you for 
being the most challenging teacher I’ve ever had and forcing me to pay attention to all 
the small details; that skill has been invaluable. Mr. Tippey, thank you for making the 
complex concepts of chemistry fun and interesting and for making a difficult subject 
approachable.  
 
To Mr. Plummer and Mr. Lakes, my cross-country coaches: Thank you for pushing me to 
my limits and beyond each and every day. Thank you for showing me that I am capable 
of so much more than I ever knew. Thank you for all your support and all your cheering. 
 
To my Purdue professors: Thank you for your dedication to higher education. Thank you 
for the time and effort you dedicated to undergraduate teaching, while also maintaining a 
culture of excellence in your labs. Thank you for the extra help sessions and office hours 
to make sure we could all keep up and understand every topic. Drs. Gelvin and 
Mesecar, thank you for taking me into your labs when I was a clueless undergraduate 




To my colleagues at Allergan: Thank you for taking me in as a summer intern, even 
when I had no idea what I was doing. Thank you for explaining concepts to me over and 
over…and over. Thank you for all your patience and effort. 
 
To my Purdue Crew family: Thank you for being a constant support system. Thank you 
for teaching me leadership and essential time management skills. Thank you for pushing 
my limits every day and teaching me to never give up.  
 
To the Johns Hopkins faculty: Thank you for teaching our classes. Thank you for the 
effort and dedication you show to graduate education. 
 
To my rotation advisors: Thank you for allowing me to rotate in your labs and for 
teaching me unique skills I wouldn’t have learned anywhere else. 
 
To my thesis committee: Thank you for your dedication to my success. Thank you for the 
countless meetings and email exchanges and all your great ideas and support 
throughout the process. 
 
To the Dinglasan lab members, past and present: Thank you for teaching me endless 
numbers of techniques and concepts. Thank you for being a sounding board for my 
ideas and for always being a source of new ideas. Thank you for your friendship and 
comradery through the good times and the bad. Always know that my spirit will 
wander the lab and harass you if you don’t keep the inventories up to date. 
 
To my CMM family: Thank you for always being there, from help with coursework to 
mock quals to life advice. Thank you for being a supportive group that has always felt 
vii 
 
like a second family. Leslie and Colleen, thank you for being my moms away from home 
and always having my back. 
 
To my friends: Thank you for all your support throughout this process. Thank you for 
listening to me complain about things and complaining right along with me. Thank you 
for showing up when I needed support. Thank you for being a rock that I can always 
count on. 
 
To Rhoel: Thank you for giving me a place to thrive. Thank you for the independence to 
pursue aims outside the realm of your grants. Thank you for your mentorship and 
guidance to allow me to grow into the scientist and the person I am today. 
 
To my mom: Thank you for blazing the trail as the first Dr. Tweedell. Thank you for 
letting me know that anything is possible if I work at it, and that the hurdles and 
obstacles on the path can be overcome.  
 
To my dad: Thank you for being the driving force behind both Drs. Tweedell. Thank you 
for always showing up, whether physically or emotionally. Thank you for being my 
constant cheerleader, even now. Thank you for looking down from heaven and letting 
me feel your support all the way through. 
 




Table of Contents 
Abstract ......................................................................................................................... ii 
Preface (or Acknowledgements) ................................................................................. v 
List of Tables ...............................................................................................................xii 
List of Figures ............................................................................................................. xiii 
Chapter 1: Introduction ................................................................................................ 1 
Historical review of malarial disease epidemiology, treatments, and preventions ...... 2 
Malaria epidemiology, causative agents, and geographic distribution ............................... 2 
Symptoms and Diagnosis ................................................................................................... 3 
Malaria disease history ....................................................................................................... 4 
Historical analysis of drug treatments for malaria ............................................................... 6 
Historical analysis of vaccine development for malaria ...................................................... 8 
Mosquito control strategies to target malaria .................................................................... 10 
Molecular mechanisms of Plasmodium parasites and interactions with the host ......11 
Overview of the Plasmodium life cycle ............................................................................. 11 
The Plasmodium sporozoite stage .................................................................................... 13 
Sporozoite traversal versus invasion ................................................................................ 15 
Studying the Plasmodium liver stage ................................................................................ 17 
Kupffer cells ...................................................................................................................... 18 
Kupffer cells and Plasmodium .......................................................................................... 21 
Thesis Overview ......................................................................................................23 
Chapter 2: Methods .....................................................................................................29 
Chapter 3: Comparing primary and immortalized Kupffer cells to develop a model 
system ..........................................................................................................................56 
The cellular and proteomic response of primary and immortalized murine Kupffer 
cells following immune stimulation diverges from that of monocyte-derived 
macrophages ...........................................................................................................58 
Introduction ....................................................................................................................... 59 
Methods ............................................................................................................................ 62 
Results .............................................................................................................................. 68 
Discussion ......................................................................................................................... 72 
Chapter 4: Understanding the interactions between Kupffer cells and Plasmodium 
sporozoites ................................................................................................................ 101 
The front-line immunological response of liver-resident Kupffer cells to Plasmodium 
berghei sporozoites ............................................................................................... 103 
Introduction ..................................................................................................................... 104 
Methods .......................................................................................................................... 108 
Results ............................................................................................................................ 114 
Discussion ....................................................................................................................... 117 
Chapter 5: Analysis of interactions between KCs and the Plasmodium berghei 
homolog of the macrophage migration inhibitory factor ........................................ 132 
Plasmodium berghei macrophage migration inhibitory factor and Kupffer cells ...... 134 
Introduction ..................................................................................................................... 134 
Methods .......................................................................................................................... 137 
Results ............................................................................................................................ 143 
Discussion ....................................................................................................................... 145 
ix 
 
Chapter 6: Development of an in vitro model for P. falciparum invasion of 
hepatocytes ............................................................................................................... 158 
Development of a novel hepatocyte model using HC-04.J7 with increased 
susceptibility to Plasmodium falciparum sporozoite invasion for multi-omics analyses 
of invasion factors .................................................................................................. 160 
Introduction ..................................................................................................................... 160 
Methods .......................................................................................................................... 165 
Results ............................................................................................................................ 177 
Discussion ....................................................................................................................... 184 
Chapter 7: Conclusions and Future Directions ....................................................... 199 
The use of immortalized Kupffer cells as a model system ...................................... 200 
Sporozoite-Kupffer cell interactions ....................................................................... 201 
Model for sporozoite invasion of hepatocytes ........................................................ 203 
The liver stage of Plasmodium ............................................................................... 205 
References ................................................................................................................. 207 
Curriculum Vitae ........................................................................................................ 244 





List of Abbreviations 
SSA  Sub-Saharan Africa 
RBC  Red Blood Cell 
RDT  Rapid Diagnostic Test 
HRP2  Histidine-Rich Protein 2 
ACT  Artemisinin-based Combination Therapy 
CSP  Circumsporozoite Protein 
SGS  Salivary Gland Surface protein 
TSR  Thrombospondin-Repeat 
HSPG  Heparan Sulfate Proteoglycan 
KC  Kupffer cell 
LPS  Lipopolysaccharide 
TLR  Toll-Like Receptor 
PD1  Programmed cell Death protein 1 
NK  Natural Killer 
PAMPs Pathogen-Associated Molecular Patterns 
DAMPs Damage-Associated Molecular Patterns 
NF-κB  Nuclear Factor-κB 
MAP  Mitogen-Associated Protein 
AP-1  Activator Protein-1 
SPECT1 Sporozoite Protein Essential for Cell Traversal 1 
SPECT2 Sporozoite Protein Essential for Cell Traversal 2 
PLP1  Perforin-Like Protein 1 
GEST  Gamete Egress and Sporozoite Traversal 
TLP  TRAP-Like Protein 
CelTOS Cell-Traversal Protein for Ookinetes and Sporozoites 
xi 
 
RON  Rhoptry Neck Protein 
AMA1  Apical Membrane Antigen 1 
HGF  Hepatocyte Growth Factor 
PbMIF  P. berghei homolog of Macrophage Migration Inhibitory Factor 
MIF  Macrophage migration Inhibitory Factor 
RKC1  Rat Kupffer Cell 1 
PRKC  Primary Rat Kupffer cell 
HIFBS  Heat-Inactivated Fetal Bovine Serum 
HBSS  Hank’s Buffered Saline Solution 
FASP  Filter-Aided Sample Preparation 
ACN  Acetonitrile 
FA  Formic Acid 
STRAP Software Tool for Rapid Annotation of Proteins 
LDH  Lactate Dehydrogenase 
FBS  Fetal Bovine Serum 
BSA  Bovine Serum Albumin 
FcR  Fc-Receptor 
GO  Gene Ontology 
LS  Liver Stage 
LLO  Listeriolysin O 
Ybx1  Nuclease sensitive element binding protein 1 
EHD4  EH-domain containing protein 4 
HSP90  Heat-Shock Protein 90 
GPC3  Glypican-3 




List of Tables 
Table 3.1 Proteins involved in cytoskeletal signaling found in primary rat Kupffer cells 
and RKC1 ......................................................................................................................81 
Table 3.2 Immune System Process protein analysis ......................................................82 
Table 3.3 Inflammatory Response protein analysis........................................................83 
Table 3.4 Immune Response protein analysis ...............................................................84 
Table 3.5 Antigen Processing and Presentation protein analysis ...................................85 
Table 3.6 Response to Bacterium protein analysis ........................................................86 
Table 3.7 Immune Effector Process protein analysis .....................................................87 
Table 3.8 Acute Inflammatory Response protein analysis..............................................88 
Table 3.9 Chemokine Signaling protein analysis ...........................................................89 
Table 3.10 Signal Transducer protein analysis ..............................................................90 
Table 3.11 Regulation of IkBK protein analysis ..............................................................91 
Table 3.12 Negative Regulation of NFkB protein analysis .............................................92 
Table 3.13 Positive Regulation of Kinase protein analysis .............................................93 
Table 3.14 MAPK signaling pathway protein analysis ....................................................94 
Table 3.15 MAPKKK cascade protein analysis ..............................................................95 
Table 3.16 Regulation of Phosphorylation protein analysis ............................................96 
Table 3.17 Positive regulation of Jak-STAT protein analysis .........................................97 
Table 3.18 Endocytosis protein analysis ........................................................................98 
Table 3.19 Cell activation protein analysis .....................................................................99 
Table 3.20 FcgR-mediated phagocytosis protein analysis ........................................... 100 
Table 4.1 KC death following exposure to stimuli ........................................................ 131 
Table 5.1 Identification of additional potential PbMIF interacting proteins .................... 155 
Table 6.1 Invasion blocking assay of Plasmodium falciparum sporozoites in HC-04.J7 
cells ............................................................................................................................. 198 
xiii 
 
 List of Figures 
Figure 1.1 Spatial distribution of P. falciparum and P. vivax malaria endemicity in 2010 25 
Figure 1.2 Malaria parasite illustrations by Laveran .......................................................26 
Figure 1.3 Malaria life cycle ...........................................................................................27 
Figure 1.4 TLR signaling pathways ................................................................................28 
Figure 3.1 Proteomic analysis of primary rat Kupffer cells and RKC1 +/– LPS ..............75 
Figure 3.2 Quantitative western blot analysis of proteins involved in cytoskeletal 
rearrangements in RKC1 ...............................................................................................76 
Figure 3.3 Coronin 1A staining in primary rat Kupffer cells and RKC1 +/-LPS ...............76 
Figure 3.4 Cofilin-1 and Phospho-Cofilin-1 staining in primary rat Kupffer cells and RKC1 
+/-LPS ...........................................................................................................................78 
Figure 3.5 Protein identification comparisons between treatment groups in primary rat 
Kupffer cells and RKC1 .................................................................................................79 
Figure 3.6 Proteins involved in cytoskeletal signaling in primary rat Kupffer cells and 
RKC1 ............................................................................................................................80 
Figure 4.1 Cytokine secretion from primary rat KCs exposed to P. berghei sporozoites
 .................................................................................................................................... 120 
Figure 4.2 Cytokine secretion from primary rat KCs exposed to P. berghei sporozoites
 .................................................................................................................................... 122 
Figure 4.3 Cytokine secretion from primary rat KCs is dependent upon live sporozoites
 .................................................................................................................................... 124 
Figure 4.4 Cytokine secretion from primary rat KCs does not occur in response to fixed, 
killed sporozoites ......................................................................................................... 125 
Figure 4.5 Cytokine secretion from primary rat KCs in response to traversal-deficient 
SPECT2-/- sporozoites ................................................................................................. 126 
Figure 4.6 FACS analysis of isolated rat liver cells ...................................................... 127 
xiv 
 
Figure 4.7 Cytokine secretion from primary rat KCs and T cells exposed to P. berghei 
sporozoites .................................................................................................................. 128 
Figure 4.8 Kupffer cells do not display increased levels of cell death following sporozoite 
exposure ..................................................................................................................... 129 
Figure 4.9 Cytokine secretion from Kupffer cells in response to LPS and IFN-g .......... 130 
Figure 5.1 Sequence comparison from mammalian and Plasmodium MIF proteins ..... 147 
Figure 5.2 PbMIF interacts with the surface of RKC1 .................................................. 148 
Figure 5.3 In solution co-immunoprecipitation of bPbMIF with RKC1 lysate proteins ... 149 
Figure 5.4 On microsphere co-immunoprecipitation of bPbMIF and RKC1 lysate proteins
 .................................................................................................................................... 150 
Figure 5.5 Comparison of proteins identified by both co-immunoprecipitation strategies 
to identify putative PbMIF interactions ......................................................................... 151 
 .................................................................................................................................... 151 
Figure 5.6 Western blot analysis of Ybx-1 following co-immunoprecipitation ............... 151 
Figure 5.7 Western blot analysis of EHD4, calnexin, and HSP90 ................................ 153 
Figure 5.8 Two different species of PbMIF are observed upon SDS-PAGE analysis of 
the recombinant protein ............................................................................................... 154 
Figure 6.1 Global proteomic analysis of HC-04 cells grown in different culture media . 189 
Figure 6.2 Mitochondrial staining of HC-04 cells grown in basic and enhanced MEM+F12 
media .......................................................................................................................... 190 
Figure 6.3 Enhanced invasion efficiency of Plasmodium falciparum in glucose-free 
(Basic) medium ........................................................................................................... 191 
Figure 6.4 Tight junction and cytoskeletal staining of HC-04 clones from limited dilution 
sub-cloning grown in enhanced MEM+F12 medium and basic medium ....................... 192 
Figure 6.5 Multi-omics analysis of HC-04, HC-04.J7, and HepG2 cell lines ................. 193 
Figure 6.6 GPC3 and EphA2 immunofluorescence assays in HC-04.J7 and HepG2 ... 195 
xv 
 
Figure 6.7 Correlation between HC-04 cell density and sporozoite invasion percentage
 .................................................................................................................................... 196 

















Historical review of malarial disease epidemiology, treatments, and preventions 
 
Malaria epidemiology, causative agents, and geographic distribution 
Malaria is a devastating disease that causes over 438,000 deaths per year, mainly 
among children in Sub-Saharan Africa (SSA) (1); this region featured 90% of malaria 
cases and 92% of malaria deaths in 2015 (2). In addition to SSA, malaria affects 
countries in South and Southeast Asia, the Western Pacific, the Middle East, and Latin 
and Meso- America (2). Approximately half the world’s population lives in areas at risk of 
malaria transmission.  
 
The Plasmodium species of protozoan parasite are the etiological agents responsible for 
malarial disease (1). The Plasmodium parasites belong to the phylum Apicomplexa; 
other members of this phylum include Toxoplasma gondii and Cryptosporidium sp., both 
of which are opportunistic human pathogens (3). The apicomplexans are obligate 
intracellular Eukaryotes, many of which are known for residing in their parasitophorous 
vacuole, within which they replicate (3). There are five major species of Plasmodium that 
infect humans: P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi. P. 
cynomolgi has also rarely been found to infect humans (4), and humans can be exposed 
to several other non-human primate malarial parasites, such as P. inui and P. coatneyi 
(5). P. falciparum and P. vivax pose the greatest threats for human infection, with P. 
falciparum being considered the deadliest; both can be found throughout SSA, Central, 
South, and East Asia, and the Americas, with P. falciparum being the more dominant in 
SSA and P. vivax being the more dominant in the Americas and Asia (Figure 1.1). 
Approximately 2.5 billion people are at risk of infection with each parasite (6; 7). P. 
malariae similarly is found in SSA, Asia, and South America, but is less frequent than P. 
falciparum. P. ovale is predominantly found in SSA, but can also be found elsewhere. P. 
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knowlesi is primarily found in Southeast Asia (8). These geographic distributions are 
subject to change depending upon outside factors, such as climate and precipitation 
changes, changes in land usage, and increasing global populations. For example, 
modeling studies predict that as global warming continues, the parasites may spread, 
with the greatest risk for increased endemicity occurring in the highlands in Africa and 
parts of South America and Southeastern Asia (9). 
 
Due to the complexity of the parasite and high levels of surface protein diversity, 
developing immunity to infection with any of the Plasmodium species requires several 
rounds of infection with the parasite. Therefore, in areas of high disease transmission for 
P. falciparum, infected adults are likely to control their parasitemia without overt clinical 
symptoms (10), while children are at an elevated risk of clinical disease (8). Additionally, 
malaria during pregnancy poses significantly elevated health risks; in high-transmission 
settings, where the pregnant female has likely developed adequate immunity against the 
parasite to prevent clinical symptoms, parasites can still infect the placenta, leading to 
maternal anemia and low birth weight, a major risk factor for infant mortality (11). These 
problems affect women in their first pregnancy more-so than in subsequent pregnancies. 
In low-transmission settings, where the pregnant female has likely not developed 
immunity, malaria during pregnancy is associated with increased risk of anemia and 
severe malaria in the mother; these factors can cause spontaneous abortion, premature 
birth, and low birth weight (11).  
 
Symptoms and Diagnosis 
The symptoms of malaria include fever, headache, chills, and vomiting, which can 
progress to more critical symptoms, such as severe anemia, metabolic acidosis, and 
cerebral malaria. Because the symptoms of malaria are similar to those of other febrile 
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illnesses, it is difficult to diagnose based on symptoms alone. Rapid diagnostic tests 
(RDTs) and microscopy can be used in clinics to determine if the illness is in fact malaria 
and which species of Plasmodium is the cause (12). However, both approaches present 
challenges. Microscopy requires a skilled microscopist to evaluate blood smears, a time-
consuming process; also, when parasitemia is low, the parasites can be missed. RDTs 
rely on the presence of a parasite protein in the blood, with Plasmodium histidine-rich 
protein 2 (HRP2) being the most commonly used for P. falciparum; however, variants of 
P. falciparum have been identified lacking HRP2 (13). The World Health Organization 
(WHO) has identified 12 malaria RDTs as “WHO prequalified.” Of these, seven detect P. 
falciparum only, four differentiate P. falciparum and non-falciparum malaria, and one 
detects all species but does not designate which (14). These limitations can impede 
successful diagnosis and speciation. Additionally, co-infection with more than one 
species of Plasmodium is possible, further complicating diagnosis and treatment if 
relying on RDTs alone.  
 
While cases and fatalities have been in significant decline since 2010 (the global 
incidence of malaria has fallen by 21% since then), the burden of malaria remains 
challenging (2). In addition to the over 400,000 deaths and 200 million infections, direct 
costs of malaria are estimated to be at least 12 billion USD per year (8). The financial toll 
presents an enormous obstacle for poor countries to continue and expand elimination 
and eradication efforts.  
 
Malaria disease history 
Malaria as a human disease has existed for several thousand years. Evidence of 
Plasmodium was found in Egyptian remains that date from 3200 to 1304 BC (15). Many 
of the great poets and writers of the past, including Homer and Aristotle, describe a 
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disease that appears to be malaria in their works. The disease likely spread from African 
rain forests to Europe in the first century AD (16), drastically affecting the course of 
history on several occasions. Historians have suggested that malaria may have played a 
role in the fall of Rome (16), and malaria has been identified as an influential factor in 
several other conflicts such as the American Civil War, World Wars I & II, and the 
Vietnam War, to name a few. At the height of its spread, malaria could be found as far 
north as England and Denmark (16). Evidence suggests that malaria parasites were 
then spread to the New World (aka North America) by the arrival of the early 
discoverers, though sustained transmission of P. falciparum likely did not exist there until 
the slave trade from Africa was established (17).  
 
Human malaria parasites were first identified by a French army clinician, Charles Louis 
Alphonse Laveran, who later received a Nobel Prize for his discovery. Laveran 
examined blood smears from soldiers suffering from malaria and identified pigment-
containing crescents in the blood (Figure 1.2) (18). This pigment was the hemozoin 
produced by the parasite as it digests hemoglobin. Using this pigment as a marker for 
the parasite, he could differentiate the blood of infected and uninfected soldiers. He also 
observed that treatment with quinine made these pigments disappear from the blood 
(19). While his initial work was viewed with skepticism, coming at a time when many still 
believed diseases were caused by vapors, future researchers Ronald Ross and Camillo 
Golgi, among others, independently confirmed his observations and added to them in 
the following years (20). Ross made the seminal discovery that the mosquito was the 
vector for the avian malaria parasite P. relictum in 1897; this, along with Patrick 
Manson’s demonstration of filarial worm transmission by mosquitoes in 1877 (21), laid 
the groundwork for establishing the mosquito as the vector for the human parasites (22). 
Golgi focused on studying the cyclical reproduction of the parasite in the blood and 
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identified P. malariae and P. vivax as two separate species. Furthermore, Golgi firmly 
established quinine as the first treatment for these parasites (23). 
 
Historical analysis of drug treatments for malaria 
The first treatment effective against the Plasmodium parasites was found using the bark 
of the cinchona tree, a tree native to South America, in the 1600s (24). The active 
ingredient in the bark, quinine, was isolated in 1820 by two French chemists, Pierre 
Joseph Pelletier and Joseph Caventou (25). For over a century, quinine was the front-
line treatment, although its mechanism of action remains largely unknown. Quinine has 
shown rapid schizonticidal action against both P. falciparum and P. vivax. It has the 
added benefit of gametocytocidal activity in P. vivax and P. malariae, though not in P. 
falciparum (26). Unfortunately, quinine also causes several side effects, ranging from 
hearing impairment to vertigo, visual symptoms (27), and hypoglycemia (28). Quinine is 
still used as an oral treatment for uncomplicated malaria and an intravenous treatment 
for severe malaria in some regions (29), though it is no longer the front-line drug of 
choice (30).  
 
In 1934, German scientists synthesized a more effective replacement for quinine, 
chloroquine. This compound belongs to the 4-aminoquinoline class, which has become 
very important for malaria treatment. It is hypothesized that chloroquine works by 
inhibiting heme polymerase activity, leading to a toxic accumulation of free heme in the 
parasite (31). Unfortunately, as early as 1957, chloroquine-resistant P. falciparum 
parasites were identified along the Thai-Cambodia border. These parasites and 
subsequent chloroquine-resistant parasites isolated across the globe contain mutations 
in the pfcrt gene, which codes for a predicted transporter on the parasite’s digestive 
vacuole membrane hypothesized to be involved in drug flux (32). The K76T mutation 
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appears to be highly important as a foci of chloroquine resistance based on 
complementation assays and the conservation of this mutation across parasites from a 
wide geographical distribution (32). Based on sequence analysis of chloroquine-resistant 
P. falciparum isolates, resistance has emerged in at least 4 different loci and has likely 
been driven by high levels of chloroquine use (33). Chloroquine-resistant P. vivax was 
also identified, though not until 1989 in Papua New Guinea (34). Since then, 
chloroquine-resistance has been observed nearly everywhere P. vivax is endemic (35).  
 
Fortunately, a new antimalarial was developed in 1972 by Chinese scientists working 
with Artemisia annua. They extracted artemisinin, which led to a Nobel Prize for Youyou 
Tu in 2015. Artemisinin is a rapidly potent antimalarial and has become the front-line 
treatment when used in combination with a partner drug featuring a longer half-life 
(artemisinin-based combination therapy, ACT). Artemisinin is also not associated with 
many of the negative side effects of its predecessors (36). The mechanism of action for 
artemisinin remains under debate, but evidence suggests that it produces reactive 
oxygen species that cause oxidative stress for the parasites (37; 38; 39), interfering with 
heme polymerization (40), the respiratory chain of the mitochondria (41), and protein 
functions through alkylation of cysteine residues (42). However, cases of resistance, 
marked by delayed parasite clearance or “drug tolerance” (43), have begun to emerge in 
the last 10 years along the Thai-Cambodia border, and many worry more widespread 
resistance is on the horizon (44). Artemisinin resistance is marked in P. falciparum by a 
mutation in the propeller region of the Kelch protein (K13) (45). Based on genetic 
analysis of resistant parasites, 11 different loci of emergence have been found in 
Cambodia and Vietnam (46; 47), and an independent isolate was found to have 
emerged in Equatorial Guinea (48). The exact mechanism by which this mutation causes 
resistance is unclear, but transcriptomic data suggest that it may be due to an up-
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regulated unfolded protein response that protects the parasite from protein defects 
caused by reactive oxygen species (49). 
 
Historical analysis of vaccine development for malaria 
In addition to developing drug treatments for Plasmodium infections, research has 
focused on designing vaccines to prevent parasite infection. The first work towards this 
goal was accomplished in the 1960s when David Clyde demonstrated that a person 
could be protected from malaria infection after being bitten by a large number of 
irradiated, infectious mosquitoes (50). While delivering a vaccine through the bites of 
nearly a thousand mosquitoes was not feasible as a large-scale, sustainable vaccination 
strategy, it provided proof of principle that a vaccine could be made.  
 
Due to the difficulties encountered with inducing immunity to Plasmodium infection, a 
wide variety of vaccine approaches have been used, including: sporozoite subunit 
vaccination, irradiated sporozoite/genetically attenuated sporozoite (typically involving 
sporozoites that arrest at the late liver stage, such as Δsap (SAP is involved in 
sporozoite transcript regulation (51)) and ΔP52ΔP36 (P52 is a 6-Cystein protein and P36 
is a closely related protein (52; 53; 54)) immunization, immunization with DNA and/or 
viral vectors to induce a T cell response, use of whole blood-stage parasites, use of 
parasite protein(s) in adjuvant vaccines to reduce blood-stage growth rates or to induce 
antibody-dependent cellular inhibition, use of peptide-based vaccines, development of 
anti-disease vaccines based on parasite toxins, immunization with parasite adhesion 
ligands, and immunization with sexual stage parasite antigens or mosquito antigens to 
block transmission (55). A major drawback with many of the vaccine candidates 
proposed to date is that they target only P. falciparum, neglecting the large number of 
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malaria cases caused by the other Plasmodium species. Also, immunity is often short-
lived, necessitating multiple boosts of the vaccine (56). 
 
The most efficacious vaccine candidates to date have targeted the pre-erythrocytic stage 
of the parasite. In the 1980s a vaccine formulation made from the P. falciparum 
circumsporozoite protein (CSP), the most abundant protein on the sporozoite surface, 
was found to provide protection against infection. GlaxoSmithKline now produces the 
RTS,S vaccine, made of a combination of the central repeat region of CSP, the T-cell 
epitope of CSP, and the hepatitis B surface antigen (57). However, in field studies, the 
efficacy of the RTS,S vaccine is sub-optimal, reducing clinical malaria by just 30-50% 
(58; 59; 60; 61; 62). More recently, the company Sanaria has used intravenous 
inoculation of radiation-attenuated whole sporozoites, building on the approach of David 
Clyde from the 1960s, to achieve complete protection against subsequent parasite 
challenge following five doses of the vaccine in a controlled human malaria infection trial 
(63). Responses in the field remain to be evaluated. Other pre-erythrocytic stage 
candidates are also under evaluation, though none have proven as efficacious as the 
Sanaria vaccine (64). 
 
Recent vaccine development trials focused on a variety of blood-stage candidate 
proteins have also not yielded a highly successful candidate (65); there are currently 10 
blood-stage candidate vaccines in clinical trials, but results so far show these candidates 
to produce sub-optimal protection (64). Additional work has focused on development of 
transmission-blocking vaccines that would block the parasite’s transmission to 
mosquitoes or development within the mosquito. There are currently 5 sexual stage 
(gametocyte and ookinete) candidates in clinical trials (64). Many additional potential 
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targets, including receptors within the mosquito, remain in the pre-clinical stages of 
development with hopes of advancing further. 
 
Mosquito control strategies to target malaria 
Another tenet of malaria treatment and prevention strategies is mosquito control. 
Environmental management, including the draining of wetlands to remove mosquito 
breeding habitats, the introduction and installation of window screens, and the 
introduction of the fish Gambusia affins and/or others that eat mosquito larvae have 
shown success, but in limited geographic regions (66; 67): These approaches met 
success in Rome, Israel, India, Brazil, Egypt, Zambia, Indonesia, and Malaysia (68; 69; 
70; 71). Bacterial agents like Bacillus thuringiensis and Bacillus sphaericus and fungal 
pathogens such as Metarhizium and Beauveria have also been introduced to reduce 
larval populations (72) with success in the United States (73), Western Kenya (74), Zaire 
(75), Madagascar (76), India (77; 78), and Honduras (79). Chemical control methods 
utilizing insecticides such as dichlorodiphenyltrichloroethane (DDT) have also proven 
effective, drastically reducing vector populations in the United States, Southern Europe, 
the former Soviet Union, and parts of South Africa (80; 81; 82). Insecticide-treated 
mosquito nets have been widely distributed throughout the population in SSA to protect 
against mosquito bites occurring inside homes while sleeping; however, vector biting 
habits have begun to vary such that more biting is occurring outdoors and during the day 
(83), reducing bed net effectiveness. Additionally, indoor residual spraying has proven to 
be effective (84; 67). However, resistance to insecticides among mosquito populations 
(2) and active avoidance of the insecticide by the mosquito present issues (85; 86; 87).  
 
Despite the successes and advancements in drug treatments, vaccine efforts, and 
mosquito control strategies, malaria remains a major global health threat (1). To direct 
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future malaria elimination and eradication efforts, more work to understand this complex 
parasite is needed. The next section outlines our current knowledge of the Plasmodium 
parasite, with specific emphasis on the liver stage of the life cycle and gaps in 
knowledge that remain. 
 
Molecular mechanisms of Plasmodium parasites and interactions with the host 
 
Overview of the Plasmodium life cycle 
Malaria parasites require two separate hosts for their life cycle, the mosquito vector and 
the mammalian host. Focusing on P. falciparum, the deadliest of the human malaria 
parasites, the life cycle in the human begins when the parasite is transmitted from an 
infected female anopheline mosquito to the skin of a human during blood feeding. Once 
the parasites have entered the skin, they use gliding motility to access the bloodstream. 
The parasites use the bloodstream as a highway to bring them to their first site of 
infection, the liver (88). Here, evidence suggests that parasites traverse the liver 
sinusoidal barrier through Kupffer cells and liver sinusoidal endothelial cells to gain 
access to hepatocytes. 
 
Infection of the liver hepatocytes is clinically silent, but this stage of infection is critical to 
allow the parasite to establish, develop, and multiply to prepare for its invasion of red 
blood cells (RBCs) (89). An individual parasite replicates within the hepatocyte over a 7-
day period to form up to 40,000 merozoites within a merosome that is released intact 
into the bloodstream (89). Based on studies in rodent models, these merosomes can 
then sequester in the lungs, where they release individual merozoites into the pulmonary 
microcirculation to allow invasion of freshly oxygenated RBCs; this step has not been 
confirmed for P. falciparum (90). Once inside RBCs the parasites undergo a cyclic 
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developmental phase during which they mature from rings to trophozoites to schizonts 
before causing RBC rupture to release the merozoites in the schizont back into the blood 
stream to invade more RBCs (Figure 1.3). This invasion of RBCs and RBC lysis leads to 
the clinical symptoms of disease. A sub-population of these invading merozoites commit 
to become the sexual stages of the parasite, the gametocytes. Male and female 
gametocytes develop within the RBCs over roughly a 9-day period before they are fully 
developed and ready to be picked up by a mosquito to continue their life cycle. When a 
mosquito takes a blood meal at this stage of infection, gametocytes are taken up into the 
mosquito midgut. Here they are activated by environmental stimuli, such as temperature 
change and the presence of xanthurenic acid, to begin gametogenesis to form male and 
female gametes (micro- and macrogametocytes, respectively) (91; 92; 93). During 
gamete formation, the gametocytes round up and egress from their RBC (94). The 
microgametocyte replicates its genome three times to become octaploid and produce 
eight flagellar microgametes, which detach and are motile (95; 96). Once the 
microgamete has migrated to locate a macrogamete, the two gametes fuse their plasma 
membranes, and the male nucleus fuses with that of the female to form a zygote. The 
zygote develops into a motile ookinete, which traverses the midgut epithelia to attach 
and develop on the basal side and form the oocyst. In the laboratory, mosquitoes can 
harbor over 100 oocysts during P. falciparum infection; however, in the field, it is much 
more likely to encounter mosquitoes with just 1-5 oocysts (97). Oocysts develop for 11-
14 days to produce approximately 3,000 sporozoites per oocyst in P. falciparum and P. 
vivax (98), which will egress from the oocyst to passively migrate to the mosquito 
salivary glands and invade the salivary gland epithelial cell. This makes the mosquito 




The Plasmodium sporozoite stage 
Sporozoites are the stage of the parasite that develop in the oocyst on the midgut of the 
mosquito. While the same “sporozoite” form is released when the oocyst ruptures as 
invades the mammalian hepatocyte, sporozoites undergo significant changes as they 
develop between leaving the oocyst and invading the hepatocyte. Analyses of transcripts 
and proteins from sporozoites isolated from oocysts or from mosquito salivary glands 
show extensive differences between these two populations (100; 101). Additionally, 
sporozoites isolated from the midgut of mosquitoes display a marked reduction in their 
ability to invade hepatocytes as compared to sporozoites isolated from the salivary 
glands (100; 102), emphasizing the importance of the development and changes 
occurring between these two populations.  
 
P. falciparum sporozoites are formed over the course of 10-14 days in oocysts. Mitotic 
divisions occur within the oocyst to produce thousands of sporozoites, with an average 
of 3,000 sporozoites per oocyst reported for P. falciparum and P. vivax (103). CSP, an 
essential Plasmodium sporozoite protein, accumulates on the oocyst’s plasma 
membrane beginning approximately 3 days after oocyst formation (104). As the 
sporozoites form within the oocyst, the plasma membrane begins to form invaginations 
segregating lobes of cytoplasm and nuclei, known as sporoblasts (105; 106; 107). 
Microtubule organizing centers form under the sporoblast membrane (104) and facilitate 
sporozoite budding (108), which occurs asynchronously in successive waves (108; 107; 
109). Micronemes and rhoptries, essential secretory organelles that play important roles 
in sporozoite invasion, are formed as the sporozoites bud (110; 111). Sporozoites are 
released from the midgut oocyst into the mosquito’s hemocoel. The rupture of the oocyst 
is dependent upon a cysteine protease ECP1 and CSP, although the exact mechanism 
of sporozoite release remains unclear (112; 113). Once in the hemocoel, sporozoites 
14 
 
use the circulation of the hemolymph to passively migrate through anterograde transport 
to the salivary glands, the site of the sporozoite’s first invasion event. The sporozoite 
actively invades the basal surface of the mosquito salivary gland epithelial cell through 
the formation of a transient parasitophorous vacuole (114). This vacuole dissolves as the 
parasite continues its invasion, allowing it to freely travel through the epithelial cell (103). 
Sporozoites then traverse the apical membrane of the epithelial cell to gain access to the 
salivary gland’s acinar lumen (115). A small number of the sporozoites then make their 
way into the secretory duct (114). The salivary gland surface protein (SGS) family of 
high molecular weight proteins are likely involved as receptors for sporozoite invasion of 
the salivary glands; antibodies raised against SGS1 from Aedes aegypti have been 
shown to inhibit invasion of Anopheles stephensi salivary glands (116). Additionally, 
antibodies against the protein saglin were shown to inhibit sporozoite invasion by 75%, 
implicating saglin as another potential receptor (117). Furthermore, knock down of 
heparan sulfate proteoglycans (HSPGs) on the salivary glands through RNAi targeting of 
the enzyme responsible for heparan sulfate biosynthesis partially inhibits sporozoite 
invasion (118). Once in the salivary gland secretory cavity, the sporozoite is ready for 
transmission to the mammalian host. When the mosquito probes and takes a blood 
meal, the sporozoites are deposited into the skin, which they must navigate to enter a 
blood vessel and migrate to the liver.  
 
The entire surface of the sporozoite is coated with CSP, which is involved in several key 
aspects of the sporozoite’s journey, including motility (119), cellular adhesion (120) and 
targeting (121; 122; 123; 120; 124; 125; 126; 127; 128; 129), and host cell invasion 
(130). Proteolytic cleavage of CSP by a cysteine protease is required before sporozoites 
can invade hepatocytes (131). However, the proper cleavage status of CSP is also 
essential for sporozoite invasion of the salivary glands and sporozoite exit from the 
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dermis. CSP conformation is altered throughout the sporozoite’s invasion processes 
between a thrombospondin-repeat (TSR) domain-exposed (adhesive) and TSR domain-
masked (non-adhesive) state (130). The current model for sporozoite entry and invasion 
in the mammalian host is that sporozoites enter the dermis and traverse capillary 
epithelial cells and then vascular endothelial cells to reach the blood stream in the non-
adhesive, TSR domain-masked state to prevent aberrant invasion (88; 123). This cell 
traversal is distinct from an invasion event in that traversal involves the breaching of the 
plasma membrane, while invasion involves the formation of a parasitophorous vacuole 
(132; 133). Some sporozoites do not reach the bloodstream and instead traverse lymph 
capillary endothelial cells to make their way into the lymphatic system to the lymph node, 
where they are internalized by dendritic cells. Some sporozoites can even initiate 
development in dendritic cells (134).  
 
Sporozoites that do make their way into the blood stream migrate to the liver. CSP is 
then involved in binding to the liver HSPGs that extend through the fenestrae of the 
sinusoid (125; 135); facilitating sporozoite traversal of the liver sinusoidal barrier through 
Kupffer cells and liver sinusoidal endothelial cells. Once sporozoites have traversed 
hepatocytes, they become activated for their final invasion event into a hepatocyte (132; 
136). This activation involves apical exocytosis, which is hypothesized to release 
necessary invasion factors (137). 
 
Sporozoite traversal versus invasion 
Sporozoites undergo many cell traversal steps before undergoing their final invasion of a 
hepatocyte. These two processes are very distinct and require unique sets of parasite 
proteins. In the process of cell traversal, sporozoites cross the plasma membrane of a 
cell to glide through the cytoplasm before breaching the plasma membrane again to exit. 
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Early work identified the sporozoite microneme protein essential for cell traversal 
(SPECT) proteins to be essential for cell traversal (138). It has since been shown that 
SPECT1 is involved in parasite entry, and SPECT2, also known as Perforin-Like Protein 
1, PLP1, is involved in parasite egress (139); it is also known that SPECT2 contains a 
membrane attack complex/perforin domain, which is involved in its cell traversal function 
and becomes activated through pH sensing to avoid degradation of the parasite in the 
lysosome (140). Based on recent studies with P. yoelii, it was found that sporozoites 
form transient vacuoles when they traverse cells, with these vacuoles being distinct from 
the parasitophorous vacuole formed during invasion. Gamete egress and sporozoite 
traversal (GEST) has been identified to play a role in sporozoite traversal of the skin, the 
first tissue the sporozoite must traverse upon entering the human body (141). 
Additionally, TRAP-Like Protein (TLP) has been found to play a role in cell traversal, 
though the exact stage of its function remains unclear, and other studies suggest that it 
may be more important in gliding motility than traversal (142; 143). Another protein, cell-
traversal protein for ookinetes and sporozoites (CelTOS), has been shown to be 
essential for traversal of the liver sinusoidal barrier specifically; rats with Kupffer cell 
depletion allow CelTOS mutant parasites to invade the liver normally (144). Additionally, 
it was shown that CelTOS forms pores targeting the inner leaflet of cell membranes, 
leading to the prevailing hypothesis that it is used by the parasite to exit the host cell 
(145). The full set of proteins involved in this process remains unknown. 
 
When a sporozoite invades a cell to form a parasitophorous vacuole, it first forms a 
moving junction to anchor itself to the host cell. Studies in both Toxoplasma and 
Plasmodium have been used to identify the proteins involved in this process. Rhoptry 
neck protein family members (RON2, RON4, RON5, and RON8 are in Toxoplasma; only 
RON4 has been confirmed in Plasmodium) from the parasite are secreted from the 
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rhoptries and attached to the host cell’s membrane (146; 147; 148; 149; 150). Then, 
apical membrane antigen 1 (AMA1) is secreted from the microneme and placed on the 
parasite’s surface to bind the RON proteins (146). This junction prevents host cell 
proteins from becoming part of the parasitophorous vacuole; this effectively protects the 
sporozoite from the host cell’s lysosomal degradation pathway (151). While the 
movement of the junction along the parasite as it invades has historically been viewed 
as a purely parasite motility-driven process, recent studies have found host cell actin 
regulation to be occurring, suggesting the host cell may also be playing a role (152). This 
invasion process is observed when sporozoites invade hepatocytes and when 
merozoites invade RBCs.  
 
Studying the Plasmodium liver stage 
Plasmodium goes through many developmental stages in both the mosquito and human 
hosts (Figure 1.3). The “liver stage” in the human, in which sporozoites injected by the 
mosquito traverse the liver sinusoidal barrier and invade hepatocytes, is one of these 
crucial steps in the parasite’s life cycle. However, this step has not been as well-studied 
as many of the other steps in the cycle for multiple reasons. P. falciparum and P. vivax 
do not infect mice, the major malaria model system, making in vivo studies of the liver 
stage of these parasites nearly impossible. While they do infect monkeys and mice with 
chimeric human livers, these mice are technically challenging to produce and both 
systems are prohibitively expensive (153; 154). In vitro studies of P. falciparum have 
proven equally challenging. The parasite will infect primary human hepatocytes, but 
these do not propagate in culture and are in short supply; they also provide highly 
variable infection rates (0.13% to 0.72%) (154; 155; 156), causing problems with 
reproducibility in experiments. Variability can be limited by screening several samples of 
primary hepatocytes from multiple human donors to select a specific lot that works 
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optimally for infection studies. While improving the efficiency of experiments, this greatly 
increases the cost. Therefore, much of our knowledge of the liver stage has come from 
studies using the related murine malaria parasites P. berghei and P. yoelii, which offer a 
well-established, relevant system and a range of reagents. Many experimental results 
established with P. berghei and P. yoelii hold true for P. falciparum.  
 
In addition to the long-used rodent malaria models, it was recently described that P. 
falciparum and P. vivax sporozoites can infect and develop in the human 
hepatocarcinoma cell line HC-04, but infection efficiency remains marginal and variable, 
customarily between 0.13% (157) and 0.7-1% (158; 159) for P. falciparum. HC-04 is a 
spontaneously immortalized cell line, isolated from normal human hepatocytes (160). 
Recent analyses of this line suggest that unlike other commonly used hepatocarcinoma 
cell lines, such as HepG2, HC-04 exhibits more plasticity and a propensity to recover its 
epithelial characteristics (158). 
 
Kupffer cells 
When studying the liver stage, it is important to consider not only sporozoite invasion of 
hepatocytes but also the steps that must precede this event. Once the sporozoites have 
arrested their transit in the liver, they must traverse the sinusoidal barrier. This barrier 
contains liver endothelial cells and Kupffer cells (KCs), the resident macrophages of the 
liver.  
 
KCs constitute approximately 35% of the liver non-parenchymal cells in adult mice (161). 
These cells are formed in the liver during development from embryonic origin (162). 
They rely primarily on self-renewal for maintenance (163), but in cases of extreme 
depletion, they can be renewed from circulating monocytes that differentiate into Kupffer-
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like cells (164). KCs populate the lining of the sinusoids across the Space of Disse from 
hepatocytes (165) and are distinguished by their CD11b+F4/80+CD68+ and C-type lectin 
domain family 4-member F expression in mice (166; 167). To date, in humans, there are 
no lineage-specific markers that denote KCs (168). Due to their unique location in the 
liver, where they are exposed to blood from both the hepatic arteries and the portal vein, 
they play major roles in microbial clearance from the blood stream (165) and immune 
tolerance promotion in the liver to prevent unnecessary inflammation (169; 170; 171; 
172). Additionally, they serve as sensors for tissue integrity (173). Under homeostatic 
conditions, KCs interact with a variety of liver-resident and circulating immune cells to 
maintain an immune tolerance phenotype. Due to their constant exposure to 
lipopolysaccharide (LPS), albeit at low levels, from the portal vein, KCs become 
somewhat refractory to activation by Toll-like receptor (TLR) 4 (174). KCs promote the 
regulatory T cell population by secreting IL-10 and prostaglandin E2 while also directly 
interacting with T cells through programmed cell death protein 1 (PD1) and the PD1 
ligand 1 (175; 176). The IL-10 secretion from KCs also plays a role in inhibiting natural 
killer (NK) cell function (177). During homeostasis, KCs are also capable of recruiting 
monocytes to the liver, where they become regulatory dendritic cells (173; 178).  
 
KCs feature several TLRs to allow them to detect pathogen-associated molecular 
patterns (PAMPs) and damage-associated molecular patterns (DAMPs). TLR2 responds 
to bacterial lipoproteins, playing a role in targeting Gram-positive bacteria (179). TLR3 
plays a role in detecting dsRNA, which is primarily used to detect viral infection (180). As 
mentioned previously, TLR4 detects LPS, typically from Gram-negative bacteria; while 
KCs are constantly exposed to low levels of LPS, higher levels can lead to activation 
instead of the typical tolerance phenotype of homeostasis (181). Finally, TLR9 detects 
non-nuclear dsDNA, which is a feature of necrotic cell death (182), and unmethylated 
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bacterial CpG DNA (183). TLR2, 4, and 9 share a similar signal transduction pathway 
following activation; the activated TLR uses its intracellular TIR domain to interact with 
MyD88 (184). MyD88 then interacts with a complex of proteins to activate a series of 
serine/threonine kinases to induce nuclear factor-kB (NF-kB) to translocate to the 
nucleus and activate transcription of genes relating to immune activation, such as pro-
inflammatory cytokines (184). Simultaneously, a mitogen-associated protein (MAP) 
kinase cascade occurs to activate activator protein-1 (AP-1), another transcription factor 
that translocates to the nucleus to activate gene expression (185). TLR3, on the other 
hand, follows a MyD88 independent pathway and instead uses a TRIF-dependent 
pathway; TLR4 can also signal through this pathway. The TRIF-dependent pathway 
signals through IRF3 and/or IRF7 to result in FADD-dependent apoptosis and NF-kB 
activation to induce production of pro-inflammatory cytokines; TRIF also leads to Type I 
interferon secretion (186; 187; 188) (Figure 1.4).  
 
Upon infection, KCs use phagocytosis to clear pathogens from the blood stream. During 
this time, activation of the TLRs also occurs to lead to cytokine secretion and further 
immune activation. In Leishmania infection, for example, the KCs detect and 
phagocytose the parasite to degrade and present to T cells (189) while engaging their 
TLRs to produce pro-inflammatory cytokines and chemokines to activate an immune 
response (190). KCs work together with other blood cells, such as platelets, to clear 
infectious agents and protect against blood stream infections, or sepsis (191). However, 
KCs are not always able to fully overcome infection. Some organisms have developed 
unique ways to deal with KCs to neutralize their killing capabilities. Listeria 
monocytogenes, for example, induces rapid necroptosis in KCs (192). It has also been 
observed in Staphylococcus aureus intravenous infection in mice that KCs are 
responsible for taking up approximately 90% of the bacteria, but not all of these bacteria 
21 
 
are killed. The bacteria can persist and actively replicate in the phagolysosome of the 
KCs before rupturing the KC and disseminating throughout the body (193). 
 
Kupffer cells and Plasmodium 
Based on studies performed using the rodent species of Plasmodium, approximately 
60% of P. berghei sporozoites pass through a KC on their way to hepatocytes (194), and 
these sporozoites traverse KCs without being phagocytosed or killed. When the KC is 
traversed by the sporozoite, it has been reported that many of the KCs become 
wounded and succumb to death (195; 196). Generally, upon cell injury, the injured 
and/or dying cells send out distress signals through the extracellular matrix. These 
signals are received by the surrounding cells, which include other KCs and hepatic 
stellate cells in the liver. In response, the stellate cells produce collagen, which is 
responsible for the resulting fibrosis seen in liver injury. KCs become activated and are 
drawn to the site of injury to engulf the debris. Upon activation, the KCs also secrete pro-
inflammatory cytokines, leading to inflammation (197). These events do not seem to take 
place upon sporozoite traversal of cells and infection of the liver, implying that the 
sporozoite is modulating the cellular responses in its favor through a mechanism that is 
not well understood.  
 
One published study has examined the putative mechanism by which P. falciparum 
sporozoites can shut down KC immunologic function. In this study, P. falciparum CSP 
(PfCSP) increased cAMP levels in the KC. The oxidative burst normally used by KCs to 
kill pathogens is inhibited by increased cAMP levels, so it was concluded that the 
sporozoites could use PfCSP to shut down the oxidative burst (198). This study co-
incubated recombinant PfCSP with KCs and allowed phagocytosis of CSP to occur. This 
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may not accurately mimic the in vivo conditions under which KCs encounter CSP, 
making these results potentially un-informative. 
 
Traversal of cells by sporozoites is on the scale of minutes (194). This has historically 
been long enough for macrophages to begin an immune response; for example, LPS 
can begin causing cellular changes in macrophages in just 5 minutes (199; 200). KCs 
are not the only cells that can be traversed by the sporozoites; in fact, studies of 
hepatocytes have shown that sporozoites can traverse multiple hepatocytes without 
causing large amounts of cell death before finally settling inside of one (194; 201), and 
that this traversal is required for preparing the sporozoites for the final cell invasion event 
(137). These reports and other’s observations suggest that the liver cells are not 
necessarily harmed and killed during traversal (137; 194). Additionally, KCs in P. berghei 
infected mice can secrete hepatocyte growth factor (HGF) to promote apoptosis of 
infected hepatocytes (202). This suggests that KCs secrete soluble molecules to affect 
the overall status of the liver during Plasmodium infection. Therefore, the true fate of the 







In the work outlined herein, we endeavored to address vital hypotheses to fill the current 
gaps in knowledge surrounding the liver stage of the Plasmodium life cycle. The first 
section of this thesis addresses the hypothesis that an ideal in vitro system can be 
developed in which to study sporozoite-KC interactions. Working in vivo leads to 
experimental challenges by limiting the ability for molecular monitoring of the specific 
cells of interest. Working with primary cells is costly, and these cells can be difficult to 
isolate and maintain. The ideal system would be an in vitro platform that uses 
immortalized cells, but still mimics in vivo phenotypes. To develop such a system, we 
performed an in-depth proteomics analysis of both primary and immortalized Kupffer 
cells before and after immune stimulation to determine if the immortalized cells behaved 
in a similar manner to the primary cells. 
 
The second section of this thesis addresses the hypothesis that the interaction between 
KCs and sporozoites is not immunologically silent and does not cause KC death. 
Previous studies have shown through in vivo imaging that sporozoites do pass through 
KCs (194) and suggest that KCs respond to this traversal by undergoing cell death 
(196). However, to date, no studies have followed the KC cytokine secretion and 
immune function following exposure to sporozoites. We performed a systematic analysis 
of KC cytokine secretion over a time-course following sporozoite exposure to address 
this gap in knowledge.  
 
Additionally, we sought to address the hypothesis that an interaction between the 
parasite protein PbMIF and KCs occurs. The P. berghei macrophage migration inhibitory 
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factor (PbMIF) is a homolog of the mammalian macrophage migration inhibitory factor. 
PbMIF is secreted during the sporozoite stage of the parasite (203) and is essential for 
liver stage development of the parasite (204). To determine if PbMIF may have an 
interacting role with KCs to affect the KC immune response, we performed co-
immunoprecipitation assays with PbMIF and KC proteins. We then followed up the 
interacting proteins to understand the biological effect of these interactions. 
 
The final section of this thesis addresses the hypothesis that we could improve the in 
vitro model for sporozoite invasion of hepatocytes by changing the culture conditions to 
more closely mimic the in vivo environment and then use this model to identify a 
sporozoite receptor on the hepatocyte surface. Several studies in the past have sought 
to identify the receptor on hepatocytes that makes them able to be invaded by 
sporozoites (205; 206; 207; 122). However, these receptors alone have not been 
sufficient to lead to the development of sustainable in vitro liver stage systems for 
studies of parasite development. We used the HC-04 cell line, which has been described 
previously to be susceptible to infection by both P. falciparum and P. vivax (157), to 
develop a more robust and reproducible in vitro culture system. By changing media and 
culture conditions and sub-cloning from the HC-04 line, we developed a more-optimal 
culture method. We then used proteomics and RNA-seq analysis to profile our system to 
understand the biology and mechanisms underpinning hepatocyte susceptibility to 






Figure 1.1 Spatial distribution of P. falciparum and P. vivax malaria endemicity in 2010   
 
  
Figure 1.1. Prevalence of P. falciparum in children ages 2-10 (top) and P. vivax in 
people ages 1-99 (bottom) across the globe. Areas shown in light grey are classified 
as “likely to be risk-free.” Areas shown in grey with stripes exhibit unstable malaria 
transmission. Modified from the Malaria Atlas Project (358; 359). 
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Figure 1.2 Malaria parasite illustrations by Laveran 
  
Figure 1.2. After examining blood smears from patients 
infected with malaria parasites, Laveran drew 
illustrations of the stages he observed. Adapted from 
Laveran, 1880 (18). 
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Figure 1.3. Sporozoites delivered into the skin by mosquito bite 
make their way to the liver, where they infect hepatocytes (liver 
stage) and undergo schizogony to form merozoites. These 
merozoites can then infect red blood cells (RBCs) for cyclical 
development of the asexual blood stages. Gametocytes (sexual 
stages) inside RBCs are the only stages that can be taken up into the 
midgut of a mosquito in a subsequent bite. Male/female gametes 
emerge and fertilize in the midgut to produce ookinetes, which invade 
the midgut wall to form oocysts. Sporozoites that are released from 
mature oocysts invade the salivary glands, rendering the mosquito 





Figure 1.4 TLR signaling pathways   
 
  
Figure 1.4. Toll-like receptors (TLRs) receive stimuli that activate a signal 
transduction pathway. TLRs 2, 4, and 9 follow a MyD88-dependent pathway that 
results in the activation of NFkB response genes and the production of pro-
inflammatory cytokines, while TLRs 3 and 4 can follow a TRIF-dependent signaling 
pathway which activates the inflammasome, production of Type I interferons, and 
activation of NFkB response genes. Blue denotes the receptors, green denotes 
proteins that undergo activation, yellow denotes proteins that are inactivated, and 
orange denotes endpoints. Adapted from “The role of pattern-recognition receptors in 
innate immunity: update on Toll-like receptors” by Taro Kawai & Shizuo Akira (186) 
and “Assembly and localization of Toll-like receptor signaling complexes” by Nicholas 

















For experiments in Chapter 3, rat Kupffer Cell 1 (RKC1) cells (a kind gift from Dr. Michel 
Murr, University of South Florida) and primary rat Kupffer cells (PRKC) (Thermo Fisher 
Scientific), were cultured in RPMI (Thermo Fisher Scientific) supplemented with 10% 
heat-inactivated fetal bovine serum (HIFBS) and Penicillin/Streptomycin (Invitrogen) in a 
humidified chamber at 5% CO2 and 37°C. Cells were grown in 6-well plates (for protein 
extraction) or 24-well plates on collagen-coated glass coverslips (for 
immunofluorescence). RKC1 cells were seeded at 25,000 cells per cm2 and grown for 24 
hours before LPS treatment, while PRKC cells were seeded at 25,000 cells per cm2 and 
grown for 1-5 days before LPS treatment. For LPS stimulation, spent medium was 
removed and replaced with fresh media supplemented with 1 µg/ml LPS (Sigma-Aldrich) 
or an equivalent amount of PBS. Cells were stimulated for 4 hours at 37°C prior to 
harvest. The 4-hour stimulation was chosen based upon observations that in RKC1, 4 
hours of LPS stimulation was a sufficient amount of time to cause significant 
morphological changes indicative of activation without resulting in large amounts of cell 
death when compared to both shorter and longer stimulation times (data not shown).  
 
For experiments in Chapter 4, PRKCs were obtained commercially (cryopreserved rat 
Kupffer cells, ThermoFisher Scientific), which were thawed and plated directly into 24-
well plates on collagen-coated coverslips for assays, or using a protocol adapted from 
Dr. Zhaoli Sun from the Johns Hopkins School of Medicine (208). Male Lewis rats (150-
250g) were anesthetized with isoflurane. The abdomen was dissected, and the portal 
vein was cannulated. The liver was then perfused with 100 ml Hank’s Buffered Saline 
Solution (HBSS) for 5 minutes. The inferior vena cava was cut to allow the fluid to drain. 
The liver was then perfused with 100 ml 0.05% collagenase (Type IV from Clostridium 
histolyticum; Sigma-Aldrich) solution in HBSS over 7-10 minutes. The liver was then 
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removed from the body cavity and washed with HBSS+30 mM HEPES+0.1% calcium 
chloride. The tissue was mashed in HBSS+30 mM HEPES+0.1% calcium chloride with 
0.05% collagenase, 0.1 mg/ml DNase, and 0.2 mg/ml Pronase. Connective tissue was 
removed, and the liver cell suspension was incubated at 37°C for 15 minutes with 
agitation. Cells were then spun down at 300xg for 5 minutes 3 times and washed with 
HBSS+30 mM HEPES+0.1% calcium chloride+0.05 mg/ml DNase+1,000 units/ml 
penicillin+1,000 µg/ml streptomycin after each spin. Cells were then spun down at 100xg 
for 1 minute to pellet hepatocytes. The supernatant was collected and spun at 300xg for 
5 minutes. The cell pellets were suspended in HBSS+30 mM HEPES+0.1% calcium 
chloride and applied to a Percoll gradient (15 ml 50% Percoll solution, 15 ml 25% Percoll 
solution, 15 ml cell suspension). The gradients were spun down at 800xg for 15 minutes 
with no brake. The top fraction of the spun gradient was removed, and Kupffer cells were 
collected from the second fraction and washed twice with HBSS+30 mM HEPES+0.1% 
calcium chloride. The final cell pellets were then suspended in complete RPMI media 
(RPMI+10% heat-inactivated fetal bovine serum (HIFBS)+1x MEM amino acids solution 
(ThermoFisher Scientific) +1,000 units/ml penicillin+1,000 µg/ml streptomycin) (cRPMI) 
and used for plating following two different methods. (1) Cells were plated on T75 flasks 
that had been coated for 48 hours with HIFBS. After cells had adhered in a humidified 
chamber at 5% CO2 and 37°C for an hour, the flasks were washed with HBSS+30 mM 
HEPES+0.1% calcium chloride 3 times, and adherent cells were lifted from the flasks in 
cold PBS on ice for 1-2 hours. This cell suspension was then used to plate cells in 
cRPMI for 12-16 hours before assays. (2) Cells were plated directly for assays on 24- or 
48-well plates previously coated for 48 hours with HIFBS; cells were allowed to adhere 
for 2 hours in a humidified chamber at 5% CO2 and 37°C and washed 3 times with 
HBSS+30 mM HEPES+0.1% calcium chloride before assays. All assays were performed 




Primary rat T cells were obtained from the matched KC donor rat. Rat spleens were 
homogenized in RPMI. Cells were then passed through a 5 ml syringe to filter out tissue 
clumps. Cells were spun down at 300xg for 7 minutes. The cell pellet was suspended in 
red blood cell lysis buffer and incubated at room temperature for 10 minutes with 
agitation. Cells were spun down at 300xg for 5 minutes, and the cell pellet was 
suspended in RPMI. The cell suspension was then allowed to adhere to plates to 
remove adherent cells. The supernatant was collected, and cells were pelleted and 
suspended in MACs buffer. Pan-T cell MACs beads were added to the cell suspension 
and incubated on ice for 15 minutes. The cells were then suspended in 500 µl MACs 
buffer and run through an LS column on a MACs magnet. T cells were collected from the 
elution of cells that bound to the column in the magnet.  
 
For Chapter 5, HC-04 (kindly provided by the Naval Research Laboratory), HC-04 sub-
cloned cell lines, and HepG2 were maintained in T75 flasks (Cell Treat) in IMDM (Life 
Technologies) supplemented with 5% HIFBS (Corning) and 1x Penicillin/Streptomycin 
(Corning). From hereon, we refer to both parental and sub-cloned cells as HC-04. Cells 
were split at a 90% confluent culture by digesting the monolayer in 5 mL of 0.05% 
Trypsin-EDTA (Life Technologies) for 10 minutes or until cells lift. The cell suspension 
was collected in a conical tube and centrifuged at 700xg for 7 minutes to ensure 
pelleting of the cells. Trypsin was removed and cells were suspended in media for 
plating, then plated at a 1:10 dilution in a new T75 flask in fresh IMDM with HIFBS and 
Penicillin/Streptomycin for maintenance of line; cells were plated as needed for other 





Immunofluorescence for KC cytoskeletal proteins 
Cells grown on coverslips were fixed in 4% paraformaldehyde for 10 minutes at room 
temperature. Samples were blocked in 5% HIFBS prior to incubation with antibodies. 
The primary antibodies anti-cofilin (D3F9 monoclonal antibodies (Cell Signaling 
Technologies); 1:200), anti-phospho-cofilin (77G2 monoclonal antibodies (Cell Signaling 
Technologies); 1:100), and anti-coronin 1A (polyclonal antibodies (Novus Biologicals); 
1:500) were added overnight at 4°C. After washing, antibodies were detected using the 
anti-rabbit DY-594 secondary antibody (Dyomics; 1:1000); ActinGreen 488 
ReadyProbes reagent (Life Technologies) was also added as a counterstain. DAPI 
(Roche) was used at a concentration of 5 µg/ml. Coverslips were then mounted to slides 
using Aqua-Poly/Mount (Polysciences Inc.). Image acquisition was performed using a 
Nikon Eclipse 90i fluorescence microscope (Nikon), and images were analyzed with 
Volocity 3D Image Analysis Software (Perkin-Elmer).  
 
Protein sample processing for KCs 
Cells were washed twice with cold PBS. For western blotting, cells were incubated in 
RIPA buffer (Cell Signaling Technologies) on ice for 5 minutes, then scraped and 
collected. The cells were then vortexed for 20 seconds and spun down at 14,000xg for 
10 minutes at 4°C. The supernatant was collected, and proteins were concentrated 
using Amicon Ultra 0.5 mL 3K centrifugal filters (EMD Millipore). For LC-MS/MS 
analyses, cells were treated with 0.01% trypsin (Life Technologies) at 37°C for 5 
minutes, and then scraped from the plate. Cells were washed two more times using cold 
PBS. Following centrifugation of the cell suspension at 800 RCF for 5 minutes at 4°C, 
the entire cell pellet was solubilized in SDST-lysis buffer (4% (w/v) SDS, 100 mM 
Tris/HCl, 0.1 M DTT, pH 7.6), and boiled at 95°C for 5 minutes. We performed protein 
digestion according to a filter-aided sample preparation (FASP) protocol (209) using a 10 
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kDa molecular weight cutoff filter (EMD Millipore). Acidified tryptic peptides were 
desalted using an HPLC C18 column on an Agilent 1200 HPLC system (Agilent 
Technologies). Peptide concentration following FASP was estimated by comparison with 
protein digest standards (the concentration of HC-04 soluble protein digest products was 
determined by BCA) using HPLC integrated peak area for further quantitation analysis 
(158). The loading peptide amount for online 2-D HPLC-MS/MS system analysis was 
normalized by the HPLC integrated peak area. 
 
Online 2D LC-MS/MS for KCs 
All the FASP desalted and digested peptides were dissolved in loading buffer (97.9% 
water, 2% acetonitrile (ACN), and 0.1% formic acid (FA)) and ~20 µg was injected to our 
constructed online 2-D HPLC-MS/MS system, using the exact method that we have 
described previously (158). In brief, we integrated one SCX column (150 μm i.d. * 2 cm 
length, PolySULFOETHYL ATM, 5 μm 300 Å, PolyLC INC) into an Agilent LC-MS 
system comprised of a 1200 LC system coupled to a 6520 QTOF via an HPLC Chip 
Cube interface. For the online SCX fractionation in the first dimension, peptides were 
loaded into the SCX column at 1.8 µl/min, and the peptides were eluted using the 
autosampler by injecting 6 μl of each increasing salt concentration (0, 15, 30, 45, 60, 
120, 160, and 300 mM NaCl in 2% ACN/0.1% FA) followed by one injection of 500 mM 
NaCl in 2% ACN/0.1% FA to wash the column. The salt elution was captured by a C18 
enrichment column integrated into the Agilent Polaris-HR-Chip-3C18 chip (360 nl, 180 Å 
C18 trap with a 75 μm i.d., 150 mm length, 180 Å C18 analytical column). In the second 
dimension, with the valve switched and the RPLC gradient started, the peptides were 
eluted from the enrichment column and separated by a C18 analytical column. Elution of 
peptides from the analytical column was performed using a gradient starting at 97% A 
(A: 99.9% water, 0.1% FA) at 300 nl/minute. The mobile phase was 3–10% B (B: 90% 
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ACN, 9.9% water, 0.1% FA) for 4 minutes, 10–35% B for 56 min, 35–99% for 2 minutes, 
and maintained at 99% B for 6 minutes, followed by re-equilibration of the column with 
3% B for 10 minutes. Data dependent (autoMS2) MS acquisition was performed by an 
Agilent 6520 QTOF at 2 GHz. Precursor MS spectra were acquired from m/z 315 to 
1700, and the top 4 peaks were selected for MS/MS analysis. Product scans were 
acquired from m/z 50 to 1700 at a scan rate of 1.5 spectra per second. A medium 
isolation width (∼4 amu) was used, and a collision energy of slope 3.6 V/100 Da with a 
2.9 V offset was applied for fragmentation. A dynamic exclusion list was applied with 
precursors excluded for 0.50 minutes after two MS/MS spectra were acquired. 
 
Database searching and label-free quantification analysis for KCs 
All the LC-MS/MS raw data were converted to Mascot generic format (.mgf) by Agilent 
MassHunter Qualitative Analysis B.04.00. Mascot version 2.4.1 was used to search the 
SwissProt RAT (Nov. 2013) protein FASTA sequence database (28,847 sequences) for 
peptide sequence assignments using the following parameters: precursor ion mass 
tolerance of 50 ppm and a fragment ion mass tolerance of 0.2 Daltons. Peptides were 
searched using fully tryptic cleavage constraints, and up to two internal cleavage sites 
were allowed for tryptic digestion. Fixed modifications consisted of 
carbamidomethylation of cysteine. Variable modifications that were considered were 
oxidation of methionine residues. The Mascot search results were exported as .DAT 
format and then imported into the Scaffold software (version 4.3.2, Proteome Software) 
for curation, label-free quantification, analysis, and visualization. Overall, protein false 
discovery rates of less than 1% and peptide false discovery rates of less than 1% were 
obtained with Scaffold filters, and each protein had ≥ 2 unique peptides. The data 
analysis pipeline meets all MIAPE standards and the proteomics data have been 
36 
 
deposited in the ProteomeExchange via the PRotein IDEntifications database (PRIDE) 
partner repository with the dataset identifier PXD001247 (210).   
 
Quantitative western blotting for KCs 
Protein extracts were dissolved in Laemmli buffer containing 4% (w/v) SDS, 20% 
glycerol, 120 mM Tris-Cl, 0.02% (w/v) bromophenol blue, and 0.71 M 2-ME and heated 
to 95°C for 5 minutes. Proteins were then separated by SDS-PAGE in a 4-20% 
polyacrylamide gel. The proteins were then transferred to a PVDF membrane, and the 
membrane was blocked in Odyssey blocking buffer (LI-COR). The blot was incubated 
with primary antibody (anti-cofilin, 1:1000; anti-phospho-cofilin; 1:1000; anti-coronin, 
1:5000; anti- β-tubulin E7 (DSHB), 1:100) overnight at 4°C. Secondary antibodies with 
near-IR emission were used (goat anti-rabbit IRDye 800CW (LI-COR) and goat anti-
mouse IRDye 680LT (LI-COR); 1:2500), and blots were imaged using a LI-COR 
Odyssey infrared imager (LI-COR). The intensity of the bands was compared using the 
Odyssey image analysis software, version 3.0 (LI-COR). Membranes were stripped for 
re-probing by washing in NewBlot Stripping Buffer (LI-COR) twice for 15 minutes. 
 
In silico analyses for KCs 
For determination of biological process, molecular function, and cellular component gene 
ontology terms for each protein, protein accession numbers were uploaded to the 
Software Tool for Rapid Annotation of Proteins (STRAP), version 1.5 (Cardiovascular 
Proteomics Center, Boston University School of Medicine). For analysis of pathways and 
protein relationships, protein UniProt ID's were uploaded to DAVID Bioinformatics 
Resource 6.7 (National Institute of Allergy and Infectious Disease, NIH). For proteins for 
which a DAVID identification could not be found based on the UniProt ID, a Basic Local 
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Alignment Search Tool (BLAST) search was used (National Center for Biotechnology 
Information, NIH) to identify the closest ortholog with a valid UniProt ID. 
 
Statistical analyses 
For chapter 3, three independent samples were used in each experiment and analyzed 
with a Student’s t-test (GraphPad Prism V. 6). P-values of <0.05 were considered 
statistically significant. 
 
P. berghei sporozoite generation 
An. stephensi (day 6-10) mosquitoes were fed on a mouse infected with P. berghei 
mCherry or P. berghei sporozoite protein essential for cell traversal 2 (SPECT2)- and 
exhibiting 0.5-2 exflagellations per field under a 40x objective. 
Sporozoites were dissected from mosquito salivary glands on day 18-24 post-feed and 
collected in cRPMI media. The tube containing the salivary glands was spun down in a 
Sorvall Legend Micro 17 centrifuge at 1,200xg for 3 minutes at room temperature. The 
salivary gland pellet was gently crushed with a plastic pestle in the 1.5 ml tube and 
vortexed 3 times for 3 seconds to suspend the salivary gland contents in the cRPMI. 
Using a 26-gauge needle (BD) heated by a Bunsen burner flame, a hole was poked in 
the bottom of a 500 µl tube. Approximately 300 µl of glass wool (Supelco) was added to 
the 500 µl tube, ensuring the glass wool fit easily at the bottom of the tube. The 500 µl 
tube containing glass wool was placed in a 1.5 ml collecting tube. The crushed salivary 
gland mixture was filtered through this 500 µl tube with glass wool approximately 200 µl 
at a time, spinning in a Sorvall Legend Micro 17 centrifuge at 1,200xg for 3 seconds for 
each 200 µl fraction at room temperature. After each spin, the liquid accumulated in the 
1.5 ml collecting tube was transferred to a fresh 1.5 ml tube on ice; all fractions were 
combined into one 1.5 ml tube on ice. The glass wool was rinsed with 200 µl PBS, 
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spinning in a Sorvall Legend Micro 17 centrifuge at 1,200xg for 10 seconds at room 
temperature; the liquid accumulated in the 1.5 ml collecting tube was transferred to the 
1.5 ml tube on ice that contained the other fractions. Sporozoites were counted using a 
hemocytometer. 
 
Bio-Plex Cytokine Assays 
Cells were plated in 24- or 48-well plates following methods (1) or (2) outlined in the 
“Cells” section. Cells were exposed to no stimuli (naïve), uninfected salivary gland 
extracts (sg), P. berghei mCherry sporozoites at a ratio of 1 sporozoite per cell (Pb), P. 
berghei SPECT2- sporozoites at a ratio of 1 sporozoite per cell (SPECT2-), 1 µg/ml LPS 
(LPS), lysed P. berghei mCherry sporozoites at a ratio of 1 sporozoite per cell (lys.), or 
P. berghei mCherry paraformaldehyde-fixed sporozoites at a ratio of 1 sporozoite per 
cell (fPb). After the appropriate amount of time, the supernatant from the culture was 
removed for analysis. Supernatants were analyzed using the Bio-Plex cytokine array 
platform following manufacturer’s instructions. Briefly, the cytokine assay standard(s) 
were reconstituted on ice for 30 minutes. A four-fold dilution series of the standard was 
made. The Bio-Plex magnetic beads were added to the assay plate and washed twice. 
Standards, blanks, and supernatants were then added to the plate and allowed to bind 
the beads for 1 hour. The plate was washed three times, and then detection antibodies 
were added for 30 minutes. The plate was washed three times, and then Streptavidin-PE 
was added for 10 minutes. The plate was washed three times again, then beads were 
suspended in assay buffer to be read on a Bio-Plex 200 using high PMT or on a 
Luminex MAGPIX instrument. Standard curves for each cytokine were analyzed and 
optimized in the Bio-Plex Manager software. Kupffer cell supernatants were run in 





Live/dead cell analysis 
The lactate dehydrogenase assay (Pierce LDH cytotoxicity assay kit) was performed 
following the manufacturer’s protocol. Supernatants from Kupffer cells exposed to no 
stimuli (naïve), uninfected salivary gland extracts (sg), Plasmodium berghei sporozoites 
(Pb), or lysed P. berghei sporozoites (lys.) were collected and used in the assay. The 
reaction mix from the kit was added to the supernatants and incubated for 30 minutes. 
Stop solution was then added, and the absorbance at 490 nm and 680 nm were 
measured. The background 680 nm absorbance was subtracted from each read, and the 
output was normalized to the kit positive control sample at 1.0.  
 
The ThermoFisher Live/Dead cell imaging kit was used following the manufacturer’s 
protocol. Kupffer cells were plated on collagen-coated coverslips overnight before 
beginning the assay. Kupffer cells were then exposed to no stimuli (naïve), uninfected 
salivary gland extracts (sg), Plasmodium berghei mCherry sporozoites (Pb), or 387.5 
ng/ml listeriolysin O, a pore forming toxin (LLO). After 15 minutes, the live/dead imaging 
reagent mix was added to the cells. Cells were imaged and the number of live and dead 
cells counted at 30 minutes, 1.5 hours, and 3 hours following cell exposure to stimuli. 
For each stimulus, three biological replicates were analyzed and five microscope fields 
under the 10x objective on the EVOS Cell Imaging System (ThermoFisher Scientific) of 
each replicate were counted at each time point. 
 
Generation of KC protein lysates  
RKC1 were grown in 6-well plates in RPMI+10% HIFBS+1x Penicillin/Streptomycin for 
48 hours. Cells were then washed twice in ice cold PBS before being scraped from the 
plates in PBS. The cells were then spun at 700xg for 5 minutes. The supernatant was 
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removed, and cells were lysed in 0.1% CHAPS in PBS with protease inhibitor cocktail 
(Sigma Aldrich). The cells were lysed on ice for 30 minutes. The lysed solution was then 
spun at 12,000xg for 10 minutes, and the supernatant was collected for use as RKC1 
lysate.  
 
Biotinylation of PbMIF 
PbMIF was biotinylated using the BirA enzyme and biotinylation reaction mixes from the 
Biotin Protein Ligase Kit (Avidity) following the manufacturer’s recommendations. Briefly, 
20 µg of PbMIF was used in each reaction with equal volumes Biomix A and Biomix B in 
10 mM Tris pH=8.0. The BirA enzyme was added to a concentration of 0.2 µg/µl, and the 
protein was incubated for 2 hours at room temperature. Zeba spin columns (Pierce) 
were then used to remove excess biotin from the biotinylated PbMIF (bPbMIF) mixture, 
and protein was concentrated using an Amicon 3K filter unit (EMD Millipore).  
 
Co-immunoprecipitation of bPbMIF and KC proteins 
Co-immunoprecipitation in solution was performed with a 10-fold excess of RKC1 lysate 
proteins to bPbMIF in PBS containing 1 mM Tris. The proteins were incubated overnight 
at 4°C. Biotinylated PbMIF and interactors were collected using PureProteome 
streptavidin magnetic beads (EMD Millipore) according to the manufacturer’s protocol. 
Briefly, PureProteome beads were added to a polystyrene tube and collected in a 
magnet. The supernatant was removed and beads were washed in PBS with 0.1% 
Tween20 (PBST). The bPbMIF+RKC1 lysate mix was then added to the beads and 
allowed to bind for 1 hour at room temperature. Unbound proteins were removed by 
collecting the beads in the magnet and removing the supernatant. The beads were then 
washed twice in PBS, using the magnet to collect the beads and remove the supernatant 
each time. The beads were then suspended in Laemmli buffer and boiled at 95°C for 5 
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minutes. The beads were then spun at 16,000xg for 5 minutes, and the supernatant was 
collected for SDS-PAGE analysis. 
 
For co-immunoprecipitation on microspheres, bPbMIF was attached to 1.0 µm 
streptavidin microspheres (Polysciences, Inc.) prior to incubation with RKC1 lysate. The 
streptavidin microspheres were spun at 10,000xg for 5 minutes, and the supernatant 
was removed. They were washed 3 times in PBS+0.1% BSA, with a 10,000xg spin for 5 
minutes used to remove supernatant after each wash. The microspheres were then 
incubated with bPbMIF for 30 minutes on ice. The microspheres were then spun at 
10,000xg for 5 minutes, and the supernatant was removed. The microspheres were 
washed 3 times with PBST before RKC1 lysate in a 10-fold excess was added PBS 
containing 1 mM Tris. This mix was allowed to incubate overnight at 4°C. The 
microspheres were then spun at 10,000xg for 5 minutes, and the supernatant was 
removed. The microspheres were washed 3 times in PBS before being suspended in 
Laemmli buffer and boiled at 95°C for 5 minutes. The microspheres were then spun at 
12,000xg for 5 minutes, and the supernatant was collected for SDS-PAGE analysis. 
 
Western blotting to confirm bPbMIF-KC protein interactions 
Proteins were transferred to a nitrocellulose membrane following SDS-PAGE. The 
membrane was then blocked in Odyssey blocking buffer (LI-COR) for 30 minutes. 
Primary antibody was added and incubated overnight at 4°C. Primary antibodies used 
were anti-Yb1 (Novus Biologicals, 1:500), anti-EDH4 (GeneTex, 1:1000), anti-calnexin 
(Cell Signaling Technologies, 1:1000), and anti-HSPH90 (Fisher Scientific, 1:1000). 
Membranes were then washed 3 times for 5 minutes each in PBST. Secondary antibody 
was added and incubated at room temperature for 1 hour. Secondary antibodies used 
were goat anti-rabbit 680 (LI-COR, 1:10,000-20,000) and goat anti-mouse 680 (LI-COR, 
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1:10,000-20,000). Membranes were then washed 3 times for 5 minutes each in PBST. 
Membranes were then scanned using a LI-COR Odyssey Fc imaging system. 
 
In-gel peptide digestion to identify bPbMIF binding partners 
Protein bands were cut from a Coomassie-stained acrylamide gel. The gel pieces were 
swelled in NH4HCO3 and dehydrated in acetonitrile alternatively twice. They were then 
reduced and alkylated by incubating in 10 mM DTT for 1 hour at 56°C and then 55 mM 
iodoacetamide for 45 minutes at room temperature. The gel pieces were then washed in 
NH4HCO3 and acetonitrile alternatively twice. The gel pieces were then dried in a 
vacuum centrifuge. Gel pieces were then swelled on ice in 56 ng/µl trypsin for 45 
minutes. Gel pieces were then covered in an excess of 20 mM NH4HCO3 and incubated 
overnight at 37°C. The supernatant was then removed, and 50 mM NH4HCO3 in 50% 
acetonitrile, 1% formic acid solution was added. The gel pieces were agitated in this 
solution for 20 minutes. The supernatant was combined with the supernatant obtained 
after the overnight incubation. Tubes with acidified peptides were placed in a vacuum 
centrifuge for 5 minutes to remove ACN, then spun at 20,000xg for 30 minutes to 
remove any remaining particulates. For analysis, 20 μl of the solution containing acidified 
and digested peptides was added to LC vials and placed in the LC-MS autosampler held 
at 4°C. 
 
LC-MS/MS of in-gel digested peptides 
Analysis of digested peptides from individual gel slices was performed using an Agilent 
1200 LC system coupled to an Agilent 6550 Q-TOF MS via a Chip Cube interface. The 
LC system consisted of a loading pump, autosampler, and an analytical pump. The 
solvent system for both pumps consisted of water/0.1% FA (Solvent A) and ACN/0.1% 
FA (Solvent B). An Agilent Polaris-HR-C18 chip (360 nL,180 Å C18 trap with a 75 μm 
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i.d., 150 mm length, 180 Å C18 analytical column) was used to first trap and then 
separate peptides for MS analysis. Injected peptides were first enriched on the trap 
column for 4 minutes at a flow of 2 μl/min using 3% B, after which the internal valve was 
automatically switched by the system, and peptides were eluted onto the RP-C18 
analytical column. Separation of peptides was accomplished using a gradient with a flow 
of 300 nl/min and a total run time of 25 minutes. The gradient was as follows: 7% B for 2 
minutes, ramping to 35% B from 2-15 minutes, then to 70% B from 15-16 minutes, then 
maintained at 70% B from 16-17 minutes, returned to 7% B from 17-19 minutes, and 
held at 7% B from 19-25 minutes to equilibrate it for the next run. Data dependent 
(autoMS2) MS acquisition was performed on eluted peptides by an Agilent 6550 Q-TOF 
MS operating in positive ionization mode. The source was maintained at 280°C with a 
drying gas flow rate of 11 L/min, the fragmentor was set to 360V, and the capillary 
voltage was set at 2000V initially and adjusted throughout the data acquisition to ensure 
steady spray. Precursor scans were obtained from 275-1700 m/z at a rate of 4 
spectra/second, while MS/MS scans were obtained from 50-1700 m/z at a rate of 3 
spectra/second. The quad was set to narrow isolation width (~1.3 m/z), and precursor 
ions were fragmented with nitrogen gas using variable collision energy determined by 
the formula 3.6V/100*m/z plus an offset of 4.8V. A dynamic exclusion list was used to 
exclude recently fragmented peptides for 0.25 minutes after 1 MS/MS spectrum had 
been collected.  
  
Database searching and label-free quantification analysis of in-gel digested 
peptides 
All the LC-MS/MS raw data were converted to Mascot generic format (.mgf) by Agilent 
MassHunter Qualitative Analysis B.06.00. Mascot version 2.4.1 was used to search the 
SwissProt RAT (Nov. 2013) protein FASTA sequence database (28,847 sequences) for 
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peptide sequence assignments using the following parameters: precursor ion mass 
tolerance of 50 ppm and a fragment ion mass tolerance of 0.2 Daltons. Peptides were 
searched using fully tryptic cleavage constraints, and up to two internal cleavage sites 
were allowed for tryptic digestion. Fixed modifications consisted of 
carbamidomethylation of cysteine. Variable modifications that were considered were 
oxidation of methionine residues. The Mascot search results were exported as .DAT 
format and then imported into the Scaffold software (version 4.3.2, Proteome Software) 
for curation, label-free quantification, analysis, and visualization. Overall, protein false 
discovery rates of less than 1% and peptide false discovery rates of less than 1% were 
obtained with Scaffold filters, and each protein had ≥ 2 unique peptides.  
 
Microscopy to visualize bPbMIF interaction with KCs 
RKC1 cells were grown on collagen-coated coverslips overnight at 37°C in 5% CO2 in 
RPMI with 10% HIFBS and 1x penicillin/streptomycin. Cells were then washed with PBS 
and fixed in 4% paraformaldehyde for 10 minutes at room temperature. Cells were 
blocked for endogenous biotin using the Endogenous Biotin Blocking Kit (ThermoFisher 
Scientific). Cells were then incubated with recombinant, biotinylated PbMIF for 1 hour at 
room temperature. Cells were then washed three times in PBS. Cells were then 
incubated with streptavidin 594 (ThermoFisher Scientific, 1:1000) for 1 hour at room 
temperature. Cells were then washed three times in PBS and incubated with DAPI 
(Roche, 5µg/ml) for 10 minutes. Cells were washed again, three times in PBS. 
Coverslips were then mounted to slides and imaged on a Zeiss Axioskop 2 microscope 






P. falciparum sporozoite generation and collection 
Using a membrane feeding apparatus (211), Anopheles stephensi (day 6-10) 
mosquitoes were fed a blood meal containing Plasmodium falciparum NF54 (WRAIR) 
gametocytes (diluted to 0.3% stage V gametocytemia) on day one of each experiment. 
On day 18 post-mosquito feed, 3 mosquitoes per well to be infected were dissected to 
obtain salivary glands; the salivary glands were kept in M199 medium (Life 
Technologies) with 1% w/v heat inactivated bovine serum albumin (BSA) (Invitrogen) in 
a 1.5 ml tube on ice during the dissection (212; 213; 214). The tube of salivary glands 
was spun down in a Sorvall Legend Micro 17 centrifuge at 1,200xg, 3 minutes at room 
temperature. The salivary gland pellet was gently crushed with a plastic pestle in the 1.5 
ml tube and vortexed 3 times for 3 seconds to suspend the salivary gland contents in the 
M199 medium. Using a 26-gauge needle (BD) heated by a Bunsen burner flame, a hole 
was poked in the bottom of a 500 µl tube. Approximately 300 µl of glass wool (Supelco) 
was added to the 500 µl tube, ensuring the glass wool fit easily at the bottom of the tube. 
The 500 µl tube containing glass wool was placed in a 1.5 ml collecting tube. The 
crushed salivary gland mixture was filtered through this 500 µl tube with glass wool 
approximately 200 µl at a time, spinning in a Sorvall Legend Micro 17 centrifuge at 
1,200xg for 3 seconds for each 200 µl fraction at room temperature. After each spin, the 
liquid accumulated in the 1.5 ml collecting tube was transferred to a fresh 1.5 ml tube on 
ice; all fractions were combined into one 1.5 ml tube on ice. The glass wool was rinsed 
with 200 µl PBS, spinning in a Sorvall Legend Micro 17 centrifuge at 1,200xg for 10 
seconds at room temperature; the liquid accumulated in the 1.5 ml collecting tube was 
transferred to the 1.5 ml tube on ice that contained the other fractions. Sporozoites were 





Plating HC-04 for infection 
On day 17 post-mosquito feed, 12 mm diameter coverslips (Electron Microscopy 
Sciences) were coated in the wells of a 24-well plate with 0.01% w/v collagen (Sigma-
Aldrich) in PBS and incubated under UV light at room temperature for 1 hour. The 
collagen was removed and coverslips were washed once with PBS. 50,000 HC-04 per 
well were plated in 24-well plates on the collagen-coated coverslips in 500 µl “basic 
medium,” which is DMEM without glucose (Life Technologies), supplemented with 1 mM 
sodium pyruvate (Life Technologies), 1% fetal bovine serum (FBS) (Corning), and 1x 
Penicillin/Streptomycin. Additional supplementations of the basic medium that were 
tested were 1x MEM amino acids without L-glutamine (Sigma-Aldrich), chemically-
defined lipid mixture 1 (Sigma-Aldrich) (containing 4 ng/ml arachidonic acid; 20 ng/ml 
linoleic, linolenic, myristic, oleic, palmitic, and stearic acids; 0.44 µg/ml cholesterol, 4.4 
µg/ml Tween-80, 140 ng/ml tocopherol acetate, and 200 µg/ml pluronic F-68), and 10% 
HIFBS. 
 
Infection of HC-04 with sporozoites 
For the testing of the 2A10 (MRA183A, Malaria Research & Reference Reagent 
Resource Center [MR4], Bei Resources) or anti-GPC3 antibody (Fisher Scientific, 
MAB2119), 50,000 sporozoites per well of HC-04 were co-incubated with antibody in 
100 µl for 20 minutes at room temperature prior to their addition to the HC-04 in 0.6 ml of 
basic medium. Unbound antibody was not removed before addition of sporozoites to the 
hepatocyte culture. 
For studies of liver-stage biology, 50,000 sporozoites were directly added to each well of 
HC-04 in 500 µl fresh basic media (same basic media fed to the cells on day 17 post-
mosquito feed).  
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For glucose supplementation upon sporozoite addition, 15 mM D-glucose (Sigma-
Aldrich) was added to the 500 µl basic media containing the sporozoites prior to addition 
to cells. 
After sporozoite addition, the plate was gently swirled 5 times by hand, and then spun at 
50xg in bench top Eppendorf 5810 centrifuge for 2 minutes at room temperature. The 
plate was then incubated at 37°C in an incubator (5% CO2) for 10 minutes. This swirling 
and spinning was repeated two more times. Following the third centrifugation, the plate 
was incubated at 37°C for 24 hours under standard ‘normoxic’ (5% CO2) conditions or 
under hypoxic conditions in a hypoxia chamber (Billups-Rothenberg) containing 5% 
oxygen. 
 
Fixing and staining to identify P. falciparum sporozoites that have invaded 
After incubating sporozoites with the HC-04 cells for 24 hours, medium was removed 
and the coverslips were rinsed with 500 µl PBS. Coverslips were then transferred to a 
new 24-well plate containing 500 µl PBS. The cells were fixed in 110 µl of 4% 
paraformaldehyde for 10 minutes at room temperature. Paraformaldehyde was removed 
and coverslips were rinsed with 500 µl PBS, then blocked in 500 µl 5% HIFBS in PBS for 
30 minutes at room temperature on a Labnet Gyrotwister shaker. HIFBS solution was 
removed and 110 µl of primary antibody was added; the primary antibody was made by 
diluting 1 µl of anti-CSP 2A10 monoclonal antibody (0.89 µg/µl) (MRA183A, Malaria 
Research & Reference Reagent Resource Center [MR4], Bei Resources) in 1 ml PBS. 
Primary antibody was incubated with the cells for 20 minutes at room temperature on a 
Labnet Gyrotwister shaker. Primary antibody was removed, and coverslips were washed 
with 500 µl PBS, 4 times for 5 minutes at room temperature on a Labnet Gyrotwister 
shaker. Next, 110 µl secondary antibody was added, 1 µl Alexa Fluor488 anti-mouse 
(Life Technologies, A-11001) diluted in 1 ml PBS, and incubated for 20 minutes in the 
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dark at room temperature on a Labnet Gyrotwister shaker. The secondary antibody was 
removed and coverslips were washed with 500 µl PBS, 2 times for 5 minutes at room 
temperature on a Labnet Gyrotwister shaker. Coverslips were then washed with 500 µl 
PBS+0.1% Tween 20, 2 times for 5 minutes at room temperature on a Labnet 
Gyrotwister shaker. Then 110 µl primary antibody was added, 1 µl anti-CSP 2A10 
diluted in 1 ml PBS+0.1% Tween 20, and incubated for 20 minutes at room temperature 
on a Labnet Gyrotwister shaker. Primary antibody was removed and coverslips were 
washed with 500 µl PBS+0.1% Tween 20, 4 times for 5 minutes at room temperature on 
a Labnet Gyrotwister shaker. Then 110 µl secondary antibody was added, 1 µl Alexa 
Fluor 594 (Life Technologies, A-11005) anti-mouse diluted in 1 ml PBS+0.1% Tween 20, 
and incubated for 20 minutes at room temperature on a Labnet Gyrotwister shaker. 
Secondary antibody was removed and coverslips were washed with 500 µl PBS+0.1% 
Tween 20, 4 times for 5 minutes at room temperature on a Labnet Gyrotwister shaker. 
Finally, 110 µl DAPI was added (diluted in PBS+0.1% Tween 20 to a final concentration 
of 5 µg/ml) and incubated for 10 minutes at room temperature on a Labnet Gyrotwister 
shaker. DAPI was removed and coverslips were washed with 500 µl PBS+0.1% Tween 
20, 4 times for 5 minutes at room temperature on a Labnet Gyrotwister shaker. 
Coverslips were then mounted to slides on a drop of Aqua Poly/Mount (Polysciences, 
Inc.). The coverslips were allowed to set for at least 12 hours in the dark at 4°C before 
visualization. 
Immunofluorescence assays of hepatocyte proteins were performed similarly. HC-04 
Navy, HC-04.J7, or HepG2 were plated on collagen-coated coverslips in 24-well plates 
and grown in the appropriate media for 24 hours. Cells were then rinsed with PBS and 
fixed in 4% paraformaldehyde for 10 minutes at room temperature. Paraformaldehyde 
was removed and coverslips were rinsed with 500 µl PBS, then blocked in 500 µl of 5% 
HIFBS in PBS for 30 minutes at room temperature on a Labnet Gyrotwister shaker. 
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HIFBS solution was removed, and 110 µl primary antibody was added overnight at 4°C; 
primary antibody was made using a 1:500 dilution of anti-EphA2 (BioLegend, clone 
SHM16) or anti-GPC3 (Fisher Scientific, MAB2119) in PBS. Primary antibody was 
removed, and the cells were washed with PBS. Secondary antibody (anti-mouse 
AlexaFluor 594) was diluted in PBS (1:1000) and added to the cells for 1 hour at room 
temperature. The antibody was then removed, and the cells were washed with PBS. 
Finally, DAPI (5 µg/ml) was added to the cells and incubated for 7 minutes at room 
temperature. DAPI was removed, and coverslips were washed with PBS. Coverslips 
were then mounted to slides on a drop of Aqua Poly/Mount. The coverslips were allowed 
to set for at least 12 hours in the dark at 4°C before visualization. 
 
Imaging and invasion quantification 
For invasion quantification, cells were visualized under a Nikon Eclipse E800 
microscope under the 40x objective. Beginning on the left side of the coverslip and 
moving in a straight line to the right, the number of red sporozoites that are NOT green 
(these are the sporozoites inside cells) and the number of HC-04 cells in all fields were 
counted. The invasion rate was calculated using the equation: 
 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑝𝑜𝑟𝑜𝑧𝑜𝑖𝑡𝑒𝑠 𝑖𝑛𝑠𝑖𝑑𝑒
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐻𝐶−04 𝑐𝑒𝑙𝑙𝑠
× 100 
 
For imaging sporozoite invasion, cells were visualized using a Nikon 90i microscope, 
and images were acquired with a Hamamatsu Orca-ER camera using the Volocity 3D 




For imaging hepatocyte proteins, cells were visualized on a Zeiss Axioskop 2 
microscope with a ProgRes MFcool camera using the ProgRes CapturePro software 
version 2.10.0.1. 
 
LC-MS/MS sample preparation for hepatocytes 
For LC-MS/MS, cells were grown in T75 flasks in the appropriate media for 24 hours. 
Cells were then washed three times with cold PBS and treated with 0.01% trypsin (Life 
Technologies) at 37°C for 5 minutes, then scraped from the flask.  
Protein sample preparation for whole proteome analysis of HC-04 grown in equal parts 
MEM and F-12 supplemented with 10% HIFBS, 15 mM HEPES, 20 mM sodium 
bicarbonate, 15 µM phenol red, 200 units/ml penicillin, and 200 µg/ml streptomycin used 
at a pH of 7.4-8.0 (hereafter referred to as enhanced MEM+F12) and basic media was 
performed as previously described (158). Briefly, cells were solubilized in SDST-lysis 
buffer and boiled at 95°C for 5 minutes.  
Protein sample preparation for membrane-enriched proteome analysis of HC-04 and 
HepG2 was performed by suspending cell pellets obtained from T75 flasks in buffer. 
Cells were lysed by five rounds of freeze thaw lysis, during which cells were frozen in 
liquid nitrogen for 1 minute, then rapidly thawed at 37°C for 4 minutes. Following lysis, 
cells were centrifuged and supernatant was collected as the non-membrane fraction. 
The pellet was then washed 3 times in PBS to remove residual non-membrane proteins. 
The remaining pellet was solubilized in SDST-lysis buffer. 
For all protein samples, a FASP protocol was performed (209) using a 10 kDa molecular 
weight cutoff filter (EMD Millipore). An HPLC C18 column on an Agilent 1260 HPLC 





Online 2D LC-MS/MS for hepatocytes 
FASP-desalted peptides were dissolved in loading buffer (97.9% water, 2% ACN, and 
0.1% FA) and around 20 µg of peptides was injected to our constructed online 2D 
HPLC-MS/MS system as described previously (215), “Online 2D LC-MS/MS for KCs” 
section. 
 
Database searching and label-free quantification analysis for hepatocytes 
All the LC-MS/MS raw data were converted to Mascot generic format (.mgf) by Agilent 
MassHunter Qualitative Analysis B.04.00. Mascot version 2.4.1 was used to search the 
SwissProt Human 2012 protein FASTA sequence database (20,234 sequences) for 
peptide sequence assignments using the following parameters: precursor ion mass 
tolerance of 50 ppm and a fragment ion mass tolerance of 0.2 Daltons. Peptides were 
searched using full tryptic cleavage constraints and up to two internal cleavage sites 
were allowed for tryptic digestion. Fixed modifications consisted of 
carbamidomethylation of cysteine. Variable modifications considered were oxidation of 
methionine residues. The Mascot searched results were exported as .DAT format and 
then imported into the Scaffold software (Version 4.0.4, Proteome Software) for curation, 
label-free quantification analysis, and visualization. Scaffold’s normalized spectral 
counting was employed to compare relative protein abundance between HC-04 cell 
samples grown in enhanced MEM+F12 and HC-04 grown in basic medium in each 
experiment as the basis for normalization of the spectral counts for all other LC-MS/MS 
data in that experiment. Overall, protein false discovery rates of less than 1% and 
peptide false discovery rates of less than 1% were obtained with Scaffold filters, and 






For RNA-seq analyses, HC-04 or HepG2 were grown in T75 flasks in the appropriate 
media for 24 hours. Cells were then washed twice in ice-cold PBS. Cells were 
suspended in TRIzol to collect RNA. RNA was prepared following the manufacturer’s 
protocol (216). RNA-seq was performed on an Illumina HiSeq3000 with 2x100 cycles 
based on the manufacturer’s guidelines (216).  
Total RNA with an OD 260/280 ratio ranging from 1.2-2.2 was used to determine the 
RNA concentration on a Qubit 2.0 Fluorometer (ThermoFisher). RNA quality was 
assessed using the Agilent 2100 Bioanalyzer. Total RNA with 28S/18S > 1 and RNA 
integrity number (RIN) ≥ 7 was used for RNA-seq library construction.  
Approximately 500 ng of protein-free and intact total RNA was used for library 
construction using the reagents provided in the NEBNext Ultra II RNA Library Prep 
following the manufacturer's protocol. First, 2 µl of diluted RNA was spiked with ERCC 
from the kit. Next, mRNA isolation was performed using the NEBNext Poly(A) mRNA 
Magnetic Isolation module (New England Biolabs). Then RNA was fragmented in a 
solution containing divalent cations, with incubation at 94°C. Next, first strand cDNA 
synthesis using reverse transcriptase and random primers was done. Synthesis of 
double stranded cDNA was done using the second strand master mix provided in the kit, 
followed by end-repair and dA-tailing. At this point, Illumina adaptors were ligated to the 
sample. Finally, the library was enriched by 11 cycles of amplification and purified by 
Agencourt AMPure beads (Beckman Coulter). Barcoded libraries were sized on the 
bioanalyzer and quantitated by QUBIT. Quantitative PCR was used to validate the 
library's functionality, using the KAPA Library Quantification kit (Kapa Biosystem) and 
monitoring with the BioRad Touch Real-Time PCR Detection System. Individual libraries 
were pooled equimolarly for sequencing runs.  
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Sequencing was performed on the Illumina HiSeq3000 instrument using the clustering 
and sequencing reagents provided by Illumina. Paired-end, 2x100 cycles runs require 
the combination of reagents from the 150 cycles and the 50 cycles kits. Sequencing 
reactions were set up using 5 μl of library (2.5 nM). Libraries were first denatured with 5 
μl 0.1 N NaOH for 8 minutes at room temperature. This was followed by neutralization 
with 5 µl of 200 mM Tris (pH 7.5) and mixing with 35 µl of the ExAmp reagents 
(contained in the PE-410-1001 clustering kit) according to the manufacturer’s protocol. 
Samples were clustered in the cBot clustering station using the “HiSeq 3000/4000 HD 
Exclusion Amp v1.0” protocol. Runs were set by choosing the ‘Generate FASTQ only’ 
workflow in the HiSeq Control Software v3.3.76 in the computer station that runs the 
HiSeq3000 sequencing machine (Illumina). Under these run conditions, the cluster pass-
filter was 70-75%, with a yield of 300-325 million pass-filter reads per lane. The %≥Q30 
score was typically above 95%. The reads that passed Illumina quality control filtering 
were used as raw data for further bioinformatics analysis. 
The RNA library construction and HiSeq 3000 sequencing run were performed at the 
Interdisciplinary Center for Biotechnology Research (ICBR) Gene Expression & 
Genotyping Core, University of Florida (UF). 
Reads were trimmed using Trimmomatic 0.36 (217). All leading and trailing bases with 
quality below 3 were trimmed. Reads were scanned from the 5’ end towards the 3’ end 
using a sliding window of size 4 and were cut when the average quality within the 
window dropped below 15. Reads shorter than 40 bases after trimming were discarded. 
Adapters were removed from reads using the TruSeq3 adapter library provided with 
Trimmomatic. 
Reads were aligned against the GRCh38 reference genome with gene annotations from 
GENCODE release 26 (both obtained April 6, 2017) using STAR 2.5.3a (218). Gene 
expression estimates were computed with the “--quantMode GeneCounts” flag, giving 
54 
 
the unambiguous, unique number of reads for each gene. The GeneCounts mode is 
equivalent to running hoses-count with the union overlap resolution mode and discarding 
ambiguous reads. 
Differentially expressed genes were identified using DESeq2 1.28.0 (219). We compared 
all possible pairs of the three different cell lines within the same media with default 
parameters provided by DESeq2. A linear model was fit to each gene with cell line as the 
dependent variable and all gene expression estimates as independent variables. 
For each gene set, we performed a statistical enrichment test to test whether the fold 
changes within the gene set were significantly different from the distribution of fold 
changes over all genes. A p-value was computed using a two-sided Mann-Whitney U 
test. 
 
In silico analyses for hepatocytes 
For analysis of pathways and protein relationships, protein UniProt ID's were uploaded 
to DAVID Bioinformatics Resource 6.7 (National Institute of Allergy and Infectious 
Disease, NIH).  
 
MitoTracker staining 
HC-04 cells were seeded on collagen-coated glass coverslips in 24-well plates at 50,000 
cells per well in either enhanced MEM+F12 medium or basic medium. Cells were grown 
for 48 hours at 37°C under standard ‘normoxic’ (5% CO2) conditions, then media was 
removed and replaced with media containing 100 nM MitoTracker Red CMXRos 
(Molecular Probes). Cells were incubated with MitoTracker for 30 minutes at 37°C. The 
MitoTracker was then removed, cells were washed twice with 500 µl PBS and mounted 
to coverslips for immediate visualization. A Zeiss Axioskop2 microscope with a 63x 
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objective was used for visualization. Image capture was performed using a Jenoptik 



















The traversal of the liver sinusoidal barrier by sporozoites is an essential step in the 
parasite’s journey to the liver. While crossing this barrier, many of the sporozoites 
traverse Kupffer cells. To study the interactions between sporozoites and Kupffer cells, 
development of an in vitro system that would allow monitoring of this interaction is 
essential. We first hypothesized that we could use an immortalized rat Kupffer cell line, 
RKC1, to do these assays. To determine if the RKC1s behaved similarly enough to 
primary cells to serve as an appropriate model, we stimulated both primary and 
immortalized KCs with LPS and studied the proteomic response of these cells to the 
stimulus. We found that while primary rat KCs and RKC1s express many of the same 
proteins under naïve conditions, once they are exposed to an immune stimulus they 
respond very differently from each other. We also found that Kupffer cells respond to 
LPS in a way that is different from monocyte-derived macrophages; in monocyte-derived 
macrophages, macropinocytosis is induced upon LPS stimulation, while in Kupffer cells, 
it is not. The proteomic analysis of RKC1 and primary Kupffer cells led us to conclude 
that while RKC1s can be used to purify specific KC proteins and look at protein-protein 
interactions, RKC1s would not serve as a suitable model for immune process studies. 
Thus, we decided to move forward with primary rat Kupffer cells for our immune function 
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The liver is a site of invasion for multiple pathogens, including Plasmodium, the 
causative agent of malaria. Plasmodium sporozoites that are inoculated into the body by 
anopheline mosquitoes journey to the liver (88), where they often traverse Kupffer cells 
(KCs) to cross the sinusoidal barrier (194) and gain access to hepatocytes, their first site 
of invasion and intracellular replication. KCs are liver-resident macrophages and the first 
line of defense against pathogens in this tissue. KCs account for approximately 15% of 
liver cells and as much as 80% of the body’s total macrophage population (220). Their 
major roles include phagocytosis of antigens for presentation to T cells and secretion of 
cytokines for immune system modulation. However, phagocytosis and pro-inflammatory 
cytokine secretion do not appear to occur when KCs are traversed by Plasmodium 
(195), underscoring the need for further studies into the intricacies of KC-sporozoite 
interaction.  
 
Studies exploring host-pathogen interactions, as well as immune functionality and 
signaling in KCs, have been performed in vivo (murine) and in vitro with primary cells 
(human and murine). However, both of these strategies require large numbers of 
animals or donated tissues for cell isolation. Primary cells only survive in culture for a 
short period of time and must be constantly replenished. To avoid this constant need for 
primary material, the first immortalized rat Kupffer cell line (RKC1) was developed to aid 
in studies of cell signaling in liver disease (221). RKC1 constitutively express TNF-α, 
FasL, IL-6, IL-1β, and Toll-like receptor-4 (TLR4), similar to primary rat Kupffer cells 
(PRKC). RKC1 also express the macrophage surface markers ED1, ED2, ED3, and 
F4/80 and upregulate TNF-α, Fas/FasL, IL-6, IL-1β, and TLR4 in response to 
lipopolysaccharide (LPS) (221). Additionally, it has been shown that RKC1 cells perform 
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efferocytosis (the removal of dying and dead cells) and exhibit sensitivity to SIRT1 
regulation of TNF-α in response to LPS akin to PRKC and murine RAW 264.7 
macrophages, respectively (222; 223). However, the full set of surface markers, 
receptors, and signaling capabilities of these cells remain unknown. RKC1 have 
potentially profound value in the study of host-pathogen interactions, immune signaling, 
and Kupffer cell functionality if they exhibit the full spectrum of signaling capabilities of 
primary cells. To test the signaling capacity of these cells, we evaluated the signaling 
protein response profile of both PKRC and RKC1 in response to LPS stimulation. 
 
LPS causes a cascade of signaling events in macrophages, signaling through TLR4 
(224) to activate many downstream pathways, such as NFκB signaling and MAPK 
pathways that lead to the expression of pro-inflammatory cytokines, including IL-1β, IL-6, 
and TNF-α. In addition to these canonical signaling pathways, inflammatory stimuli also 
induce cytoskeletal changes in macrophages to facilitate antigen uptake (225). The 
typical process by which this occurs in antigen presenting cells, including macrophages, 
is Fc-receptor (FcR)-mediated phagocytosis. This process involves actin remodeling and 
pseudopodia formation for antigen uptake (226; 227; 228). Actin remodeling occurs 
downstream of FcR engagement, using a signaling phosphorylation cascade involving 
many kinases and adaptor proteins, including Src-family kinases, Syk kinase, 
phosphatidyl inositol 3-kinase, phospholipase C, the Src homology 2 containing 5’ 
inositol phosphatase, among others (229; 230; 231; 232; 233; 234). Recently, it has 
been shown that inflammatory stimuli can have a different effect in macrophages.  
 
In response to specific pro-inflammatory stimuli, macrophages can be reprogrammed to 
perform macropinocytosis (an alternative form of antigen uptake independent of 
receptors), instead of receptor-mediated phagocytosis through a protein kinase C (PKC) 
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activation cascade. TNF-receptor activation through TNF-α signaling causes PKC 
activation and a shift to macropinocytosis (235). This requires coronin 1A, a known 
component of phagosome formation (236) that is also implicated in macropinosome 
formation. PKC activates coronin 1A, which then activates the phosphinositol-3-kinase 
activity that facilitates the downstream activation of proteins required for the switch to 
macropinocytosis (235). These include the Rac family (237) and Rho family (238) 
proteins, which facilitate actin polymerization and depolymerization to drive the 
membrane extension/ruffling during macropinocytosis, and calcium signaling-regulated 
calcineurin activity (239). Calcineurin activates Slingshot 1L, a phosphatase that then 
acts on phosphorylated-cofilin. Once cofilin is dephosphorylated, it is in its activated 
state and can play a role in further facilitating actin polymerization (240). Actin-related 
protein complexes and cell division control protein 42 are also involved in this switch by 
facilitating the branching of actin chains (237). It is clear that these two different forms of 
cytoskeletal change, phagocytosis and coronin 1A-mediated macropinocytosis, both 
involve actin remodeling, but reach these phenotypes using unique signaling cascades. 
 
We used a global quantitative proteomics approach to evaluate signaling cascades and 
cellular outcomes in KCs by comparing the signaling capabilities of RKC1 with PRKC. 
We report on the signaling response of both PRKC and RKC1 following exposure to LPS 
and discuss the ramifications of the results viz. the utility of the systems for the study of 







Cells. Rat Kupffer Cell 1 (RKC1) cells (a kind gift from Michel Murr, University of South 
Florida) and primary rat Kupffer cells (PRKC) (Thermo Fisher Scientific, Waltham, MA), 
were cultured in RPMI (Thermo Fisher Scientific) supplemented with 10% heat-
inactivated fetal bovine serum and Penicillin/Streptomycin (Invitrogen, Carlsbad, CA) in a 
humidified chamber at 5% CO2 and 37°C. Cells were grown in 6-well plates (for protein 
extraction) or 24-well plates on collagen-coated glass coverslips (for 
immunofluorescence). RKC1 cells were seeded at 25,000 cells per cm2 and grown for 24 
hours before LPS treatment, while PRKC cells were seeded at 25,000 cells per cm2 and 
grown for 1-5 days before LPS treatment. For LPS stimulation, spent medium was 
removed and replaced with fresh media supplemented with 1 µg/ml LPS (Sigma-Aldrich, 
St. Louis, MO) or an equivalent amount of PBS. Cells were stimulated for 4 hours at 
37°C prior to harvest. The 4-hour stimulation was chosen based upon observations that 
in RKC1, 4 hours of LPS stimulation was a sufficient amount of time to cause significant 
morphological changes indicative of activation without resulting in large amounts of cell 
death when compared to both shorter and longer stimulation times (data not shown). 
 
Antibodies. Cofilin D3F9 monoclonal antibodies (Cell Signaling Technologies, Danvers, 
MA) were used at 1:1000 for western blotting and 1:200 for immunofluorescence. 
Serine-3 phospho-cofilin 77G2 monoclonal antibodies (Cell Signaling Technologies) 
were used at 1:1000 for western blotting and 1:100 for immunofluorescence. Coronin-1a 
polyclonal antibodies (Novus Biologicals, Littleton, CO) was used at 1:5000 for western 
blotting and 1:500 for immunofluorescence. The β-tubulin E7 monoclonal antibody was 
provided by the Developmental Studies Hybridoma Bank and was used at 1:100 for 
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western blotting. Western blot secondary antibodies goat anti-rabbit IRDye 800CW (LI-
COR, Lincoln, NE) and goat anti-mouse IRDye 680LT (LI-COR) were used at 1:2500. 
Immunofluorescence secondary anti-rabbit DY-594 (Dyomics, Jena, Germany) antibody 
was used at 1:1000. 
 
Immunofluorescence. Cells grown on coverslips were fixed in 4% paraformaldehyde 
for 10 minutes at room temperature. Samples were blocked in 5% fetal bovine serum 
prior to incubation with antibodies. Primary antibodies anti-cofilin, anti-phospho-cofilin, 
and anti-coronin 1A were added overnight at 4°C. After washing, antibodies were 
detected using the anti-rabbit DY-594 secondary antibody; ActinGreen 488 
ReadyProbes reagent (Life Technologies, Grand Island, NY) was also added as a 
counterstain. DAPI (Roche, Indianapolis, IN) was used at a concentration of 5 µg/ml. 
Coverslips were then mounted to slides using Aqua-Poly/Mount (Polysciences Inc., 
Warrington, PA). Image acquisition was performed using a Nikon Eclipse 90i 
fluorescence microscope (Nikon, Melville, NY), and images were analyzed with Volocity 
3D Image Analysis Software (Perkin-Elmer, Waltham, MA).  
 
Protein sample processing. Cells were washed twice with cold PBS. For western 
blotting, cells were incubated in RIPA buffer (Cell Signaling Technologies) on ice for 5 
minutes, then scraped and collected. The cells were then vortexed for 20 seconds and 
spun down at 14,000xg for 10 minutes at 4 °C. The supernatant was collected, and 
proteins were concentrated using Amicon Ultra 0.5 ml 3K centrifugal filters (EMD 
Millipore, Billerica, MA). For LC-MS/MS analyses, cells were treated with 0.01% trypsin 
(Life Technologies) at 37 °C for 5 minutes, and then scraped from the plate. Cells were 
washed two more times using cold PBS. Following centrifugation of the cell suspension 
at 800 RCF for 5 min at 4 °C, the entire cell pellet was solubilized in SDST-lysis buffer 
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(4% (w/v) SDS, 100 mM Tris/HCl, 0.1 M DTT, pH 7.6), and boiled at 95 °C for 5 min. We 
performed protein digestion according to a filter-aided sample preparation (FASP) 
protocol (209) using a 10 kDa molecular weight cutoff filter (EMD Millipore). Acidified 
tryptic peptides were desalted using an HPLC C18 column on an Agilent 1200 HPLC 
system (Agilent Technologies, Santa Clara, CA). Peptide concentration following FASP 
was estimated by comparison with protein digest standards (the concentration of HC-04 
soluble protein digest products was determined by BCA) using HPLC integrated peak 
area for further quantitation analysis (158). The loading peptide amount for online 2-D 
HPLC-MS/MS system analysis was normalized by the HPLC integrated peak area. 
 
Online 2D LC-MS/MS. All the FASP desalted and digested peptides were dissolved in 
loading buffer (97.9% water, 2% CAN, and 0.1% formic acid (FA)) and ~20 µg was 
injected to our constructed online 2-D HPLC-MS/MS system, using the exact method 
that we have described previously (158). In brief, we integrated one SCX column (150 
μm i.d. * 2 cm length, PolySULFOETHYL ATM, 5 μm 300 Å, PolyLC INC) into an Agilent 
LC-MS system comprised of a 1200 LC system coupled to a 6520 QTOF via an HPLC 
Chip Cube interface. For the online SCX fractionation in the first dimension, peptides 
were loaded into the SCX column at 1.8 μl/min, and the peptides were eluted using the 
autosampler by injecting 6 μl of each increasing salt concentration (0, 15, 30, 45, 60, 
120, 160, and 300 mM NaCl in 2% ACN/0.1% FA) followed by one injection of 500 mM 
NaCl in 2% ACN/0.1% FA to wash the column. The salt elution was captured by a C18 
enrichment column integrated into the Agilent Polaris-HR-Chip-3C18 chip (360 nl, 180 Å 
C18 trap with a 75 μm i.d., 150 mm length, 180 Å C18 analytical column). In the second 
dimension, with the valve switched and the RPLC gradient started, the peptides were 
eluted from the enrichment column and separated by a C18 analytical column. Elution of 
peptides from the analytical column was performed using a gradient starting at 97% A 
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(A: 99.9% water, 0.1% FA) at 300 nl/min. The mobile phase was 3–10% B (B: 90% ACN, 
9.9% water, 0.1% FA) for 4 min, 10–35% B for 56 min, 35–99% for 2 min, and 
maintained at 99% B for 6 min, followed by re-equilibration of column with 3% B for 10 
min. Data dependent (autoMS2) MS acquisition was performed by an Agilent 6520 
QTOF at 2 GHz. Precursor MS spectra were acquired from m/z 315 to 1700 and the top 
4 peaks were selected for MS/MS analysis. Product scans were acquired from m/z 50 to 
1700 at a scan rate of 1.5 spectra per second. A medium isolation width (∼4 amu) was 
used, and a collision energy of slope 3.6 V/100 Da with a 2.9 V offset was applied for 
fragmentation. A dynamic exclusion list was applied with precursors excluded for 0.50 
min after two MS/MS spectrum was acquired. 
 
Database searching and label-free quantification analysis. All the LC-MS/MS raw 
data were converted to Mascot generic format (.mgf) by Agilent MassHunter Qualitative 
Analysis B.04.00. Mascot version 2.4.1 was used to search the SwissProt RAT (Nov. 
2013) protein FASTA sequence database (28847 sequences) for peptide sequence 
assignments using the following parameters: precursor ion mass tolerance of 50 ppm 
and a fragment ion mass tolerance of 0.2 Daltons. Peptides were searched using fully 
tryptic cleavage constraints, and up to two internal cleavage sites were allowed for 
tryptic digestion. Fixed modifications consisted of carbamidomethylation of cysteine. 
Variable modifications that were considered were oxidation of methionine residues. The 
Mascot search results were exported as .DAT format and then imported into the Scaffold 
software (version 4.3.2, Proteome Software) for curation, label-free quantification, 
analysis, and visualization. Overall, protein false discovery rates of less than 1% and 
peptide false discovery rates of less than 1% were obtained with Scaffold filters, and 
each protein had ≥ 2 unique peptides. The data analysis pipeline meets all MIAPE 
standards and the proteomics data have been deposited in the ProteomeExchange via 
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the Proteins Identification’s database (PRIDE) partner repository with the dataset 
identifier PXD001247 (210).   
 
Quantitative western blotting. Protein extracts were dissolved in Laemmli buffer 
containing 4% (w/v) SDS, 20% glycerol, 120 mM Tris-Cl, 0.02% (w/v) bromophenol blue, 
and 0.71 M 2-ME and heated to 95°C for five minutes. Proteins were then separated by 
SDS-PAGE in a 4-20% polyacrylamide gel. The proteins were then transferred to a 
PVDF membrane, and the membrane was blocked in Odyssey blocking buffer (LI-COR). 
The blot was incubated with primary antibody overnight at 4°C. Secondary antibodies 
with near IR emission were used, and blots were imaged using a LI-COR Odyssey 
infrared imager (LI-COR). The intensity of the bands was compared using the Odyssey 
image analysis software, version 3.0 (LI-COR). Membranes were stripped for re-probing 
by washing in NewBlot Stripping Buffer (LI-COR) twice for 15 minutes. 
 
In silico analyses. For determination of biological process, molecular function, and 
cellular component gene ontology terms for each protein, protein accession numbers 
were uploaded to the Software Tool for Rapid Annotation of Proteins (STRAP), version 
1.5 (Cardiovascular Proteomics Center, Boston University School of Medicine). For 
analysis of pathways and protein relationships, protein UniProt ID's were uploaded to 
DAVID Bioinformatics Resource 6.7 (National Institute of Allergy and Infectious Disease, 
NIH). For proteins for which a DAVID identification could not be found based on the 
UniProt ID, a Basic Local Alignment Search Tool (BLAST) search was used (National 





Statistical analyses. Three independent samples were used in each experiment and 
analyzed with a Student’s t-test (GraphPad Prism V. 6). P-values of <0.05 were 







Global proteomic profiles of naïve and stimulated PRKC and RKC1 are largely 
conserved. 
RKC1 was originally developed to serve as an in vitro model for studying Kupffer cell 
functions and processes (221). To determine whether these cells sufficiently mimic the 
phenotype of Kupffer cells, we evaluated the global proteome of both PRKC and RKC1. 
We found that of 944 total identified proteins (Table 3.2), 824 (87.3%) were shared 
between PRKC and RKC1; just 42 proteins were found only in PRKC, while 120 proteins 
were found only in RKC1 (Figure 3.5A).  
 
To further test the similarities and differences between these cell types, we performed an 
LPS stimulation to activate the cells. We identified 941 proteins, 760 (80.8%) of which 
were shared between PRKC and RKC1 post-stimulation. However, we observed that 
PRKC had 38 proteins that were not detectable in RKC1, while RKC1 had 181 proteins 
that were not found in PRKC (Figure 3.5B). 
 
Quantitative proteomic profiles of PRKC and RKC1 are altered differently after LPS 
stimulation. 
With LPS stimulation, the number of proteins identified in PRKC changed from 866 to 
798, 759 (95.1%) of which were shared between the naïve and LPS stimulated groups 
(Figure 3.5C). The number of proteins identified in RKC1 changed from 944 to 941, with 
908 (96.5%) being shared between the naïve and LPS stimulated groups (Figure 3.5D). 
To analyze these proteins further, we grouped them by pre-defined biological process 
Gene Ontology (GO) terms. When we examined the cells based on these groupings, we 
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noted no difference between the two cell types or between naïve and LPS stimulated 
conditions (Figure 3.6A-D). However, when we considered protein abundance, large 
changes in pre- vs. post-LPS stimulation were observed (Figure 3.1A-B). We noted 
significant changes in many proteins related to the basic cellular functions of DNA 
replication, translation, and transcription in response to LPS stimulation in both PRKC 
and RKC1. 
 
To further analyze these changes, we used the DAVID database 
(http://david.abcc.ncifcrf.gov/) to group the proteins into cellular pathways. We grouped 
the pathways with notable changes into three broad categories, pathways involved in 
immune functionality (Table 3.4), signaling pathways (Table 3.5), and cytoskeletal 
processes (Table 3.6). Within the proteins involved in immune functionality, we observed 
an overall trend of an increase in protein expression upon LPS stimulation, with PRKC 
demonstrating increased protein expression by at least 1.2-fold in 4 of the 8 examined 
pathway categories, while RKC1 did not increase protein expression by 1.2-fold in any 
(Table 3.4). We had expected to see a large increase in protein expression in those 
pathways involved in signaling, but did not actually observe such a trend. In fact, many 
signaling pathways actually showed a decrease in protein expression (Table 3.5).  
 
Cytoskeletal changes occurred in response to LPS stimulation. 
With respect to cytoskeletal processes, we noted that PRKC showed an increase in 
protein expression in the FcR-mediated phagocytosis pathway and a decrease in the 
endocytosis pathway. Conversely, RKC1 showed a decrease in protein expression in the 
FcR-mediated phagocytosis pathway and no appreciable change in protein abundance 
for the endocytosis pathway (Table 3.6). Given the changes in cytoskeletal protein 
abundance that we had observed independently of grouping the proteins into pathways 
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(Figure 3.1A-B, red data points), we elected to further analyze these cytoskeletal 
alterations. 
We had observed that many proteins involved in the signal transduction pathways that 
are involved in macrophage activation and the subsequent switch from phagocytosis to 
macropinocytosis (235) had been identified in our global proteomics approach (Table 
3.1). We therefore focused our analysis on coronin 1A expression due to its newly 
elucidated role in this phenotypic switch (235). Looking further down the phago-to-
macropinocytosis switch pathway, we also focused on cofilin, an actin severing protein 
that can be activated through a dephosphorylation event following coronin 1A-induced 
calcium signaling (240).  
 
Macropinocytosis is not induced in Kupffer cells by LPS stimulation. 
Previous reports suggested that coronin 1A was not present in Kupffer cells (241). 
However, using RKC1 as a model, we confirmed the presence of coronin 1A. In addition, 
we also identified downstream signaling proteins, cofilin and phospho-cofilin, in these 
cells by western blot (Figure 3.2A). We also observed that there was a low level of the 
phosphorylated form of cofilin, and that most of the cofilin was in the activated state in 
naïve or LPS-stimulated RKC1. Note that due to the limited number of PRKC available 
and the general conservation of the PRKC/RKC1 protein response profile viz. the phago-
to-macropinocytosis switch pathway, a western blot was not performed with PRKC cells.  
 
It had been previously reported that during the induction of macropinocytosis, coronin 1A 
forms punctate cytoplasmic staining that differs from its normal cell cortex concentration 
(235). We observed by immunofluorescence microscopy that coronin 1A exhibited a 
concentration at the cell cortex with some cytoplasmic staining in both PRKC and RKC1 
(Figure 3.3A, 3.3C), and LPS stimulation did not result in a switch to more punctate 
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distribution (Figures 3.3B, 3.3D). As expected, we observed a slight increase in coronin 
1A expression in RKC1 by quantitative western blot (Figure 3.2D), which is in agreement 
with our proteomic data (Table 3.3).  
 
We examined cofilin expression to monitor downstream signaling and observed that 
cofilin localized to the nucleus in both PRKC and RKC1 (Figure 3.4A, 3.4C), which is 
consistent with the localization of dephosphorylated cofilin (241). We did not observe an 
appreciable change in the localization of total cofilin upon LPS stimulation (Figure 3.4B, 
3.4D), in the localization of phospho-cofilin upon LPS stimulation (Figure 3.4E-H), or in 







Kupffer cells are essential immune sentinels in the liver. We hypothesized that the 
immortalized cell line RKC1 would perform similar signaling cascades to PRKC when 
given a pro-inflammatory stimulus. We found that while many of the proteins identified 
between the two cell populations were shared (Figure 3.5A-B), the levels of protein 
expression both before and after stimulation were much more different between the cell 
types than we had expected. PRKC displayed a more notable modulation of the entire 
proteome in response to LPS stimulation than did RKC1 (Figure 3.A-B). Not only did 
PRKC exhibit broader global changes, they also exhibited significant upregulation of 
immune process and inflammatory pathways in response to LPS (Table 3.4). In light of 
these observations, it seems RKC1 is not as responsive to immune stimulation as its 
primary cell counterparts. This may be important to bear in mind for future studies using 
this cell line, especially in the context of studying host-pathogen interactions. The RKC1 
line may not respond to a pathogenic insult in the same way as PRKC, so PRKC should 
still be used as the gold standard for immunological studies. However, our study does 
not diminish the utility of RKC1 in the study of ethanol-induced liver injury and other liver 
pathologies which involve the cellular activation of non-parenchymal cells in disease 
progression (221; 222; 223).  
 
We identified and quantified several proteins that are involved in the cytoskeletal 
modulation signal transduction pathways during KC and macrophage activation (Table 
3.1, 3.6). We focused on the coronin 1A pathway and the downstream cofilin pathway 
during the phago-to-macropinocytosis switch (235) and observed that KCs do not 
respond in this manner to LPS stimulation within the 4-hour time frame of our study. We 
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also examined coronin 1A distribution at 24 hours post-LPS stimulation and, again, did 
not observe the expected punctate staining (data not shown) that would indicate a shift 
to macropinocytosis. Taken together our study suggests, although they do not 
conclusively show, that KCs respond to LPS through classical FcR-mediated 
phagocytosis without switching to macropinocytosis. 
 
These results suggest a functional difference between KCs and monocyte-derived 
macrophages in terms of signal transduction in response to inflammatory stimuli. This is 
not surprising in light of the mounting evidence that these two lineages of macrophages 
are indeed unique (242; 243; 244; 245) and are established separately, with the tissue 
macrophages being seeded prior to birth from embryonic hematopoietic tissues (162). It 
has also been recently shown that there can be phenotypic differences between 
peritoneal tissue-resident and monocyte-derived macrophages (246). The full extent of 
the differences between KCs and monocyte-derived macrophages remains to be 
determined, but our work provides evidence that there are key functional differences 
between lineages. 
 
Our data also has potential implications for studies focused on KC-pathogen interactions 
and microbial pathogenesis. Our primary interest in understanding the fundamental 
biology of primary and immortalized KC models is rooted in the biology of malaria 
sporozoite traversal of these liver KCs, which interestingly leads to asymptomatic liver 
infection and the complete absence of a detectable inflammatory response in infected 
mammals. Our observation that KCs behave quite differently to a model inflammatory 
stimulus, such as LPS, suggests that we must take on a different tack in approaching the 
analysis of “activation” and inflammatory response cascade in these cells, especially 
when addressing the questions surrounding “immune-silencing” that have been 
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Figure 3.1. A-B. Volcano plot of quantifiable protein comparisons in primary rat 
Kupffer cells, PRKC (A) and RKC1 (B) +/–LPS with denotation of the proteins 
involved in cytoskeletal processes, translation, transcription, as well as DNA 
replication and chromatin binding. 
 





Figure 3.2 Quantitative western blot analysis of proteins involved in cytoskeletal 
rearrangements in RKC1 
Figure 3.2. A. Western blot of cofilin, phospho-cofilin, and coronin 1A with β-tubulin 
as a loading control. B-D. Relative quantification of cofilin (B), phospho-cofilin (C), 





Figure 3.3 Coronin 1A staining in primary rat Kupffer cells and RKC1 +/-LPS 
  
Figure 3.3. A-B. Immunofluorescence analysis of primary rat Kupffer cells showing 
cell morphology, DAPI staining (blue), actin (green), and coronin 1A (red) without (A) 
and with (B) LPS stimulation. C-D. Immunofluorescence of RKC1 cells showing cell 
morphology, DAPI staining (blue), actin (green), and coronin 1A (red) without (C) and 




Figure 3.4. A-B. Primary rat Kupffer cell morphology without (A) and with (B) 
LPS stimulation. C-D. RKC1 cell morphology without (C) and with (D) LPS 
stimulation. A-D. DAPI staining (blue), actin (green), and cofilin-1 (red). E-F. 
Primary rat Kupffer cells showing cell morphology, without (E) and with (F) 
LPS stimulation. G-H. RKC1 cell morphology without (G) and with (H) LPS 
stimulation. E-H. DAPI staining (blue), actin (green), and serine-3 phospho-
cofilin-1 (red). Scale bar = 7 µm. 
 





Figure 3.5 Protein identification comparisons between treatment groups in primary rat 
Kupffer cells and RKC1 
  
Figure 3.5. A. Comparison of proteins identified in PRKC and RKC1 
under naïve conditions. B. Comparison of proteins identified in 
PRKC and RKC1 after LPS stimulation. C. Comparison of proteins 
identified in PRKC under naïve conditions and after LPS stimulation. 
D. Comparison of proteins identified in RKC1 under naïve conditions 
and after LPS stimulation. 
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Figure 3.6. A-B. Biological process Gene Ontology terms from primary rat Kupffer 
cells without (A) and with (B) LPS stimulation. C-D. Biological process Gene 
Ontology terms from RKC1 without (C) and with (D) LPS stimulation. 
 
Figure 3.6 Proteins involved in cytoskeletal signaling in primary rat Kupffer cells and 
RKC1 
  
A B C D 
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Table 3.1. Proteins involved in two cytoskeletal signaling pathways, the coronin 1A 
pathway (†) and the cofilin-1 pathway (‡) are shown. Spectral counts for primary rat 
Kupffer cells and RKC1 with and without LPS stimulation are indicated. The notation 
“n.d.” indicates that the protein was not detected in a given sample. Refer to text for 
determination of spectral count values. 
Table 3.1 Proteins involved in cytoskeletal signaling found in primary rat Kupffer cells 
and RKC1 
  
   Spectral Count 
   PRKC RKC1 
Access. No. Protein Description 
Mr  
(kDa) 
naïve LPS naïve LPS 
Q5U1Y2_RAT Rac2† 21 22.39 43.88 28.16 18.04 
COR1A_RAT Coronin-1A† 51 38.33 30.35 24.71 24.75 
ARHG7_RAT Rho guanine nucleotide exchange factor 7† 73 1.65 2.39 n.d. n.d. 
PAK2_RAT Serine/threonine-protein kinase PAK 2† 58 0.97 1.2 2.06 0.31 
RHOA_RAT Transforming protein RhoA† 22 4.63 6.48 3.8 2.87 
GDIR1_RAT Rho GDP-dissociation inhibitor 1† 23 34.46 35.39 33.65 36.15 
ARP2_RAT Actin-related protein 2† 45 7.33 7.25 5.52 4.47 
ARP3_RAT Actin-related protein 3† 47 21.27 24.95 16.92 19.33 
CDC42_RAT Cell division control protein 42 homolog† 21 3.9 6.6 n.d. n.d. 
R9PXU3_RAT Protein kinase C† 52 0.34 1.69 4.09 1.24 
AT2A2_RAT 
Isoform SERCA2A of 
Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2† 
110 21.01 25.06 30.61 24.66 
CALM_RAT Calmodulin† 17 35.26 22.89 52.83 52.13 
AT2B3_RAT 
Isoform XC of Plasma membrane calcium-
transporting ATPase 3† 
138 0.67 0 1.76 0.33 
SNX5_RAT Sorting nexin-5† 47 1.32 1.21 1.19 2.23 
G3V624_RAT Coronin† 53 7.04 1.64 5.85 5.09 
COF1_RAT Cofilin-1‡ 19 33.25 32.33 68.7 50.81 




38 2.29 2.47 7.02 4.47 
PP2AA_RAT 
Serine/threonine-protein phosphatase 2A 
catalytic subunit alpha isoform‡ 
36 2.66 1.22 3.23 2.56 
82 
 
Table 3.2. Proteins identified as part of the immune system process pathway based 
on biological process Gene Ontology terms were selected from the proteomic data. 
These proteins were analyzed with respect to LPS-induced changes in each protein's 
level and in the overall expression of all proteins in the pathway. A summary showing 
the number of proteins upregulated more than 1.5-fold, between 1.0 and 1.5-fold, 
downregulated between 0.5 and 1.0-fold, and less than 0.5-fold in response to LPS 
treatment in each cell type is shown. This is further quantified as the percentage of 
proteins upregulated (greater than 1.0-fold) and downregulated (less than 1.0-fold) is 
shown. Additionally, the total relative spectral counts for all proteins within the 
pathway was added before (total naive quant.) and after LPS treatment (total LPS 
quant.) and compared (LPS/naive) as another evaluation of the pathway's overall 
change.  
 
































PRKC 7 3 4 5 202.60 167.76 0.828 36.8% 26.3% 













Table 3.3. Proteins identified as part of the inflammatory response pathway based on 
DAVID pathway classification were selected from the proteomic data. These proteins 
were analyzed with respect to LPS-induced changes in each protein's level and in 
the overall expression of all proteins in the pathway. A summary showing the number 
of proteins upregulated more than 1.5-fold, between 1.0 and 1.5-fold, downregulated 
between 0.5 and 1.0-fold, and less than 0.5-fold in response to LPS treatment in 
each cell type is shown. This is further quantified as the percentage of proteins 
upregulated (greater than 1.0-fold) and downregulated (less than 1.0-fold) is shown. 
Additionally, the total relative spectral counts for all proteins within the pathway was 
added before (total naive quant.) and after LPS treatment (total LPS quant.) and 
compared (LPS/naive) as another evaluation of the pathway's overall change.  
 



































PRKC 5 1 3 3 276.81 340.86 1.23 41.7% 25.0% 
RKC1 4 2 5 1 242.97 255.13 1.05 33.3% 8.3% 
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Table 3.4. Proteins identified as part of the immune response pathway based on 
DAVID pathway classification were selected from the proteomic data. These proteins 
were analyzed with respect to LPS-induced changes in each protein's level and in 
the overall expression of all proteins in the pathway. A summary showing the number 
of proteins upregulated more than 1.5-fold, between 1.0 and 1.5-fold, downregulated 
between 0.5 and 1.0-fold, and less than 0.5-fold in response to LPS treatment in 
each cell type is shown. This is further quantified as the percentage of proteins 
upregulated (greater than 1.0-fold) and downregulated (less than 1.0-fold) is shown. 
Additionally, the total relative spectral counts for all proteins within the pathway was 
added before (total naive quant.) and after LPS treatment (total LPS quant.) and 
compared (LPS/naive) as another evaluation of the pathway's overall change.  
 

































PRKC 8 2 4 1 607.99 808.85 1.33 53.3% 6.7% 
RKC1 3 4 7 1 600.80 588.91 0.98 20.0% 6.7% 
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Table 3.5. Proteins identified as part of the antigen processing and presentation 
pathway based on DAVID pathway classification were selected from the proteomic 
data. These proteins were analyzed with respect to LPS-induced changes in each 
protein's level and in the overall expression of all proteins in the pathway. A summary 
showing the number of proteins upregulated more than 1.5-fold, between 1.0 and 
1.5-fold, downregulated between 0.5 and 1.0-fold, and less than 0.5-fold in response 
to LPS treatment in each cell type is shown. This is further quantified as the 
percentage of proteins upregulated (greater than 1.0-fold) and downregulated (less 
than 1.0-fold) is shown. Additionally, the total relative spectral counts for all proteins 
within the pathway was added before (total naive quant.) and after LPS treatment 
(total LPS quant.) and compared (LPS/naive) as another evaluation of the pathway's 
overall change.  
 


































PRKC 0 2 5 1 3376.56 3350.46 0.99 0.0% 12.5% 
RKC1 1 3 4 0 2651.6 3016.43 1.14 12.5% 0.0% 
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Table 3.6. Proteins identified as part of the response to bacterium pathway based on 
DAVID pathway classification were selected from the proteomic data. These proteins 
were analyzed with respect to LPS-induced changes in each protein's level and in 
the overall expression of all proteins in the pathway. A summary showing the number 
of proteins upregulated more than 1.5-fold, between 1.0 and 1.5-fold, downregulated 
between 0.5 and 1.0-fold, and less than 0.5-fold in response to LPS treatment in 
each cell type is shown. This is further quantified as the percentage of proteins 
upregulated (greater than 1.0-fold) and downregulated (less than 1.0-fold) is shown. 
Additionally, the total relative spectral counts for all proteins within the pathway was 
added before (total naive quant.) and after LPS treatment (total LPS quant.) and 
compared (LPS/naive) as another evaluation of the pathway's overall change.  
 

































PRKC 3 2 3 0 970.92 1031.21 1.06 37.5% 0.0% 
RKC1 2 4 3 0 844.23 879.37 1.04 22.2% 0.0% 
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Table 3.7. Proteins identified as part of the immune effector process pathway based 
on DAVID pathway classification were selected from the proteomic data. These 
proteins were analyzed with respect to LPS-induced changes in each protein's level 
and in the overall expression of all proteins in the pathway. A summary showing the 
number of proteins upregulated more than 1.5-fold, between 1.0 and 1.5-fold, 
downregulated between 0.5 and 1.0-fold, and less than 0.5-fold in response to LPS 
treatment in each cell type is shown. This is further quantified as the percentage of 
proteins upregulated (greater than 1.0-fold) and downregulated (less than 1.0-fold) is 
shown. Additionally, the total relative spectral counts for all proteins within the 
pathway was added before (total naive quant.) and after LPS treatment (total LPS 
quant.) and compared (LPS/naive) as another evaluation of the pathway's overall 
change.  
 

































PRKC 4 2 1 0 525.43 707.38 1.35 57.1% 0.0% 
RKC1 0 3 4 0 513.45 505.90 0.98 0.0% 0.0% 
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Table 3.8. Proteins identified as part of the acute inflammatory response pathway 
based on DAVID pathway classification were selected from the proteomic data. 
These proteins were analyzed with respect to LPS-induced changes in each protein's 
level and in the overall expression of all proteins in the pathway. A summary showing 
the number of proteins upregulated more than 1.5-fold, between 1.0 and 1.5-fold, 
downregulated between 0.5 and 1.0-fold, and less than 0.5-fold in response to LPS 
treatment in each cell type is shown. This is further quantified as the percentage of 
proteins upregulated (greater than 1.0-fold) and downregulated (less than 1.0-fold) is 
shown. Additionally, the total relative spectral counts for all proteins within the 
pathway was added before (total naive quant.) and after LPS treatment (total LPS 
quant.) and compared (LPS/naive) as another evaluation of the pathway's overall 
change.  
 

































PRKC 2 1 0 1 167.42 207.78 1.24 50.0% 25.0% 
RKC1 1 2 1 0 117.16 120.01 1.02 25.0% 0.0% 
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Table 3.9. Proteins identified as part of the chemokine signaling pathway based on 
DAVID pathway classification were selected from the proteomic data. These proteins 
were analyzed with respect to LPS-induced changes in each protein's level and in 
the overall expression of all proteins in the pathway. A summary showing the number 
of proteins upregulated more than 1.5-fold, between 1.0 and 1.5-fold, downregulated 
between 0.5 and 1.0-fold, and less than 0.5-fold in response to LPS treatment in 
each cell type is shown. This is further quantified as the percentage of proteins 
upregulated (greater than 1.0-fold) and downregulated (less than 1.0-fold) is shown. 
Additionally, the total relative spectral counts for all proteins within the pathway was 
added before (total naive quant.) and after LPS treatment (total LPS quant.) and 
compared (LPS/naive) as another evaluation of the pathway's overall change.  
 

































PRKC 2 1 2 3 164.58 209.67 1.27 25.0% 37.5% 
RKC1 1 0 5 1 247.50 212.24 0.86 14.3% 14.3% 
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Table 3.10. Proteins identified as part of the signal transducer category based on 
molecular function Gene Ontology terms were selected from the proteomic data. 
These proteins were analyzed with respect to LPS-induced changes in each protein's 
level and in the overall expression of all proteins in the pathway. A summary showing 
the number of proteins upregulated more than 1.5-fold, between 1.0 and 1.5-fold, 
downregulated between 0.5 and 1.0-fold, and less than 0.5-fold in response to LPS 
treatment in each cell type is shown. This is further quantified as the percentage of 
proteins upregulated (greater than 1.0-fold) and downregulated (less than 1.0-fold) is 
shown. Additionally, the total relative spectral counts for all proteins within the 
pathway was added before (total naive quant.) and after LPS treatment (total LPS 
quant.) and compared (LPS/naive) as another evaluation of the pathway's overall 
change.  
 

































PRKC 2 2 3 3 614.22 581.41 0.95 20.0% 30.0% 
RKC1 3 0 6 2 606.09 559.88 0.92 27.3% 18.2% 
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Table 3.11. Proteins identified as part of the regulation of I-kappaB kinase/NF-
kappaB cascade and positive regulation of I-kappaB kinase/NF-kappaB cascade 
pathways based on DAVID pathway classification were selected from the proteomic 
data. These proteins were analyzed with respect to LPS-induced changes in each 
protein's level and in the overall expression of all proteins in the pathway. A summary 
showing the number of proteins upregulated more than 1.5-fold, between 1.0 and 
1.5-fold, downregulated between 0.5 and 1.0-fold, and less than 0.5-fold in response 
to LPS treatment in each cell type is shown. This is further quantified as the 
percentage of proteins upregulated (greater than 1.0-fold) and downregulated (less 
than 1.0-fold) is shown. Additionally, the total relative spectral counts for all proteins 
within the pathway was added before (total naive quant.) and after LPS treatment 
(total LPS quant.) and compared (LPS/naive) as another evaluation of the pathway's 
overall change.  
 

































PRKC 1 1 1 2 79.57 53.45 0.67 20.0% 40.0% 
RKC1 1 0 3 1 132.40 106.09 0.80 20.0% 20.0% 
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Table 3.12. Proteins identified as part of the negative regulation of NF-kappaB 
pathway based on DAVID pathway classification were selected from the proteomic 
data. These proteins were analyzed with respect to LPS-induced changes in each 
protein's level and in the overall expression of all proteins in the pathway. A summary 
showing the number of proteins upregulated more than 1.5-fold, between 1.0 and 
1.5-fold, downregulated between 0.5 and 1.0-fold, and less than 0.5-fold in response 
to LPS treatment in each cell type is shown. This is further quantified as the 
percentage of proteins upregulated (greater than 1.0-fold) and downregulated (less 
than 1.0-fold) is shown. Additionally, the total relative spectral counts for all proteins 
within the pathway was added before (total naive quant.) and after LPS treatment 
(total LPS quant.) and compared (LPS/naive) as another evaluation of the pathway's 
overall change.  
 

































PRKC 1 1 1 0 224.32 283.06 1.26 33.3% 0.0% 
RKC1 0 1 2 0 164.66 148.76 0.90 0.0% 0.0% 
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Table 3.13. Proteins identified as part of the positive regulation of kinase activity 
pathway based on DAVID pathway classification were selected from the proteomic 
data. These proteins were analyzed with respect to LPS-induced changes in each 
protein's level and in the overall expression of all proteins in the pathway. A summary 
showing the number of proteins upregulated more than 1.5-fold, between 1.0 and 
1.5-fold, downregulated between 0.5 and 1.0-fold, and less than 0.5-fold in response 
to LPS treatment in each cell type is shown. This is further quantified as the 
percentage of proteins upregulated (greater than 1.0-fold) and downregulated (less 
than 1.0-fold) is shown. Additionally, the total relative spectral counts for all proteins 
within the pathway was added before (total naive quant.) and after LPS treatment 
(total LPS quant.) and compared (LPS/naive) as another evaluation of the pathway's 
overall change.  
 

































PRKC 5 2 6 3 556.83 497.10 0.89 31.3% 18.8% 
RKC1 2 4 8 3 629.96 548.13 0.87 11.8% 17.6% 
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Table 3.14. Proteins identified as part of the MAPK signaling pathway based on 
DAVID pathway classification were selected from the proteomic data. These proteins 
were analyzed with respect to LPS-induced changes in each protein's level and in 
the overall expression of all proteins in the pathway. A summary showing the number 
of proteins upregulated more than 1.5-fold, between 1.0 and 1.5-fold, downregulated 
between 0.5 and 1.0-fold, and less than 0.5-fold in response to LPS treatment in 
each cell type is shown. This is further quantified as the percentage of proteins 
upregulated (greater than 1.0-fold) and downregulated (less than 1.0-fold) is shown. 
Additionally, the total relative spectral counts for all proteins within the pathway was 
added before (total naive quant.) and after LPS treatment (total LPS quant.) and 
compared (LPS/naive) as another evaluation of the pathway's overall change.  
 

































PRKC 5 2 2 2 382.71 460.91 1.20 45.5% 18.2% 
RKC1 1 0 7 2 390.25 319.70 0.82 10.0% 20.0% 
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Table 3.15. Proteins identified as part of the MAPKKK cascade pathway based on 
DAVID pathway classification were selected from the proteomic data. These proteins 
were analyzed with respect to LPS-induced changes in each protein's level and in 
the overall expression of all proteins in the pathway. A summary showing the number 
of proteins upregulated more than 1.5-fold, between 1.0 and 1.5-fold, downregulated 
between 0.5 and 1.0-fold, and less than 0.5-fold in response to LPS treatment in 
each cell type is shown. This is further quantified as the percentage of proteins 
upregulated (greater than 1.0-fold) and downregulated (less than 1.0-fold) is shown. 
Additionally, the total relative spectral counts for all proteins within the pathway was 
added before (total naive quant.) and after LPS treatment (total LPS quant.) and 
compared (LPS/naive) as another evaluation of the pathway's overall change.  
 

































PRKC 3 0 3 1 64.69 58.32 0.90 42.9% 14.3% 
RKC1 1 2 5 2 127.99 104.72 0.82 10.0% 20.0% 
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Table 3.16. Proteins identified as part of the regulation of phosphorylation pathway 
based on DAVID pathway classification were selected from the proteomic data. 
These proteins were analyzed with respect to LPS-induced changes in each protein's 
level and in the overall expression of all proteins in the pathway. A summary showing 
the number of proteins upregulated more than 1.5-fold, between 1.0 and 1.5-fold, 
downregulated between 0.5 and 1.0-fold, and less than 0.5-fold in response to LPS 
treatment in each cell type is shown. This is further quantified as the percentage of 
proteins upregulated (greater than 1.0-fold) and downregulated (less than 1.0-fold) is 
shown. Additionally, the total relative spectral counts for all proteins within the 
pathway was added before (total naive quant.) and after LPS treatment (total LPS 
quant.) and compared (LPS/naive) as another evaluation of the pathway's overall 
change.  
 

































PRKC 6 0 4 3 316.18 224.21 0.71 46.2% 23.1% 
RKC1 3 4 5 3 435.41 379.87 0.87 20.0% 20.0% 
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Table 3.17. Proteins identified as part of the positive regulation of Jak-STAT pathway 
based on DAVID pathway classification were selected from the proteomic data. 
These proteins were analyzed with respect to LPS-induced changes in each protein's 
level and in the overall expression of all proteins in the pathway. A summary showing 
the number of proteins upregulated more than 1.5-fold, between 1.0 and 1.5-fold, 
downregulated between 0.5 and 1.0-fold, and less than 0.5-fold in response to LPS 
treatment in each cell type is shown. This is further quantified as the percentage of 
proteins upregulated (greater than 1.0-fold) and downregulated (less than 1.0-fold) is 
shown. Additionally, the total relative spectral counts for all proteins within the 
pathway was added before (total naive quant.) and after LPS treatment (total LPS 
quant.) and compared (LPS/naive) as another evaluation of the pathway's overall 
change.  
 

































PRKC 1 0 2 0 49.81 46.54 0.93 33.3% 0.0% 
RKC1 1 0 2 0 55.51 44.86 0.81 33.3% 0.0% 
98 
 
Table 3.18. Proteins identified as part of the endocytosis pathway based on DAVID 
pathway classification were selected from the proteomic data. These proteins were 
analyzed with respect to LPS-induced changes in each protein's level and in the 
overall expression of all proteins in the pathway. A summary showing the number of 
proteins upregulated more than 1.5-fold, between 1.0 and 1.5-fold, downregulated 
between 0.5 and 1.0-fold, and less than 0.5-fold in response to LPS treatment in 
each cell type is shown. This is further quantified as the percentage of proteins 
upregulated (greater than 1.0-fold) and downregulated (less than 1.0-fold) is shown. 
Additionally, the total relative spectral counts for all proteins within the pathway was 
added before (total naive quant.) and after LPS treatment (total LPS quant.) and 
compared (LPS/naive) as another evaluation of the pathway's overall change.  
 

































PRKC 2 1 7 4 674.52 541.79 0.80 14.3% 28.6% 
RKC1 1 6 6 2 620.77 599.33 0.97 6.7% 13.3% 
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Table 3.19. Proteins identified as part of the cell activation/leukocyte activation 
pathway based on DAVID pathway classification were selected from the proteomic 
data. These proteins were analyzed with respect to LPS-induced changes in each 
protein's level and in the overall expression of all proteins in the pathway. A summary 
showing the number of proteins upregulated more than 1.5-fold, between 1.0 and 
1.5-fold, downregulated between 0.5 and 1.0-fold, and less than 0.5-fold in response 
to LPS treatment in each cell type is shown. This is further quantified as the 
percentage of proteins upregulated (greater than 1.0-fold) and downregulated (less 
than 1.0-fold) is shown. Additionally, the total relative spectral counts for all proteins 
within the pathway was added before (total naive quant.) and after LPS treatment 
(total LPS quant.) and compared (LPS/naive) as another evaluation of the pathway's 
overall change.  
 

































PRKC 5 2 2 0 592.30 647.28 1.09 55.6% 0.0% 
RKC1 1 5 3 0 517.41 544.48 1.05 11.1% 0.0% 
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Table 3.20. Proteins identified as part of the Fc gamma receptor-mediated 
phagocytosis pathway based on DAVID pathway classification were selected from 
the proteomic data. These proteins were analyzed with respect to LPS-induced 
changes in each protein's level and in the overall expression of all proteins in the 
pathway. A summary showing the number of proteins upregulated more than 1.5-
fold, between 1.0 and 1.5-fold, downregulated between 0.5 and 1.0-fold, and less 
than 0.5-fold in response to LPS treatment in each cell type is shown. This is further 
quantified as the percentage of proteins upregulated (greater than 1.0-fold) and 
downregulated (less than 1.0-fold) is shown. Additionally, the total relative spectral 
counts for all proteins within the pathway was added before (total naive quant.) and 
after LPS treatment (total LPS quant.) and compared (LPS/naive) as another 
evaluation of the pathway's overall change.  
 

































PRKC 4 2 3 0 314.23 449.19 1.43 44.4% 0.0% 




















Before initiation of the liver stage of infection, many Plasmodium sporozoites traverse 
Kupffer cells to reach hepatocytes. Previous studies have suggested that the Kupffer 
cells are immunologically silent during and following this interaction, and that the Kupffer 
cells undergo cell death in the aftermath. Little work had been previously done to 
thoroughly analyze these hypotheses. We hypothesized that upon exposure to 
Plasmodium sporozoites, Kupffer cells would indeed display an immune response and 
would not undergo cell death. By stimulating primary rat Kupffer cells with P. berghei 
sporozoites, we found that these cells do secrete a rapid, diverse, and non-specific array 
of cytokines, which was initiated by exposure to live parasites. Also, by measuring 
lactate dehydrogenase levels in the supernatant along with intracellular esterase activity 
and membrane integrity, we found that the Kupffer cells do not undergo significant 







The front-line immunological response of liver-resident Kupffer cells to 
Plasmodium berghei sporozoites 
 







Malaria is a devastating disease that causes over 400,000 deaths per year, mainly 
among children in sub-Saharan Africa. The Plasmodium parasites responsible for this 
disease use two separate hosts for their life cycle, the mosquito vector and a 
mammalian host (1). The parasite is transmitted from infected female anopheline 
mosquitoes to the skin of a human during blood feeding. Once the parasites have 
entered the subcutaneous tissue, they make their way by gliding motility to blood vessels 
and enter the bloodstream. The parasites use the bloodstream as a highway to bring 
them to their first site of invasion and development, the liver (88). Within hepatocytes, 
the parasite replicates over a 2-7-day period to form up to 40,000 merozoites that are 
capable of infecting red blood cells (RBCs) once released into the bloodstream. Unlike 
the cyclical development of Plasmodium in erythrocytes, which results in the 
manifestation of disease, the liver stage of infection is clinically silent (89).  
 
Although liver stage development marks the establishment of parasite infection in the 
vertebrate host, this step has not been as well-studied as many other steps in the 
parasite life cycle. When studying the liver stage, it is important to consider not only 
sporozoite invasion of hepatocytes but also the steps leading up to this event. The 
sporozoites must first find the liver and cross the liver sinusoidal barrier. When they have 
reached the liver through the bloodstream, the sporozoites bind to heparan sulfate 
glycosaminoglycans emanating from liver proteoglycans that are exposed through the 
vascular endothelial fenestrae via the sporozoite surface circumsporozoite protein (CSP) 
(121; 124; 135). Once the sporozoites have arrested their transit in the liver, they must 
traverse the sinusoidal barrier. This barrier notably contains liver endothelial cells and 
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Kupffer cells (KCs). Using in vivo imaging in a murine model of invasion, it is estimated 
that at least 60% of P. berghei sporozoites pass through a KC on their way to 
hepatocytes (194).  
 
KCs are also known as the liver-resident macrophages. Evidence suggests that KCs are 
formed in the liver from precursor cells derived from embryonic hematopoietic tissues 
during fetal development (162). There is also evidence for renewal from hematopoietic 
stem cells throughout life (248). KCs make up about 35% of the liver non-parenchymal 
cells in adult mice (161). They line the liver sinusoids across the Space of Disse from 
hepatocytes. Their major role is to rapidly clear bacteria and other foreign particles from 
the blood stream (165). They also play an important role in promoting immune tolerance 
in the liver to prevent unnecessary inflammation (169; 170; 171; 172). However, in cases 
of high infection levels or liver injury, KCs can serve as immune activators (249). For 
example, in Leishmania infections, KCs detect and phagocytose foreign bacteria for 
degradation and presentation as antigens to T cells (189) while simultaneously 
producing pro-inflammatory cytokines and chemokines to stimulate immune recruitment 
and activation (190). However, in the case of Plasmodium infection, studies have shown 
that sporozoites are able to traverse these KCs without being phagocytosed or killed 
(195). On the other hand, a recent report highlighted that hepatocyte growth factor 
(HGF) from KCs of infected mice is essential for promoting apoptosis of infected 
hepatocytes (202), suggesting that the KCs can produce soluble molecules to affect the 
overall state of the liver within the infection. Additionally, it was previously shown that an 
innate immune response can be induced during the liver stage, which contributes to host 
resistance to reinfection (250) and that leukocytes in the liver can respond to a 
hepatocyte-propagated type I interferon signal to respond to sporozoite infection (251). 
Furthermore, transmission of Plasmodium by mosquito bite leads to an increase in the 
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innate immune response when compared to transmission by direct injection of blood 
stage parasites, suggesting a strong role for the liver’s innate immune system in 
infection control (252). However, the full milieu of proteins released from Kupffer cells 
upon sporozoite exposure remains unknown.  
 
Additionally, when the KC is traversed by the sporozoite, it has been reported that many 
of the KCs become wounded and succumb to death (195; 196). Generally, upon cell 
injury, the injured and/or dying cells send out distress signals through the extracellular 
matrix. These signals are received by the surrounding cells, which include other KCs 
and hepatic stellate cells in the liver. In response, the stellate cells produce collagen, 
which is responsible for the resulting fibrosis seen in liver injury, and the KCs become 
activated and are drawn to the site of injury to engulf the debris. Upon activation, the 
KCs also secrete pro-inflammatory cytokines, leading to inflammation (197). These 
events have not been seen to take place upon sporozoite traversal of cells and infection 
of the liver, implying that the sporozoite is modulating the cellular responses in its favor 
through a mechanism that is not well understood. KCs are not the only cells that can be 
traversed by sporozoites; in fact, studies of hepatocytes have shown that sporozoites 
can traverse multiple hepatocytes without causing large amounts of cell death before 
finally settling inside of one (194; 136), and that this traversal is required for preparing 
the sporozoites for the final cell invasion event (137). Current data indicates that most of 
the traversed KCs become permeable to a cell-impermeant dye after traversal (194); 
however, hepatocytes do not seem to share the same fate (137).  
 
Furthermore, traversal of cells by sporozoites has been shown to be on the scale of 
minutes (194). This has historically been long enough for macrophages to begin an 
immune response; for example, lipopolysaccharide (LPS) initiates cellular changes in 
107 
 
macrophages in just 5 minutes (199; 200). While previous studies have examined 
downstream effects of sporozoite exposure on the ability of KCs to mount an immune 
response against a subsequent LPS challenge (196), few studies have addressed the 
KC’s immediate response to sporozoite exposure. Therefore, the true fate and activity of 
the KC upon traversal remain unclear.  
 
In this study, we determined the innate immunological response of primary rat Kupffer 
cells (PRKCs) to P. berghei sporozoite exposure. We also evaluated if the PRKCs 
undergo death following exposure. Our work captured a short-lived KC-cytokine 
secretion profile that was unique to live sporozoite exposure and waned over time while 








Cells. All animals and experimental protocols used in this study were approved by the 
Johns Hopkins Animal Care and Use committee and the IACUC, and the methods were 
carried out in accordance with IACUC and institutional guidelines and regulations. 
Primary rat Kupffer cells were obtained commercially (cryopreserved rat Kupffer cells, 
ThermoFisher Scientific). The cells were thawed and plated directly into 24-well plates 
on collagen-coated coverslips for assays. Alternatively, primary Kupffer cells were 
isolated using a protocol adapted from Dr. Zhaoli Sun from the Johns Hopkins School of 
Medicine (208). Male Lewis rats (150-250g) were anesthetized with isoflurane. The 
abdomen was dissected, and the portal vein was cannulated. The liver was then 
perfused with 100 ml Hank’s Buffered Saline Solution (HBSS) for 5 minutes. The inferior 
vena cava was cut to allow the fluid to drain. The liver was then perfused with 100 ml 
0.05% collagenase (Type IV from Clostridium histolyticum; Sigma-Aldrich) solution in 
HBSS over 7-10 minutes. The liver was then removed from the body cavity and washed 
with HBSS+30 mM HEPES+0.1% calcium chloride. The tissue was mashed in HBSS+30 
mM HEPES+0.1% calcium chloride with 0.05% collagenase, 0.1 mg/ml DNase, and 0.2 
mg/ml Pronase. Connective tissue was removed, and the liver cell suspension was 
incubated at 37°C for 15 minutes with agitation. Cells were then spun down at 300xg for 
5 minutes 3 times and washed with HBSS+30 mM HEPES+0.1% calcium chloride+0.05 
mg/ml DNase+1,000 units/ml penicillin+1,000 µg/ml streptomycin after each spin. Cells 
were then spun down at 100xg for 1 minute to pellet hepatocytes. The supernatant was 
collected and spun at 300xg for 5 minutes. The cell pellets were suspended in HBSS+30 
mM HEPES+0.1% calcium chloride and applied to a Percoll gradient (15 ml 50% Percoll 
solution, 15 ml 25% Percoll solution, 15 ml cell suspension). The gradients were spun 
109 
 
down at 800xg for 15 minutes without brake. The top fraction of the spun gradient was 
removed, and Kupffer cells were collected from the second fraction and washed twice 
with HBSS+30 mM HEPES+0.1% calcium chloride. The final cell pellets were then 
suspended in complete RPMI media (RPMI+10% heat-inactivated fetal bovine serum 
(HIFBS)+1x MEM amino acids solution (ThermoFisher Scientific) +1,000 units/ml 
penicillin+1,000 µg/ml streptomycin) (cRPMI) and used for plating following two different 
methods, referred to as methods 1 and 2 from hereon. (1) Cells were plated on T75 
flasks that had been coated for 48 hours with HIFBS. After cells had adhered in a 
humidified chamber at 5% CO2 and 37°C for an hour, the flasks were washed with 
HBSS+30 mM HEPES+0.1% calcium chloride 3 times, and adherent cells were lifted 
from the flasks in cold PBS on ice for 1-2 hours. This cell suspension was then used to 
plate cells in cRPMI for 12-16 hours before assays. (2) Cells were plated directly for 
assays on 24- or 48-well plates previously coated for 48 hours with HIFBS; cells were 
allowed to adhere for 2 hours in a humidified chamber at 5% CO2 and 37°C and washed 
3 times with HBSS+30mM HEPES+0.1% calcium chloride before assays. All assays 
were performed in cRPMI media. 
 
Primary rat T cells were obtained from the matched Kupffer cell donor rat. Rat spleens 
were homogenized in cRPMI. Cells were then passed through a 5-ml syringe to filter out 
tissue clumps. Cells were spun down at 300xg for 7 minutes. The cell pellet was 
suspended in red blood cell lysis buffer (ammonium chloride buffer) and incubated at 
room temperature for 10 minutes with agitation. Cells were spun down at 300xg for 5 
minutes, and the cell pellet was suspended in cRPMI. This cell suspension was then 
allowed to adhere to plates to remove adherent cells. The supernatant was collected, 
and cells were pelleted and suspended in MACs buffer (Miltenyi Biotec). Pan-T cell 
MicroBeads (Miltenyi Biotec) were added to the cell suspension and incubated on ice for 
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15 minutes. The cells were then suspended in 500 µl MACs buffer and run through an 
LS column on a MACs magnet (Miltenyi Biotec). T cells were collected from the elution 
of cells that bound to the column in the magnet.  
 
FACS analysis of isolated primary KC preparations. Primary rat Kupffer cells and T 
cells were used fresh after isolation; Kupffer cells were isolated using method (1) above 
with cells being taken for FACS analysis after lifting in PBS on ice. Kupffer cells and T 
cells were blocked with anti-FcɣR II/III (BD) to prevent nonspecific binding. Cells were 
then stained with anti-F4/80-PE-Cy7 and anti-CD3-AF488 (BioLegend). Propidium iodide 
was used to determine cell viability. Cells were analyzed on a DakoCytomation MoFlo 
(Beckman Coulter). 
 
Sporozoite generation and collection. Anopheles stephensi (day 6-10) mosquitoes 
were fed on a mouse infected with P. berghei mCherry parasites or P. berghei SPECT2- 
parasites exhibiting 0.5-2 exflagellations per field under a 40x objective. Fully fed 
mosquitoes were dissected 18-24 days post-feed to collect salivary gland sporozoites; 
unfed mosquitoes reared in parallel were dissected simultaneously to collect uninfected 
salivary gland extracts. Mosquitoes were collected in 70% ethanol, then transferred to 
PBS in a petri dish on ice; salivary gland pairs were dissected and collected into 500 µl 
cRPMI on ice; the glands were lightly spun for 3 minutes at 1,200xg and then crushed by 
hand with a plastic, sterile pestle; this 500 µl crushed preparation was then filtered 
through glass wool before use. Both sporozoites and uninfected salivary gland extracts 
were then diluted identically at least 10-fold in sterile cRPMI before being added to cells 
in a volume of 500 µl in 24-well plates or 200 µl in 48-well plates. Sporozoites were used 
at a ratio of 1 sporozoite:1 KC, and the analogous volume of uninfected salivary gland 
extract was used. Although we noted that direct salivary gland dissections as opposed to 
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commonly used thorax-dissections produced sporozoites without any large mosquito 
cellular debris, these sequential “dilution-washing” steps were included to “dilute” the 
potential gland-derived contaminants from the sporozoites; especially since low speed 
centrifugation does not effectively pellet sporozoites that have been released from 
salivary glands, and higher centrifugal force negatively impacts sporozoite 
viability/activity.  
 
Lysis of sporozoites was achieved by rapid freezing and thawing of sporozoites in liquid 
nitrogen (1 minute) and a 37°C water bath (4 minutes) 5 times. Fixation-mediated killing 
of sporozoites was achieved by incubating the released sporozoites in 4% 
paraformaldehyde for 20 minutes at room temperature. The sporozoites were then 
further washed in 1 ml of cRPMI and spun down to remove excess paraformaldehyde 
that would otherwise affect the KC response.    
 
Bio-Plex Cytokine Assays. Cells were plated in 24- or 48-well plates following methods 
(1) or (2) outlined in the “Cells” section. Cells were exposed to no stimuli (naïve), 
uninfected salivary gland extracts (sg), P. berghei mCherry sporozoites at a ratio of 1 
sporozoite per cell (Pb), P. berghei SPECT2- sporozoites at a ratio of 1 sporozoite per 
cell (SPECT2-), 1 µg/ml LPS (LPS), lysed P. berghei mCherry sporozoites at a ratio of 1 
sporozoite per cell (lys.), or P. berghei mCherry paraformaldehyde-fixed sporozoites at a 
ratio of 1 sporozoite per cell (fPb) and incubated in a humidified chamber at 5% CO2 and 
37°C. After the appropriate amount of time, the supernatant from the culture was 
removed and spun at 12,000xg for 10 minutes to remove any cellular debris before 
being used for analysis. Supernatants were analyzed using the Bio-Plex cytokine array 
platform following manufacturer’s instructions (Bio-Rad). Briefly, the cytokine assay 
standard(s) were reconstituted on ice for 30 minutes. A fourfold dilution series of the 
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standard was made. The Bio-Plex magnetic beads were added to the assay plate and 
washed twice. Standards, blanks, and supernatants were then added to the plate and 
allowed to bind the beads for 1 hour. The plate was washed three times, and then 
detection antibodies were added for 30 minutes. The plate was washed three times, and 
then Streptavidin-PE was added for 10 minutes. The plate was washed three times 
again, and then the beads were suspended in assay buffer to be read on a Bio-Plex 200 
instrument (Bio-Rad) using high PMT or the Luminex MAGPIX instrument. Standard 
curves for each cytokine were analyzed and optimized in the Bio-Plex Manager software 
(Bio-Rad). Kupffer cell supernatants were run in biological triplicate with technical 
duplicates. T cell supernatants were run with technical duplicates.  
 
Lactate Dehydrogenase (LDH) Assay. The lactate dehydrogenase assay (Pierce LDH 
cytotoxicity assay kit) was performed following the manufacturer’s protocol. We 
determined in our initial pilot experiments that the dextran assay, commonly used to 
determine hepatocyte cell fate following sporozoite cell traversal (253), is inappropriate 
for our system. We observed that naïve primary KCs take up dextran without any 
stimulus, which would significantly compromise qualitative/quantitative measures of cell 
viability. We collected supernatants from Kupffer cells exposed to no stimuli (naïve), 
uninfected salivary gland extracts (sg), Plasmodium berghei sporozoites (Pb), or lysed 
P. berghei sporozoites (lys.) for use in the LDH assay. The reaction mix from the kit was 
added to the supernatants and incubated for 30 minutes. Stop solution was then added, 
and the absorbances at 490 nm and 680 nm were measured. The background 680 nm 
absorbance was subtracted from each read, and the output was normalized to the kit 




Live/Dead cell imaging assay. Due to the existence of multiple forms of cell death that 
can involve many different pathways (254), we included an orthogonal assay to measure 
KC viability following sporozoite exposure. The LDH assay typically detects cells 
undergoing necrosis, but not necessarily other forms of cell death such as apoptotic, 
quasi-apoptotic, and nonapoptotic mechanisms (255; 256). Additionally, the LDH assay 
focuses on a population of cells instead of single-cell death events, which can provide 
additional information about the cell death process (257). Therefore, to supplement the 
LDH assay, we included an additional live/dead assay that allows single-cell analysis 
and is not necrosis-specific. The ThermoFisher Live/Dead cell imaging kit was used 
following the manufacturer’s protocol. Kupffer cells were plated on collagen-coated 
coverslips overnight before beginning the assay. Kupffer cells were then exposed to no 
stimuli (naïve), uninfected salivary gland extracts (sg), Plasmodium berghei mCherry 
sporozoites (Pb), or 387.5 ng/ml listeriolysin O, a pore forming toxin (LLO). After 15 
minutes, the live/dead imaging reagent mix was added to the cells. Cells were imaged 
and the number of live and dead cells counted at 30 minutes, 1.5 hours, and 3 hours 
following cell exposure to stimuli. For each stimulus, three biological replicates were 
analyzed and five microscope fields using the 10x objective on the EVOS Cell Imaging 







Kupffer cells secrete a diverse array of cytokines in response to sporozoite exposure. 
The cytokine response of Kupffer cells to Plasmodium sporozoites remains largely 
unknown. To address this gap in knowledge, primary rat Kupffer cells (PRKC) were 
isolated and plated for the determination of cytokine secretion levels. PRKCs were 
exposed to P. berghei sporozoites, uninfected salivary gland extracts, or LPS, and 
supernatants were collected for analysis by the Bio-Plex cytokine assay. Uninfected 
salivary gland extracts that were equivalently processed (see Methods) were used as a 
control to account for mosquito proteins and other potential mosquito-derived 
contaminants that cannot be separated from sporozoites despite the most rigorous 
washing and purification steps (203; 258). We used two different methods for culturing 
the PRKCs in an attempt to minimize the natural death that occurs over time of primary 
cells kept in culture. Using both culture methods, we obtained comparable results 
(Figures 4.1, 4.2). We observed the secretion of M1 and M2 cytokines (M1: IFN-ɣ, IL-1β, 
IL-2, IL-6, IL-12p70, MCP-1, Mip-1α, Mip-3α (CCL20), RANTES (CCL5), TNF; M2: IL-1α, 
IL-4, IL-5, IL-10, IL-13, erythropoietin (EPO), vascular endothelial growth factor (VEGF); 
both/neither M1/M2: IL-7 (neither), IL-17a (both)) into the PRKC culture supernatants 
that were at significantly higher levels following exposure to P. berghei sporozoites 
(isolated from mosquito salivary glands) as compared to following exposure to 
uninfected salivary gland controls (Figure 4.1). These responses occurred rapidly after 
the exposure and typically demonstrated a decrease in cytokine level from the 30 minute 
to the 1.5-hour time point. Cytokines typically seen after exposure to LPS were not 
observed with LPS treatment at such early time points. To understand the kinetics of the 
response more fully and try our alternative culturing method, we extended our time 
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series to both earlier and later time points. After just 10 minutes of exposure to 
sporozoites, Kupffer cells secreted significantly higher levels of both M1 and M2 
cytokines (Figure 4.2). This increase in cytokine secretion was also seen at 1-hour post 
exposure, but waned over the 4-hour timeframe.  
 
KC cytokine secretion is specific to exposure to live sporozoites. 
To determine if a live, intact sporozoite or simply sporozoite lysate is sufficient to activate 
KC cytokine secretion, we used freeze-thaw lysis to generate a sporozoite lysate (lys.). 
We then compared the cytokine secretion profile resulting from exposure to the 
sporozoite lysate to the cytokine secretion levels observed upon exposure to whole, live 
sporozoites. We again observed statistically significant increases in levels of cytokine 
secretion upon exposure to live sporozoites at just 10 minutes after the exposure, but 
only noted very low, if any, cytokine secretion after exposure to the lysed sporozoites 
(Figure 4.3). The rapid cytokine release waned over time, returning to baseline levels 
within 2-4 hours post exposure. To explore the requirement for live parasites and active 
secretion of parasite factor, we examined the KC cytokine secretion profile following 
exposure to either paraformaldehyde-fixed (killed) sporozoites or SPECT2- mutant 
sporozoites, which are deficient in cell traversal. Exposure to killed sporozoites also 
produced very low cytokine secretion (Figure 4.4), while exposure to the SPECT2- 
mutant sporozoites produced slightly lower cytokine secretion (Figure 4.5). 
 
T cells are not major contributors to the observed cytokine secretion. 
Several cytokines observed to be secreted in our assays were unexpected, as they are 
not stereotypically associated with macrophages (e.g., IL-2). To rule out that these 
cytokines were emanating from T cell contamination of our PRKCs, we performed FACS 
analysis following PRKC isolation. We found that our PRKCs were in fact contaminated 
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with approximately 0.6% T cells (Figure 4.6). To understand the effect these T cells may 
have on our cytokine secretion assay results, we isolated T cells from the spleen of the 
matched donor rat and stimulated these cells with P. berghei sporozoites. Supernatants 
were collected and analyzed using the same Bio-Plex assay. We conclude that the T 
cells played no significant role in secreting the cytokines assayed in the PRKCs at the 
time points studied (Figure 4.7). 
 
Kupffer cells do not undergo increased levels of cell death following sporozoite 
exposure. 
Given that previous reports have suggested that Kupffer cells undergo apoptosis and 
cell death following sporozoite exposure (196), we measured the levels of lactate 
dehydrogenase in the supernatants of PRKCs exposed to stimuli. Host cell LDH is 
released into the supernatant upon cell wounding, indicating the cells are entering the 
cell death pathway. We did not see an increase in the level of lactate dehydrogenase in 
the supernatant of the PRKCs following exposure to P. berghei sporozoites (Figure 
4.8A), suggesting that the cells were not being significantly wounded or killed. We also 
performed an alternative live/dead cell staining approach using a cell permeable calcein 
AM that measures both intracellular esterase activity and membrane integrity. When a 
cell is alive and has an intact membrane, calcein AM enters the cell and is converted to 
fluorescent calcein by intracellular esterase activity, while a dead cell with a damaged 
membrane takes up the cell impermeable nuclear dye. Similar to the results we obtained 
using the LDH assay, no significant difference was observed between the proportion of 
live cells present under naïve conditions and the proportion of live cells after exposure to 
P. berghei sporozoites (Figure 4 4B, Table 4.1). We also visually observed wounding 
using propidium iodide and fluorescent dextran, but saw no differences between 





Our data demonstrate that PRKCs mount a rapid and diverse cytokine response to 
sporozoite exposure. This PRKC response is remarkable since exposure to LPS 
resulted in more protracted release kinetics; TNF secretion from PRKCs, for example, 
does not increase until the 4-12-hour timeframe (Figures 4.1, 4.9). Additionally, the 
response to sporozoite exposure was markedly different than exposure to uninfected 
salivary gland extract. While low levels of pro- and anti-inflammatory cytokines were 
secreted in response to the uninfected salivary gland extract, secretion was statistically 
significantly higher upon exposure to sporozoites for 10 minutes, 30 minutes, 1 hour, 
and 1.5 hours for the M1-associated cytokines IFNγ, IL-12p70, Mip-3α, IL-2, and 
RANTES; the M2-associated cytokines IL-1α, IL-13, IL-4, EPO, IL-5, IL-10, and VEGF; 
and the non-M1-M2 partitioning cytokines IL-7 and IL-17 (Figures 4.1, 4.2). Uninfected 
salivary gland extract would contain any potential contaminants derived from the 
mosquito itself that would have also been present in the sporozoite pool, importantly 
allowing for a distinction between a mosquito contaminant-driven and sporozoite-driven 
cytokine response. The rapid response is also short-lived, with cytokine levels dropping 
to control levels within 2-4 hours. It has long been known that IL-1β and IL-18 can be 
stored in the cell as a soluble, inactive form that is activated for rapid secretion and 
response (259), but all other cytokines studied herein do not share this phenotype. This 
may suggest that the KCs do in fact have additional stored cytokine stocks that can be 
released immediately, as opposed to what has been observed for a targeted, PAMP-
activated response. Alternatively, the parasite may be interfering with calcium signaling 
within the cells, causing a rapid cytokine release that is not maintained as calcium 
signaling returns to normal over a 2-4-hour timeframe following traversal (260; 261). If a 
sustained production of cytokines were occurring, we would expect to see an increase in 
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secretion again by the later time points; this was not observed (Figures 4.1, 4.2). 
Additionally, cytokine secretion resulted from both MyD88-dependent and MyD88-
independent pathways. For example, IL-2 and IL-18 have both been shown to be 
secreted from monocytes and/or Kupffer cells in a MYD88-independent manner (262; 
263; 264), while IL-6 is secreted following MYD88-dependent pathways (265). These 
data suggest that the cytokine response is non-specific and not reliant on any particular 
TLR signaling path. Previous studies in Plasmodium have shown that 
glycosylphosphatidylinositol anchors can stimulate TLRs and that innate immune cells 
can recognize TLR ligands (266), though the exact roles of these processes during the 
pre-erythrocytic stages have not been well characterized.  
 
Although many of the cytokines and chemokines that we have measured in our assays 
are not frequently associated with KC responses, they have been shown to be secreted 
by KCs and/or macrophages in previous studies, i.e. RANTES, EPO, IL-5, VEGF, and 
M-CSF (263; 267; 268; 269; 270; 271). Of particular note, IL-7 is a cytokine that has not 
been previously associated with secretion by KCs. IL-7 is known to be associated with 
secretion from hepatocytes (272), but our KC isolation method excludes the collection of 
hepatocytes, and hepatocytes were never observed by microscopy in the KC cultures 
used, suggesting that KCs may also contribute to IL-7 levels in the liver. 
 
Only active, viable sporozoites can trigger this secretion of the diverse cytokine profile. 
The freeze-thaw lysed sporozoites did not stimulate any significant cytokine secretion 
(Figure 4.3), nor did fixed, killed sporozoites (Figure 4.4). Sporozoite motility was used 
as a proxy for sporozoite viability, and sporozoites maintained their motility for the entire 
4-hour culture period (data not shown). Similarly, exposure to the traversal-deficient 
SPECT2- mutant sporozoites produced slightly lower cytokine secretion than wild type 
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sporozoites, though this trend did not achieve significance (Figure 4.5). These data 
highlight the importance of parasite factors that can actively interact with the KC innate 
immune response. For example, it has been previously shown that CSP binds the low-
density lipoprotein receptor-like protein (LRP-1) on KCs to induce a cAMP-dependent 
signaling pathway to suppress the oxidative burst normally used to kill pathogens (198). 
It has also been shown that the Plasmodium sporozoite protein essential for cell 
traversal (SPECT) protein putatively interacts with KC surface proteins to facilitate cell 
traversal (273). It is likely many other poorly characterized Plasmodium proteins have 
roles that strongly affect KC function and activation. 
 
In contrast to previous reports (196), our data suggest that KCs are not in fact being 
massively wounded and killed by sporozoite exposure (Figure 4.8). A major difference 
between previous work and our study is the species and number of sporozoites used to 
interact with the KCs. In our study, we used P. berghei at a ratio of 1 sporozoite to 1 KC, 
while previous work on KC response to sporozoites used P. yoelii at a ratio of 1 
sporozoite to 1 KC and 3 sporozoites to 1 KC (196). It has been previously shown that 
memory CD8 T cell effector paths for targeting P. berghei and P. yoelii sporozoites are 
quite different (274), so it is likely there would also be species to species variation in how 
KCs respond to Plasmodium sporozoites. 
 
Overall, our study provides key insight into the KC-sporozoite interaction and opens the 
door to answering further questions about this essential step in the parasite’s life cycle. If 
we could identify a way to tailor the KC’s response towards a more effective activation of 
the body’s immune system, we could potentially eliminate the parasite’s ability to enter 








Figure 4.1. A. M1 cytokines observed in the supernatant of primary rat KCs under 
naïve conditions (naïve), after uninfected salivary gland extract exposure (sg), after 
P. berghei sporozoite exposure (Pb), or after 1 µg/ml LPS treatment (LPS). B. M2 
cytokines observed in the supernatant. C. Cytokines associated with both M1 and 
M2 phenotypes or neither observed in the supernatant. Data represent three 
biological replicates and two technical replicates with SEM. (Unpaired t test, 











Figure 4.2. A. M1 cytokines observed in the supernatant of primary rat Kupffer cell 
cultures at various times after uninfected salivary gland extract exposure (sg) or after 
P. berghei sporozoite exposure (Pb). B. M2 cytokines observed in the supernatant. 
C. Cytokines associated with both M1 and M2 or neither observed in the 
supernatant. Data represent three biological replicates and two technical replicates 
with SEM. (Bonferroni’s multiple comparison test, *p < 0.05, **p<0.01, ***p<0.001, 







Figure 4.3 Cytokine secretion from primary rat KCs is dependent upon live sporozoites 
  
Figure 4.3. A. M1 cytokines observed in the supernatant of primary rat Kupffer cell 
cultures after various times under naïve conditions (naïve), after uninfected salivary 
gland extract exposure (sg), after P. berghei sporozoite exposure (Pb), or after lysed 
P. berghei sporozoite exposure (lys.). B. M2 cytokines observed in the supernatant. 
C. Cytokines associated with both M1 and M2 or neither observed in the supernatant. 
Data represent three biological replicates and two technical replicates with SEM. 








Figure 4.4 Cytokine secretion from primary rat KCs does not occur in response to fixed, 




Figure 4.5 Cytokine secretion from primary rat KCs in response to traversal-deficient 
SPECT2-/- sporozoites  
  
Figure 4.5. A. M1 cytokines observed in the supernatant of primary rat Kupffer cell 
cultures after various times under naïve conditions (naïve), after uninfected salivary 
gland extract exposure (sg), after P. berghei sporozoite exposure (Pb), or after 
SPECT2- P. berghei sporozoite exposure (SPECT2-). B. M2 cytokines observed in 
the supernatant. Data represent three biological replicates and two technical 






Figure 4.6 FACS analysis of isolated rat liver cells   
Figure 4.6. Kupffer cells isolated 
from rats were FACS sorted using 
the F4/80 PE.Cy7 dye to stain for 
Kupffer cells and the CD3-AF488 
dye to stain for T cells. R6 
denotes where T cells fall on the 
scatter plot. The gating for T cells 
was determined using a positive 
control of T cells isolated from the 
spleen to identify which region 
these cells would populate. 
Approximately 0.6% of cells in the 





Figure 4.7. A. IL-10 cytokine levels observed in the supernatant of primary rat 
Kupffer cell cultures or purified primary rat T cell cultures after various times under 
naïve conditions (naïve), after P. berghei sporozoite exposure (Pb), after uninfected 
salivary gland extract exposure (sg), or after LPS exposure (LPS). KC data represent 
three biological replicates with SEM. T cell data represents one biological replicate 
and two technical replicates. B. Levels of various cytokines observed in the 
supernatant of primary rat T cells after 1 hour of P. berghei sporozoite exposure. 
 





Figure 4.8 Kupffer cells do not display increased levels of cell death following sporozoite 
exposure 
  
Figure 4.8. A. LDH levels in supernatants from primary rat KCs exposed to P. berghei 
sporozoites. Lactate dehydrogenase levels in the supernatant of primary rat Kupffer 
cell cultures after various times under naïve conditions (naïve), after uninfected 
salivary gland extract exposure (sg), after P. berghei sporozoite exposure (Pb), or 
after lysed P. berghei sporozoite exposure (lys). Data represent three biological 
replicates with two technical duplicates with SEM. All data is normalized to the 
positive control at 1.0. B. Live/dead cell imaging was performed on primary rat Kupffer 
cells after various times under naïve conditions (naïve), after uninfected salivary gland 
extract exposure (sg), after P. berghei sporozoite exposure (Pb), or after listerolysin O 





Figure 4.9 Cytokine secretion from Kupffer cells in response to LPS and IFN-g  
  
Figure 4.9. Primary rat Kupffer cells were exposed to 1 
µg/ml LPS, 500 U/ml IFN-γ, or 1000 U/ml IFN-γ. 
Supernatants were analyzed for the amount of TNF-α 
secreted at various time points after exposure. Data 




Table 4.1 KC death following exposure to stimuli 
  
Table 4.1. Kupffer cells were exposed to no stimuli (naïve), uninfected salivary gland 
extracts (sg), Plasmodium berghei mCherry sporozoites (Pb), or 387.5 ng/ml 
listeriolysin O, a pore forming toxin (LLO). After 15 minutes, the live/dead imaging 
reagent mix was added to the cells. Cells were imaged and the number of live and 
dead cells counted at 30 minutes, 1.5 hours, and 3 hours following cell exposure to 
stimuli. For each stimulus, three biological replicates (indicated by Coverslips 1, 2, 
and 3) were analyzed and five microscope fields using the 10x objective on the 
EVOS Cell Imaging System of each replicate were counted at each time point. The 















Chapter 5: Analysis of interactions between KCs and the Plasmodium berghei 





Macrophage migration inhibitory factor (MIF) in mammals is known to exert pro-
inflammatory effects on macrophages. Plasmodium species have a homolog of this 
protein. The P. berghei MIF (PbMIF) has been shown to be a putatively secreted protein 
from sporozoites that is essential for liver stage parasite development and can influence 
T cell function during the blood stage infection. We hypothesized that PbMIF would play 
a role in influencing Kupffer cell function during the liver stage. We sought to identify 
PbMIF interacting proteins from Kupffer cell protein lysates through SDS-PAGE analysis 
and mass spectrometry-based proteomic analysis. While our rigorous analysis identified 
putative interacting proteins, the data was not entirely compelling, and the interactions 
identified could not be confirmed through analogous methods. However, through this 
study we demonstrated that PbMIF binds to Kupffer cells, suggesting that an interaction, 
although a potentially transient one, is occurring.  
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Plasmodium berghei macrophage migration inhibitory factor and Kupffer cells 
 
Introduction 
Considering the findings outlined in the previous chapter, that Kupffer cells respond to 
sporozoite exposure with a short-lived, broad range cytokine response, it is of interest to 
understand why such a response occurs. It is known that Plasmodium sporozoites 
secrete proteins that can interact with the host cell and influence its actions. One prime 
example is CSP, which is known to be secreted into infected hepatocytes and those 
cells traversed before invasion, suggesting that CSP may even be playing a role when 
left behind inside the cell (119). CSP has also been previously shown to modify KC 
biology during sporozoite traversal (198). Another putatively secreted sporozoite protein, 
the Plasmodium homolog of the mammalian macrophage migration inhibitory factor 
(PbMIF) (203), has been found that is essential for liver stage parasite development 
(204).  
 
In mammals, MIF exists predominantly as a homotrimer made up of three 114 amino 
acid monomers; each of these is composed of two antiparallel α-helices and a four-
stranded β-sheet (275; 276). The β-sheets from the monomers fit together to form a 
barrel that can act as a channel through the center of the protein (275). The MIF protein 
contains two catalytic sites, one with keto-enol tautomerase activity and one with 
oxidoreductase activity; however, the physiological substrates and biological functions of 
these sites remain unknown (277; 278). In early studies, mammalian MIF was the first 
cytokine identified that could prevent migration of macrophages out of capillary tubes 
during a pro-inflammatory response (279; 280). Since then, MIF has been identified to 
play multiple roles in multiple cell types, such as: 1) regulating macrophage function by 
sustaining a pro-inflammatory phenotype through the inhibition of p53 (281), 2) 
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modulating cellular metabolism by inducing glycolysis and glucose uptake in skeletal 
muscles (282), 3) playing a chaperone-like function (283), and 4) acting as a ligand for 
receptor binding (284). 
 
MIF is known to bind to the HLA class II histocompatibility antigen gamma chain, also 
known as CD74; this complex also interacts with CD44, which plays a major role in the 
signaling functions (285; 286). Upon binding CD74 on B cells, MIF influences cell 
survival through a signaling cascade that results in changes in the expression of Bcl-XL 
and Bcl-2, proteins involved in the apoptosis and cell survival pathways (287). 
Furthermore, when MIF binds CD74, the cytosolic intracellular domain of CD74 can be 
released via CD74 cleavage; this domain has been shown to bind chromatin and induce 
cell survival (288). 
 
In addition to CD74, MIF is known to bind and signal through CXCR2 and CXCR4. Upon 
binding to CXCR2 or CXCR4 on monocytes and T cells, MIF induces integrin-dependent 
arrest and chemotaxis, along with calcium influx. Additionally, CXCR2 and CD74 can 
form a receptor complex to interact with MIF that leads to monocyte arrest (289). The 
ability of MIF to bind distinct receptors likely leads to its diversity of biological functions. 
 
The Plasmodium MIF proteins display high amino acid similarity and a similar structure 
to the mammalian MIF proteins (290; 291) (Figure 5.1). Additionally, it has been shown 
that PbMIF interacts with CD74 from mammalian cells (290). Plasmodium MIF is 
expressed at all stages of the parasite’s lifecycle and is important for late liver stage 
development, as mice infected with a mutant P. yoelii lacking PyMIF displayed a delay to 
patency or a complete lack of blood stage parasite development (204; 292). In the blood 
stage of Plasmodium infection, MIF is not essential, but PbMIF has been shown to play 
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a role in increasing production of pro-inflammatory cytokines in T cells, which may help 
protect the parasite from being cleared by the immune system (293). Additionally, 
neither mammalian MIF nor Plasmodium MIF contain a signal sequence for secretion; 
however, mammalian MIF is known to be secreted through a non-canonical secretion 
pathway (294), and Plasmodium MIF has also been putatively shown to be secreted 
during the sporozoite stage (203).  
 
Due to PbMIF’s pre-established roles in influencing the host immune response (293), 
along with the known roles of mammalian MIF homologs (281) and the presence of the 
PbMIF binding partner CD74 on the surface of primary rat KCs (data not shown), we 
hypothesized that PbMIF could be exerting a similar effect on the liver-resident 
macrophages, the KCs, during sporozoite traversal.  
 
The first step towards characterizing any putative effect that PbMIF may have on KCs is 
to identify the KC cell surface receptor(s) of PbMIF. Towards this goal, we produced a 
recombinant PbMIF protein containing a C-terminal biotinylation sequence for use in co-
immunoprecipitation assays aimed at identifying PbMIF-interacting proteins from the 
RKC1 cell line, which we previously confirmed to contain a nearly identical protein 







Microscopy. RKC1 cells were grown on collagen-coated coverslips overnight at 37°C in 
5% CO2 in RPMI with 10% HIFBS and penicillin/streptomycin. Cells were washed with 
PBS and fixed in 4% paraformaldehyde for 10 minutes at room temperature. Cells were 
blocked for endogenous biotin using the Endogenous Biotin Blocking Kit (ThermoFisher 
Scientific). Cells were incubated with recombinant, biotinylated PbMIF for 1 hour at room 
temperature. Cells were washed three times in PBS. Cells were incubated with a 
Streptavidin, AlexaFluor 594 conjugate (ThermoFisher Scientific, 1:1000) for 1 hour at 
room temperature. Cells were washed three times in PBS and incubated with DAPI 
(Roche, 5µg/ml) for 10 minutes. Cells were washed three times with PBS. Coverslips 
were mounted to slides and imaged on a Zeiss Axioskop 2 microscope with a ProgRes 
MFcool camera using the ProgRes CapturePro software version 2.10.0.1. 
 
Generation of KC proteins. RKC1 cells were grown in 6-well plates in RPMI+10% 
HIFBS+1x penicillin/streptomycin for 48 hours. Cells were washed twice in ice-cold PBS 
before being scraped from the plates in PBS. The cells were spun at 700xg for 5 
minutes. The supernatant was removed, and cells were lysed in 0.1% CHAPS in PBS 
with protease inhibitor cocktail (Sigma Aldrich). The cells were lysed on ice for 30 
minutes. The lysate was spun at 12,000xg for 10 minutes, and the supernatant was 
collected for use as RKC1 lysate.  
 
Biotinylation of PbMIF. PbMIF was biotinylated using the BirA enzyme and biotinylation 
reaction mixes from the Biotin Protein Ligase Kit (Avidity) following the manufacturer’s 
recommendations. Briefly, 20 µg of PbMIF was used in each reaction with equal 
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volumes Biomix A and Biomix B in 10 mM Tris pH 8.0. The BirA enzyme was added to a 
concentration of 0.2 µg/µl, and the protein was incubated for 2 hours at room 
temperature. Zeba spin columns (Pierce) were used to remove excess biotin from the 
biotinylated PbMIF (bPbMIF) mixture, and protein was concentrated using an Amicon 3K 
filter unit (EMD Millipore).  
 
Co-immunoprecipitation (in solution). Co-immunoprecipitation was performed with a 
10-fold excess of RKC1 lysate proteins to bPbMIF in PBS containing 1 mM Tris. The 
proteins were incubated overnight at 4°C. Biotinylated PbMIF and interactors were 
collected using PureProteome streptavidin magnetic beads (EMD Millipore) according to 
the manufacturer’s protocol. Briefly, PureProteome beads were added to a polystyrene 
tube and collected in a magnet. The supernatant was removed and beads were washed 
in PBS with 0.1% Tween20 (PBST). The bPbMIF+RKC1 lysate mix was then added to 
the beads and allowed to bind for 1 hour at room temperature. Unbound proteins were 
removed by collecting the beads in the magnet and removing the supernatant. The 
beads were then washed twice in PBS, using the magnet to collect the beads and 
remove the supernatant each time. The beads were suspended in Laemmli buffer and 
boiled at 95°C for 5 minutes. The beads were spun at 16,000xg for 5 minutes, and the 
supernatant was collected for SDS-PAGE analysis. 
 
Co-immunoprecipitation (on microspheres). While evidence suggests that PbMIF is a 
secreted protein during the sporozoite stage (203), the timeframe for this secretion and 
the way in which it is secreted have not been identified. For this reason, we decided to 
present PbMIF attached to a 1.0 µm microsphere to KC proteins to mimic a situation in 
which PbMIF is still attached to the sporozoite or is in complex with other secreted 
proteins upon interaction with the KCs. For this approach, bPbMIF was attached to 1.0 
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µm streptavidin microspheres (Polysciences, Inc.) prior to incubation with RKC1 lysate. 
The streptavidin microspheres were spun at 10,000xg for 5 minutes, and the 
supernatant was removed. The microspheres were washed 3 times in PBS+0.1% BSA, 
with a 10,000xg spin for 5 minutes used to remove supernatant after each wash. The 
microspheres were incubated with bPbMIF for 30 minutes on ice. The microspheres 
were then spun at 10,000xg for 5 minutes, and the supernatant was removed. The 
microspheres were washed 3 times with PBST before RKC1 lysate in a 10-fold excess 
of protein concentration compared to bPbMIF was added in PBS+1 mM Tris. This mix 
was allowed to incubate overnight at 4°C. The microspheres were spun at 10,000xg for 
5 minutes, and the supernatant was removed. The microspheres were washed 3 times 
in PBS before being suspended in Laemmli buffer and boiled at 95°C for 5 minutes. The 
microspheres were spun at 12,000xg for 5 minutes, and the supernatant was collected 
for SDS-PAGE analysis. 
 
Western blotting. Proteins were transferred to a nitrocellulose membrane following 
SDS-PAGE. The membrane was blocked in Odyssey blocking buffer (LI-COR) for 30 
minutes. Primary antibody was added and incubated overnight at 4°C. Primary 
antibodies included: anti-Yb1 (Novus Biologicals, 1:500), anti-EDH4 (GeneTex, 1:1000), 
anti-calnexin (Cell Signaling Technologies, 1:1000), and anti-HSPH90 (Fisher Scientific, 
1:1000). Membranes were washed 3 times for 5 minutes each in PBST. Secondary 
antibody was added and incubated at room temperature for 1 hour. Secondary 
antibodies used were goat anti-rabbit 680 (LI-COR, 1:10,000-20,000) and goat anti-
mouse 680 (LI-COR, 1:10,000-20,000). Membranes were washed 3 times for 5 minutes 




In-gel peptide digestion. Protein bands were cut from a Coomassie-stained acrylamide 
gel. The gel pieces were re-swelled in NH4HCO3 and dehydrated in acetonitrile 
alternatively twice. They were reduced and alkylated by incubating in 10 mM DTT for 1 
hour at 56°C and then 55 mM iodoacetamide for 45 minutes at room temperature. The 
gel pieces were washed in NH4HCO3 and acetonitrile alternatively twice. The gel pieces 
were dried in a vacuum centrifuge. Gel pieces were re-swelled on ice in 56 ng/µl trypsin 
for 45 minutes. Gel pieces were covered in an excess of 20 mM NH4HCO3 and 
incubated overnight at 37°C. The supernatant was then removed, and 50 mM NH4HCO3 
in 50% acetonitrile, 1% formic acid solution was added. The gel pieces were agitated in 
this solution for 20 minutes. The supernatant was combined with the supernatant 
obtained after the overnight incubation. Tubes with acidified peptides were placed in a 
vacuum centrifuge for 5 minutes to remove ACN, then spun at 20,000xg for 30 minutes 
to remove any remaining particulates. For analysis, 20 μl of the solution containing 
acidified and digested peptides was added to LC vials and placed in the LC-MS 
autosampler held at 4°C. 
 
LC-MS/MS of in-gel digested peptides. Analysis of digested peptides from individual 
gel slices was performed using an Agilent 1200 LC system coupled to an Agilent 6550 
Q-TOF MS via a Chip Cube interface. The LC system consisted of a loading pump, 
autosampler, and an analytical pump. The solvent system for both pumps consisted of 
water/0.1% FA (Solvent A) and ACN/0.1% FA (Solvent B). An Agilent Polaris-HR-C18 
chip (360 nL,180 Å C18 trap with a 75 μm i.d., 150 mm length, 180 Å C18 analytical 
column) was used to first trap and then separate peptides for MS analysis. Injected 
peptides were first enriched on the trap column for 4 minutes at a flow of 2 μl/minute 
using 3% B, after which the internal valve was automatically switched by the system and 
peptides were eluted onto the RP-C18 analytical column. Separation of peptides was 
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accomplished using a gradient with a flow of 300 nl/minute and a total run time of 25 
minutes. The gradient was as follows: 7% B for 2 minutes, ramping to 35% B from 2-15 
minutes, then to 70% B from 15-16 minutes, held at 70% B from 16-17 minutes, returned 
to 7% B from 17-19 minutes, and held at 7% B from 19-25 minutes to equilibrate it for 
the next run. Data dependent (autoMS2) MS acquisition was performed on eluted 
peptides by an Agilent 6550 Q-TOF MS operating in positive ionization mode. The 
source was maintained at 280 °C with a drying gas flow rate of 11 L/minute, the 
fragmentor was set to 360V, and the capillary voltage was set at 2000V initially and 
adjusted throughout the data acquisition to ensure steady spray. Precursor scans were 
obtained from 275-1700 m/z at a rate of 4 spectra/second, while MS/MS scans were 
obtained from 50-1700 m/z at a rate of 3 spectra/second. The quad was set to narrow 
isolation width (~1.3 m/z), and precursor ions were fragmented with nitrogen gas using 
variable collision energy determined by the formula 3.6V/100*m/z plus an offset of 4.8V. 
A dynamic exclusion list was used to exclude recently fragmented peptides for 0.25 
minutes after 1 MS/MS spectrum had been collected.  
  
Database searching and label-free quantification analysis. All the LC-MS/MS raw 
data were converted to Mascot generic format (.mgf) by Agilent MassHunter Qualitative 
Analysis B.06.00. Mascot version 2.4.1 was used to search the SwissProt RAT (Nov. 
2013) protein FASTA sequence database (28,847 sequences) for peptide sequence 
assignments using the following parameters: precursor ion mass tolerance of 50 ppm 
and a fragment ion mass tolerance of 0.2 Daltons. Peptides were searched using fully 
tryptic cleavage constraints, and up to two internal cleavage sites were allowed for 
tryptic digestion. Fixed modifications consisted of carbamidomethylation of cysteine. 
Variable modifications that were considered were oxidation of methionine residues. The 
Mascot search results were exported as .DAT format and then imported into the Scaffold 
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software (version 4.3.2, Proteome Software) for curation, label-free quantification, 
analysis, and visualization. Overall, protein false discovery rates of less than 1% and 
peptide false discovery rates of less than 1% were obtained with Scaffold filters, and 








PbMIF binds to Kupffer cell proteins. 
To determine whether PbMIF does in fact interact with Kupffer cell proteins, we co-
incubated bPbMIF and RKC1. We visualized the cells and bPbMIF by microscopy. 
bPbMIF could be seen binding to RKC1s both with and without RKC1 permeabilization 
(Figure 5.2), suggesting that PbMIF interacts with proteins on the surface of KCs and 
internally. 
 
In solution and on microsphere co-immunoprecipitation approaches identify putative 
PbMIF-Kupffer cell interacting protein(s). 
We used two complementary approaches to identify PbMIF-KC protein interactions. 
Using both the in solution and on microsphere approaches to pull down bPbMIF and 
potential KC-associated interacting molecules (Figures 5.3, 5.4), we initially identified 3 
proteins by mass spectrometry (Figure 5.5). These proteins were nuclease-sensitive 
element-binding protein 1 (Ybx1), a 26S protease regulatory subunit, and an 
uncharacterized protein. Previous work with Ybx1 has shown that this protein is 
traditionally a DNA and RNA binding protein involved in regulation of transcription and 
translation, but that it can also be secreted through a non-classical pathway (295); upon 
secretion, it is a regulator of inflammatory mediators and is associated with lower 
responses to inflammation (296). Based on this evidence, we chose to further pursue 
Ybx1 to probe its potential interaction with PbMIF. 
 
Subsequent analysis of Ybx-1 shows it is not a true interactor. 
Following the same procedure used for the initial bPbMIF-pulldown experiments, we 
attempted to identify Ybx-1 in the bPbMIF-pulldown protein pool by western blot. 
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Unfortunately, Ybx-1 was found after bPbMIF-pulldown both with and without bPbMIF, 
suggesting that it was not truly interacting with PbMIF specifically (Figure 5.6).  
 
In solution and on microsphere co-immunoprecipitation approaches identify additional 
putative PbMIF-Kupffer cell interacting proteins. 
After identifying Ybx-1, we performed additional bPbMIF-pulldown assays in attempts to 
identify additional interactors we may have missed in our original analysis. We further 
narrowed our results by looking for only proteins that were membrane or secreted, as we 
felt this gave us the best likelihood of finding a protein that would have the appropriate 
opportunity to interact with PbMIF in vivo. We identified three additional proteins that 
showed a putative interaction with PbMIF (Table 5.1), EH-domain containing protein 4 
(EHD4), calnexin, and heat-shock protein 90 (HSP90). EHD4 has been shown to play a 
role in vesicle budding on the plasma membrane (297). Calnexin is known for its 
endoplasmic reticulum chaperone function, but has been identified as a plasma 
membrane protein as well (298). HSP90 is another essential molecular chaperone and is 
involved in stress responses (299). We pursued all three of these putative interactors for 
further analysis. 
 
Analysis of EHD4, calnexin, and HSP90. 
As with Ybx-1, we followed the same procedure used for the initial bPbMIF-pulldown 
experiments to identify these three proteins in the co-precipitated pool by western blot. 
However, we were unable to find EHD4 or calnexin, and HSP90 appeared in both the 
bPbMIF-pulldown protein pool and the RKC1 alone protein pool (pulled down without the 







Despite using multiple bPbMIF-pulldown methods and multiple attempts, we were 
unable to confirm any verifiable PbMIF interacting proteins from the RKC1 lysate. While 
this may suggest that there is not, in fact, an interaction between PbMIF and Kupffer 
cells, this is by no means the only possibility. Another alternative is that a complex of 
proteins may be involved in an interaction, which is too large and/or complex to be pulled 
down without the proper membrane orientation and chaperones. Using an intact RKC1, 
we do see interaction between PbMIF and the cell surface (Figure 5.2), which implies 
there is some interaction that we are simply not capturing in our simplistic bPbMIF-
pulldown assays. Additionally, it could be that the biotinylated, recombinant version of 
PbMIF that we produced is not folded appropriately or not remaining folded 
appropriately. We often observed two different species of PbMIF upon gel 
electrophoresis of the recombinant protein (Figure 5.8), suggesting that there may be an 
issue with the protein’s stability or that it may be self-cleaving. Furthermore, MIF 
contains cysteines that could form disulfide bonds; while the structure of mammalian MIF 
suggests that no such bonds are formed and that the structure of MIF is very rigid (300), 
our recombinant protein could be generating aberrant disulfide bonds and taking on an 
incorrect structure. Any of these factors could play a role in complicating our bPbMIF-
pulldown. 
 
While the four proteins identified as putative PbMIF interactors could not be confirmed 
as interactors, our microscopy data (Figure 5.2) and the previous reports of PbMIF 
interactions with the mammalian host during other stages of infection (204; 293), along 
with the likelihood that PbMIF is secreted during the sporozoite stage (203), provide 
strong evidence that an interaction is occurring during the liver stage. Since it is known 
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that mammalian MIF binds to CD74, CXCR2, and CXCR4 (286; 289), and that PbMIF 
binds CD74 in previous studies (290), we hypothesize that PbMIF likely binds to one or 
more of those proteins from KCs, even though we were unable to pull them down by co-
immunoprecipitation. Based on our data, it seems likely that this interaction is between 
PbMIF and Kupffer cells, but it could be between PbMIF and other liver cells, such as 
hepatocytes, stellate cells, or other liver immune cells. Alternatively, PbMIF could have 
multiple roles in interacting with a number of different cell types within the liver. Further 
work will need to be done to characterize these interactions and produce a full picture of 




Figure 5.1 Sequence comparison from mammalian and Plasmodium MIF proteins 
  
Figure 5.1. A. Sequence alignment of the amino acid sequences of human, mouse, 
Plasmodium falciparum (Pf), and Plasmodium berghei (Pb) macrophage migration 
inhibitory factor proteins. Asterisks denote identical residues, while colons and dots 
denote residues with either high or low levels of similarity, respectively. B. Ribbon 
structure of human MIF. The conserved first residue is shown in red. Image adapted 
from Augustijn, et al., Functional characterization of the Plasmodium falciparum and 
P. berghei homologues of macrophage migration inhibitory factor. Infection and 









Figure 5.2. RKC1 cells were grown on collagen-coated coverslips 
overnight before being fixed and probed with bPbMIF. The 
interaction of bPbMIF and the RKC1 cells was probed with a 
streptavidin-594 dye. The scale bar is 100µm. 
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Figure 5.3 In solution co-immunoprecipitation of bPbMIF with RKC1 lysate proteins 
  
Figure 5.3. SDS-PAGE was used to separate and identify proteins that were pulled 
down in the presence of bPbMIF but were not pulled down from RKC1 alone. Boxes 
denote the bands that were cut from lanes 7 (RKC1 without bPbMIF) and 10 (RKC1 
with bPbMIF) for further analysis and protein identification. 
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Figure 5.4 On microsphere co-immunoprecipitation of bPbMIF and RKC1 lysate proteins 
  
Figure 5.4. SDS-PAGE was used to separate and identify proteins that were pulled 
down in the presence of bPbMIF but were not pulled down from RKC1 alone. The 
lane containing the RKC1 elution and the lane containing bPbMIF+RKC1 elution 
were cut into 15 identical bands for further analysis and protein identification. 
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Figure 5.5 Comparison of proteins identified by both co-immunoprecipitation strategies 










Nuclease-sensitive element-binding protein 1 








26S protease regulatory subunit 8 OS=Rattus 







Uncharacterized protein OS=Rattus 
norvegicus PE=1 SV=1 (homolog of human 





    
    
Figure 5.5. Proteins were identified by mass spectrometry following two different co-
immunoprecipitation strategies. A Venn-diagram showing the overlap in proteins 
identified by each method is shown. The table below provides the protein name, 
accession number, molecular weight, and sub-cellular localization for the 3 proteins 
identified in both methods. Red text denotes Ybx-1, our protein of interest.  
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Figure 5.6. SDS-PAGE was used to separate proteins, then proteins were 
transferred to a nitrocellulose membrane for western blotting. Ybx-1 was consistently 
found in both immunoprecipitations with and without bPbMIF, suggesting that this 
protein was non-specifically interacting with other components of the pull-down 
methods and not PbMIF itself. A representative blot is shown. 
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Figure 5.7 Western blot analysis of EHD4, calnexin, and HSP90 
  
Figure 5.7. SDS-PAGE was used to separate proteins, then proteins were 
transferred to a nitrocellulose membrane for western blotting. EHD4 and calnexin 
were consistently not identified on the blot, suggesting that they were not interacting 
with PbMIF. HSP90 was consistently found in both immunoprecipitations with and 
without bPbMIF, suggesting that this protein was non-specifically interacting with 
other components of the pull-down methods and not PbMIF itself. Representative 
blots are shown. 
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Figure 5.8 Two different species of PbMIF are observed upon SDS-PAGE analysis of 
the recombinant protein 
  
Figure 5.8. Recombinant PbMIF, which includes a 6xHis tag for 
purification, produced at two different times (1 and 2) was 
analyzed using SDS-PAGE (left) and western blotting (right). 
The expected size of the recombinant protein is 16 kDa. 
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Table 5.1 Identification of additional potential PbMIF interacting proteins 
Accession number Protein name MW Sub-cellular localization 
A0A0G2JW69_RAT 
Protein Krt79 (Fragment) OS=Rattus 
norvegicus GN=Krt79 PE=1 SV=1 
53 kD Intermediate filaments 
K1C15_RAT 
Keratin, type I cytoskeletal 15 
OS=Rattus norvegicus GN=Krt15 PE=1 
SV=1 
49 kD Intermediate filaments 
TIF1B_RAT 
Transcription intermediary factor 1-beta 
OS=Rattus norvegicus GN=Trim28 
PE=1 SV=2 
89 kD Nucleus 
A0A0A0MY09_RAT 
Endoplasmin OS=Rattus norvegicus 
GN=Hsp90b1 PE=1 SV=1 
93 kD Cytosol/ER 
TERA_RAT 
Transitional endoplasmic reticulum 
ATPase OS=Rattus norvegicus GN=Vcp 
PE=1 SV=3 
89 kD Cytosol/ER/nucleus 
HS90B_RAT 
Heat shock protein HSP 90-beta 






Protein Sfpq OS=Rattus norvegicus 
GN=Sfpq PE=1 SV=1 
75 kD Chromatin/nucleus/ECM 
A0A0G2K2B3_RAT 
Far upstream element-binding protein 2 







Calnexin OS=Rattus norvegicus 
GN=Canx PE=1 SV=1 
67 kD ER/ER membrane 
Q6IFZ5_RAT 
Protein Krt76 OS=Rattus norvegicus 
GN=Krt76 PE=2 SV=1 
62 kD Intermediate filament 
G3V8L3_RAT 
Lamin A, isoform CRA_b OS=Rattus 
norvegicus GN=Lmna PE=1 SV=1 
74 kD ECM/nucleoplasm 
D4A4S3_RAT 
Heat shock cognate 71 kDa protein 
OS=Rattus norvegicus GN=Hspa8 PE=3 
SV=3 
71 kD ER 
A0A140TAJ3_RAT 
Far upstream element-binding protein 1 
OS=Rattus norvegicus GN=Fubp1 PE=1 
SV=1 
68 kD Nucleus 
Q8R3Z7_RAT 
EH-domain containing 4 OS=Rattus 






T-complex protein 1 subunit gamma 








ATP synthase subunit beta (Fragment) 
OS=Rattus norvegicus GN=Atp5b PE=2 
SV=1 
37 kD Cytoplasm 
SYFA_RAT 
Phenylalanine--tRNA ligase alpha 
subunit OS=Rattus norvegicus 
GN=Farsa PE=1 SV=1 
58 kD Cytoplasm 
RLA0_RAT 
60S acidic ribosomal protein P0 
OS=Rattus norvegicus GN=Rplp0 PE=1 
SV=2 
34 kD Nucleus/cytoplasm 
Q5PQK2_RAT 
Fusion, derived from t(1216) malignant 
liposarcoma (Human) OS=Rattus 





Keratin, type II cytoskeletal 2 epidermal 







Protein Aimp1 OS=Rattus norvegicus 





Protein Krt79 (Fragment) OS=Rattus 





Keratin, type II cytoskeletal 2 epidermal 
OS=Rattus norvegicus GN=Krt2 PE=3 
SV=1 
69 kD Keratin filament 
A0A0H2UHH5_RAT 
Keratin, type II cytoskeletal 75 
OS=Rattus norvegicus GN=Krt75 PE=1 
SV=1 
62 kD Keratin filament 
A0A0H2UHU0_RAT 
40S ribosomal protein S25 OS=Rattus 
norvegicus GN=Rps25 PE=4 SV=1 
14 kD Ribosome 
RL10_RAT 
60S ribosomal protein L10 OS=Rattus 
norvegicus GN=Rpl10 PE=1 SV=3 
25 kD Cytosolic/ribosome 
D3ZX87_RAT 
Protein LOC100910017 OS=Rattus 
norvegicus GN=LOC100910017 PE=4 
SV=2 
16 kD Ribosome 
K1C13_RAT 
Keratin, type I cytoskeletal 13 







Uncharacterized protein OS=Rattus 
norvegicus PE=4 SV=1 
10 kD 
Cytosolic large ribosomal 
subunit 
M0RC65_RAT 
Cofilin 2, muscle (Predicted), isoform 
















Protein RGD1564698 OS=Rattus 
norvegicus GN=RGD1564698 PE=4 
SV=2 
19 kD 
Cytosolic small ribosomal 
subunit 
F1LT35_RAT 
Protein RGD1564606 OS=Rattus 
norvegicus GN=RGD1564606 PE=3 
SV=1 
18 kD 
Cytosolic large ribosomal 
subunit 
B2RZD1_RAT 
Protein Sec61b OS=Rattus norvegicus 





Protein Snrpd2 OS=Rattus norvegicus 
GN=Snrpd2 PE=1 SV=1 
14 kD Nucleus/cytosol/snRNPs 
K2C8_RAT 
Keratin, type II cytoskeletal 8 OS=Rattus 





Rps16 protein (Fragment) OS=Rattus 
norvegicus GN=Rps16 PE=2 SV=1 
18 kD Ribosome 
F1M9X0_RAT 
Transient receptor potential cation 
channel subfamily M member 1 




Integral component of 
membrane 
Q6IFZ5_RAT 
Protein Krt76 OS=Rattus norvegicus 






Table 5.1. Proteins from in-gel digestion performed following bPbMIF-RKC1 protein 
lysate co-immunoprecipitation were identified by mass spectrometry. Proteins were 
further analyzed by determining their sub-cellular localization. Those having a 



















Studying the Plasmodium falciparum and P. vivax liver stage has long been a challenge 
in the malaria field. There is no convenient in vivo system, as the only current options 
are a highly expensive and technically challenging humanized mouse system or 
monkeys. Even in vitro studies have proven challenging as for many years the parasites 
would only infect and develop in primary hepatocytes, which are expensive and provide 
highly variable infection rates. This has led to the need for development of an alternative 
in vitro model. Using the HC-04 cell line that was identified as being a possible substitute 
for primary hepatocytes, we have sub-cloned and modified the culture system to achieve 
higher and more reproducible levels of infection with P. falciparum. We additionally 
profiled our optimized cell line by global transcriptomic analyses, along with membrane-
targeted proteomics, to further understand what makes them susceptible to invasion. We 
identified glypican-3 as an hepatocyte surface receptor important for sporozoite invasion. 
We also identified many classes of genes involved in metabolism to be up- or down-
regulated in invasion-susceptible (HC-04) versus invasion-resistant (HepG2) 
hepatocytes. Overall, our findings have led to the creation of a new resource for the 
malaria community in the form of a facile, reproducible in vitro liver stage culture system 
featuring a well-characterized host cell for future studies.  
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Development of a novel hepatocyte model using HC-04.J7 with increased 
susceptibility to Plasmodium falciparum sporozoite invasion for multi-omics 




Malaria is a devastating disease that affects over 200 million people each year and 
causes over 438,000 deaths, mainly among young children (1). Plasmodium falciparum 
is one of the major parasites responsible for the morbidity and mortality. This parasite is 
transmitted to humans as a sporozoite through the bite of an infected female anopheline 
mosquito during blood feeding. From the bite site, the sporozoite makes its way to the 
liver, where it infects hepatocytes (88). The infection of hepatocytes is silent and causes 
no clinical symptoms, but this stage is necessary to allow the parasite to develop and 
multiply to prepare for its invasion of red blood cells, where clinical disease begins (89; 
301). The liver stage (LS) is a crucial step in the parasite’s lifecycle and progression 
towards disease; however, this step has not been as well studied as many other stages 
in the cycle for several reasons. P. falciparum can infect mice with chimeric human livers 
for in vivo modeling of this stage, but these mice are expensive and technically 
challenging to produce (153; 154). In vitro LS studies have proven equally difficult. The 
parasite infects primary human hepatocytes, but these cells do not propagate in culture, 
are in short supply, and produce highly variable infection rates (0.13% to 0.72%) (153; 
155; 156). Moreover, to help limit variability, several samples of primary hepatocytes 
from human donors need to be initially screened prior to selection of a specific lot that 
would be useful for P. falciparum LS studies. This process, while potentially mitigating 
risk of unsuccessful infections, greatly increases the cost of the approach. Together, 
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these technical challenges have limited efforts towards understanding fundamental, 
mechanistic processes mediating hepatocyte-parasite interactions.  
 
P. falciparum and P. vivax sporozoites can infect and develop in the human 
hepatocarcinoma cell line HC-04, but infection efficiency remains marginal, customarily 
between 0.13% (157) and 0.7-1% (158; 159) for P. falciparum. HC-04 is a 
spontaneously immortalized cell line, isolated from normal human hepatocytes (160). 
Recent analyses of this line suggest that unlike other commonly used hepatocarcinoma 
cell lines, such as HepG2, HC-04 exhibits more plasticity and a propensity to recover its 
epithelial characteristics (158). 
 
Recent efforts to improve P. falciparum LS culture have relied heavily on primary 
hepatocytes rather than a cell line (212) (302; 303; 304) and involved complicated and 
potentially difficult to replicate bioengineered co-culture platforms; this expertise is 
limited to a select number of laboratories. Yet, these efforts have only achieved infection 
efficiencies on par with HC-04 monoculture (158; 159). To create a more convenient and 
consistent system, it would be ideal to develop a platform that uses a readily available 
hepatocyte cell line that can be distributed as a shared resource to laboratories all over 
the world. Since it has already been shown that HC-04 can support the development of 
P. falciparum liver stages, we leveraged this capacity to develop a methodology that 
increased the invasion rate for these cells to enable downstream biological and 
therapeutic experiments.  
 
One of the key areas of focus for studies of sporozoite invasion of the liver hepatocyte 
has been the identification of molecule(s) that act as receptor(s) for the sporozoite. By 
identifying proteins on the hepatocyte surface that are responsible for sporozoite 
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invasion, vaccines or small molecule inhibitors can be developed to block these 
receptors and prevent sporozoite invasion. Over the years, several proteins have been 
identified as sporozoite receptors on hepatocytes. The first such molecule was 
Syndecan. CSP was found to bind heparan sulfate proteoglycans (HSPGs) on the 
surface of hepatocytes, and it was first hypothesized that the receptor was a member of 
the Syndecan family of HSPGs (122). Both syndecan-1 and syndecan-2 have been 
identified on hepatocytes (305); however, it was found that mice deficient in Syndecan-1 
displayed similar levels of liver infection with P. yoelii sporozoites as wild type mice 
(306). This leaves Syndecan-2 as a likely sporozoite receptor on hepatocytes (307).  
 
Another HSPG implicated as a sporozoite receptor on the hepatocyte is the low density 
lipoprotein-receptor related protein-1 (LRP1). The primary role of LRP1, which is an 
endocytic receptor that was initially isolated from the liver, is to regulate lipid metabolism 
(308; 309). CSP was found to bind tightly to this protein, and blocking LRP1 with 
receptor-associated protein (RAP) on HepG2 cells inhibited sporozoite invasion by 65% 
(310).  
 
By following up on the discovery of LRP1 and screening LRP-related host factors by 
RNAi, the class B, type I scavenger receptor (SR-BI or SCARB1) was identified as 
another receptor for sporozoites. SCARB1 is typically involved in mediating cellular 
uptake of cholesteryl esters (311). RNAi knock-down of SCARB1 reduced infection of 
Huh7 cells with P. berghei sporozoites. Furthermore, blocking SCARB1 with an antibody 
or synthetic peptides also decreased the infection rate with both P. berghei in Huh7 cells 
and P. falciparum in primary human hepatocytes (206). However, more recent results 
bring into question SCARB1’s role in P. falciparum infection; antibodies against SCARB1 
were unable to block infection in humanized mice (312). Additionally, another study 
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found that SCARB1 is involved in P. vivax sporozoite invasion, but not P. falciparum 
invasion in primary human hepatocyte culture (313). These conflicting results may be 
due to differences in lots of human hepatocytes used, which can introduce significant 
experimental variation.  
 
Another hepatocyte receptor for Plasmodium sporozoites is CD81, a tetraspanin that has 
also been implicated as a receptor for Hepatitis C virus (314). CD81-deficient mice have 
reduced parasite invasion of hepatocytes and a complete lack of late liver stage 
development following challenge with P. yoelii sporozoites. Furthermore, antibodies 
against CD81 inhibit the development of liver stage infection by P. falciparum in primary 
human hepatocyte cultures. These results were not duplicated in P. berghei, suggesting 
that this parasite invades in a CD81-independent manner (205). More recently, it has 
been shown that CD81 is essential for sporozoite rhoptry discharge in P. yoelii (315). 
 
The most recently identified hepatocyte receptor for sporozoites is EphA2. The Eph 
receptors from the receptor tyrosine kinase family and the Ephrin ligands they typically 
bind are known to be responsible for many cell-cell contacts (316). An Ephrin-like fold 
was identified in the 6-Cysteine protein family in Plasmodium (317), leading to the 
hypothesis that an Eph receptor could be involved on the hepatocyte surface. It was 
found that P. yoelii sporozoites were more likely to invade Hepa1-6 cells in vitro or 
murine hepatocytes in vivo with high levels of EphA2 expression than those with low 
levels of expression. The same phenomenon was observed with P. falciparum infection 
in HC-04 hepatocytes (207). 
 
Although multiple receptors for sporozoite invasion of hepatocytes have been identified, 
blockade against any one of these receptors does not provide complete protection from 
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the parasite (205; 206; 207; 310). This suggests that more than one molecule is involved 
and that the full set of proteins responsible for acting as sporozoite receptors for P. 
falciparum may not yet have been found.  
 
Here we report the successful establishment of a facile, reproducible platform that allows 
great than 2% invasion of P. falciparum sporozoites in an hepatocarcinoma line to 
expand the utility of in vitro studies of the liver stage. Additionally, we perform a 
comparative multi-omics analysis of our optimized HC-04 cell line to identify key 
characteristics necessary for a hepatocyte to support P. falciparum invasion, identifying 
glypican-3, an HSPG, as a key molecule involved in this process. Furthermore, we offer 
a simple template to evaluate the inhibitory activity of existing antibodies that target 
sporozoite surface antigens, which can be expanded to larger screens of panels of 
human antibodies acquired from clinical trials as well as new non-vaccine based 







Cell line maintenance. HC-04 (kindly provided by the Naval Research Laboratory) and 
HC-04 sub-cloned cell lines were maintained in T75 flasks in IMDM supplemented with 
5% heat-inactivated fetal bovine serum (HIFBS) and 1x Penicillin/Streptomycin. From 
hereon, we refer to both parental and sub-cloned cells as HC-04. Cells were split at a 
90% confluent culture by digesting the monolayer in 5 ml of 0.05% Trypsin-EDTA for 10 
minutes or until cells lift. The cell suspension was collected in a conical tube and 
centrifuged at 700xg for 7 minutes to ensure pelleting of the cells. Trypsin was removed 
and cells were suspended in media for plating, then plated at a 1:10 dilution in a new 
T75 flask in fresh IMDM with HIFBS and Penicillin/Streptomycin for maintenance of the 
line; cells were plated as needed for other uses of cells (as outlined below). 
 
Sporozoite generation. Using a membrane feeding apparatus (211), Anopheles 
stephensi (day 6-10) mosquitoes were fed a blood meal containing Plasmodium 
falciparum NF54 (WRAIR) gametocytes (diluted to 0.3% stage V gametocytemia) on day 
one of each experiment. 
 
Plating HC-04 for infection. On day 17 post-mosquito feed, 12 mm diameter coverslips 
were coated in the wells of a 24-well plate with 0.01% w/v collagen in PBS and 
incubated under UV light at room temperature for 1 hour. The collagen was removed 
and coverslips were washed once with PBS. HC-04 (50,000 per well) were plated in 24-
well plates on the collagen-coated coverslips in 500 µl “basic medium,” which is DMEM 
without glucose (Life Technologies), supplemented with 1 mM sodium pyruvate (Life 
Technologies), 1% fetal bovine serum (FBS) (Corning), and 1x Penicillin/Streptomycin 
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(Corning). Additional supplementations of the basic medium that were tested were 1x 
MEM amino acids without L-glutamine (Sigma-Aldrich), chemically-defined lipid mixture 
1 (Sigma-Aldrich) (containing 4 ng/ml arachidonic acid; 20 ng/ml linoleic, linolenic, 
myristic, oleic, palmitic, and stearic acids; 0.44 µg/ml cholesterol, 4.4 µg/ml Tween-80, 
140 ng/ml tocopherol acetate, and 200 µg/ml pluronic F-68), and 10% HIFBS. 
 
Sporozoite collection. On day 18 post-mosquito feed, 3 mosquitoes per well to be 
infected were dissected to obtain salivary glands; the salivary glands were kept in M199 
medium with 1% w/v heat inactivated bovine serum albumin (BSA) in a 1.5 ml tube on 
ice during the dissection (212; 213; 214). The tube of salivary glands was spun down at 
1,200xg for 3 minutes at room temperature. The salivary gland pellet was gently crushed 
with a plastic pestle in the 1.5 ml tube and vortexed 3 times for 3 seconds to suspend 
the salivary gland contents in the M199 medium. Using a 26-gauge needle (BD) heated 
by a Bunsen burner flame, a hole was poked in the bottom of a 500 µl tube. 
Approximately 300 µl of glass wool (Supelco) was added to the 500 µl tube, ensuring the 
glass wool fit easily at the bottom of the tube. The 500 µl tube containing glass wool was 
placed in a 1.5 ml collecting tube. The crushed salivary gland mixture was filtered 
through this 500 µl tube with glass wool approximately 200 µl at a time, spinning at 
1,200xg for 3 seconds for each 200 µl fraction at room temperature. After each spin, the 
liquid accumulated in the 1.5 ml collecting tube was transferred to a fresh 1.5 ml tube on 
ice; all fractions were combined into one 1.5 ml tube on ice. The glass wool was rinsed 
with 200 µl PBS, spinning at 1,200xg for 10 seconds at room temperature; the liquid 
accumulated in the 1.5 ml collecting tube was transferred to the 1.5 ml tube on ice that 




Infection of HC-04 with sporozoites. For the testing of the 2A10 (MRA183A, Malaria 
Research & Reference Reagent Resource Center [MR4], Bei Resources) antibody or the 
GPC3 antibody (Fisher Scientific, MAB2119), 50,000 sporozoites per well of HC-04 were 
co-incubated with antibody (for example, CSP-specific mAb clone 2A10 and mouse 
control mAb clone 1D9, diluted in culture media as outlined in Table 6.1), in 100 µl for 20 
minutes at room temperature prior to their addition to the HC-04 in 0.6 ml of basic 
medium. Unbound antibody was not removed before addition of sporozoites to the 
hepatocyte culture. 
 
For studies of liver-stage biology, 50,000 sporozoites were directly added to each well of 
HC-04 in 500 µl fresh basic media (same basic media fed to the cells on day 17 post-
mosquito feed).  
 
For glucose supplementation upon sporozoite addition, 15 mM D-glucose was added to 
the 500 µl basic media containing the sporozoites prior to addition to cells. 
 
After sporozoite addition, the plate was gently swirled 5 times by hand, and then spun at 
50xg for 2 minutes at room temperature. The plate was then incubated at 37°C in an 
incubator (5% CO2) for 10 minutes. This swirling and spinning were repeated two more 
times. Following the third centrifugation, the plate was incubated at 37°C for 24 hours 
under standard ‘normoxic’ (5% CO2) conditions or under hypoxic conditions in a hypoxia 
chamber (Billups-Rothenberg) containing 5% oxygen. 
 
Fixing and staining. After incubating sporozoites with the HC-04 cells for 24 hours, 
media was removed, and the coverslips were rinsed with 500 µl PBS. Coverslips were 
then transferred to a new 24-well plate containing 500 µl PBS. The cells were fixed in 
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110 µl 4% paraformaldehyde for 10 minutes at room temperature. Paraformaldehyde 
was removed and coverslips were rinsed with 500 µl PBS, then blocked in 500 µl 5% 
HIFBS in PBS for 30 minutes at room temperature on a shaker. HIFBS solution was 
removed, and 110 µl primary antibody was added; primary antibody was prepared by 
diluting 1 µl anti-circumsporozoite protein (CSP) 2A10 monoclonal antibody (0.89 µg/µl) 
(MRA183A, Malaria Research & Reference Reagent Resource Center [MR4], Bei 
Resources) in 1 ml PBS. Primary antibody was incubated with the cells for 20 minutes at 
room temperature on a shaker. Primary antibody was removed and coverslips were 
washed with 500 µl PBS, 4 times for 5 minutes at room temperature on a shaker. Next, 
110 µl secondary antibody was added; secondary antibody was prepared by diluting 1 µl 
Alexa Fluor488 anti-mouse (Life Technologies, A-11001) in 1 ml PBS. This was 
incubated for 20 minutes in the dark at room temperature on a shaker. The secondary 
antibody was removed, and coverslips were washed with 500 µl PBS, 2 times for 5 
minutes at room temperature on a shaker. Coverslips were then washed with 500 µl 
PBS+0.1% Tween 20 (PBST), 2 times for 5 minutes at room temperature on a shaker. 
Then 110 µl primary antibody was added, 1 µl anti-CSP 2A10 diluted in 1 ml PBST, and 
incubated for 20 minutes at room temperature on a shaker. Primary antibody was 
removed and coverslips were washed with 500 µl PBST, 4 times for 5 minutes at room 
temperature on a shaker. Then 110 µl secondary antibody was added, 1 µl Alexa Fluor 
594 (Life Technologies, A-11005) anti-mouse diluted in 1 ml PBST, and incubated for 20 
minutes at room temperature on a shaker. Secondary antibody was removed and 
coverslips were washed with 500 µl PBST, 4 times for 5 minutes at room temperature on 
a shaker. Finally, 110 µl DAPI was added (diluted in PBST to a final concentration of 5 
µg/ml) and incubated for 10 minutes at room temperature on a shaker. DAPI was 
removed and coverslips were washed with 500 µl PBST, 4 times for 5 minutes at room 
temperature on a shaker. Coverslips were then mounted to slides on a drop of Aqua 
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Poly/Mount (Polysciences, Inc.). The coverslips were allowed to set for at least 12 hours 
in the dark at 4°C before visualization. 
 
Immunofluorescence assays of hepatocyte proteins were performed similarly. HC-04 
Navy, HC-04.J7, or HepG2 were plated on collagen-coated coverslips in 24-well plates 
and grown in the appropriate media for 24 hours. Cells were then rinsed with PBS and 
fixed in 4% paraformaldehyde for 10 minutes at room temperature. Paraformaldehyde 
was removed, and coverslips were rinsed with 500 µl PBS, then blocked in 500 µl of 5% 
HIFBS in PBS for 30 minutes at room temperature on a Labnet Gyrotwister shaker. 
HIFBS solution was removed and 110 µl primary antibody was added overnight at 4°C; 
primary antibody was made using a 1:500 dilution of anti-EphA2 (BioLegend, clone 
SHM16) or anti-GPC3 (Fisher Scientific, MAB2119) in PBS. Primary antibody was 
removed, and the cells were washed with PBS. Secondary antibody (anti-mouse 
AlexaFluor 594) was diluted in PBS (1:1000) and added to the cells for 1 hour at room 
temperature. The antibody was then removed, and the cells were washed with PBS. 
Finally, DAPI (5 µg/ml) was added to the cells and incubated for 7 minutes at room 
temperature. DAPI was removed, and coverslips were washed with PBS. Coverslips 
were then mounted to slides on a drop of Aqua Poly/Mount. The coverslips were allowed 
to set for at least 12 hours in the dark at 4°C before visualization. 
 
Imaging and invasion quantification. Cells were visualized under a Nikon Eclipse 
E800 microscope using a 40x objective for invasion quantification. Beginning on the left 
side of the coverslip and moving in a straight line to the right, the number of red 
sporozoites that are NOT green (these are the sporozoites inside cells) and the number 
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of HC-04 cells in all fields were counted. The invasion rate was calculated using the 
equation:   
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑝𝑜𝑟𝑜𝑧𝑜𝑖𝑡𝑒𝑠 𝑖𝑛𝑠𝑖𝑑𝑒
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐻𝐶−04 𝑐𝑒𝑙𝑙𝑠
× 100 
 
For imaging sporozoite invasion, cells were visualized using a Nikon 90i microscope, 
and images were acquired with a Hamamatsu Orca-ER camera using the Volocity 3D 
Image Analysis Software. 
 
LC-MS/MS sample preparation. For LC-MS/MS, cells were grown in T75 flasks in the 
appropriate media for 24 hours. Cells were then washed three times with cold PBS and 
treated with 0.01% trypsin at 37°C for 5 minutes, then scraped from the flask.  
Protein sample preparation for whole proteome analysis of HC-04 in equal volumes 
MEM and F-12 supplemented with 10% HIFBS, 15 mM HEPES, 20 mM sodium 
bicarbonate, 15 µM phenol red, 200 units/ml penicillin, and 200 µg/ml streptomycin used 
at a pH of 7.4-8.0 (hereafter referred to as enhanced MEM+F12) and basic medium was 
performed as previously described (215). Briefly, cells were solubilized in SDST-lysis 
buffer and boiled at 95°C for 5 minutes. A filter-aided sample preparation (FASP) 
protocol was performed (209) using a 10 kDa molecular weight cutoff filter (EMD 
Millipore). An HPLC C18 column on an Agilent 1260 HPLC system (Agilent 
Technologies) was then used to desalt the acidified tryptic peptides. 
 
Protein sample preparation for membrane-enriched proteome analysis of HC-04 and 
HepG2 was performed by suspending cell pellets obtained from T75 flasks in lysis 
buffer. Cells were lysed by five rounds of freeze thaw lysis, during which cells were 
frozen in liquid nitrogen for 1 minute, then rapidly thawed at 37°C for 4 minutes. 
Following lysis, cells were centrifuged, and supernatant was collected as the non-
171 
 
membrane fraction. The pellet was then washed 3 times in PBS to remove residual non-
membrane proteins. The remaining pellet was solubilized in SDST-lysis buffer and 
subjected to the FASP protocol (209) using a 10 kDa molecular weight cutoff filter. An 
HPLC C18 column on an Agilent 1260 HPLC system was then used to desalt the 
acidified tryptic peptides.  
 
Online 2D LC-MS/MS. FASP-desalted peptides were dissolved in loading buffer (97.9% 
water, 2% Acetonitrile (ACN), and 0.1% formic acid (FA)) and ~20 µg of peptides was 
injected to our constructed online 2D HPLC-MS/MS system as described previously 
(158). Briefly, one SCX column was integrated into an Agilent LC-MS system comprised 
of a 1200 LC system coupled to a 6520 QTOF via an HPLC Chip Cube interface. 
Peptides were loaded into the SCX column for online SCX fractionation in the first 
dimension. The peptides were then eluted using the autosampler by injecting increasing 
concentrations of sodium chloride (NaCl) (0, 15, 30, 45, 60, 120, 160 and 300 mM NaCl 
in 2% ACN/0.1% FA; followed by one injection of 500 mM NaCl in 2% ACN/0.1% FA to 
wash the column). The salt elution was captured by a C18 enrichment column integrated 
into the Agilent Polaris-HR-Chip-3C18 chip. For separation in the second dimension, 
with the valve switched and the RPLC gradient started, the peptides were eluted from 
the enrichment column and separated by a C18 analytical column. Peptides were eluted 
from the analytical column using a gradient starting at 97% A (A: 99.9% water, 0.1% FA) 
at 300 nl/minute. The mobile phase was 3–10% B (B: 90% ACN, 9.9% water, 0.1% FA) 
for 4 minutes, 10–35% B for 56 minutes, 35–99% B for 2 minutes, and maintained at 
99% B for 6 minutes, followed by re-equilibration of the column with 3% B for 10 
minutes. Data-dependent MS acquisition was performed by an Agilent 6520 QTOF. 
Precursor MS spectra were acquired from m/z 315 to 1,700, and the top four peaks were 
selected for MS/MS analysis. Product scans were acquired from m/z 50 to 1,700 at a 
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scan rate of 1.5 spectra per second. A medium isolation width (~4 amu) was used, and a 
collision energy of slope 3.6 V/100 Da with a 2.9 V offset was applied for fragmentation. 
A dynamic exclusion list was applied with precursors excluded for 0.50 minutes after two 
MS/MS spectrum were acquired. 
 
Database searching and label-free quantification analysis. All the LC-MS/MS raw 
data were converted to Mascot generic format (.mgf) by Agilent MassHunter Qualitative 
Analysis B.04.00. Mascot version 2.4.1 was used to search the SwissProt human 2012 
protein FASTA sequence database (20,234 sequences) for peptide sequence 
assignments using the following parameters: precursor ion mass tolerance of 50 ppm 
and a fragment ion mass tolerance of 0.2 Daltons. Peptides were searched using fully 
tryptic cleavage constraints, and up to two internal cleavage sites were allowed for 
tryptic digestion. Fixed modifications consisted of carbamidomethylation of cysteine. 
Variable modifications considered were oxidation of methionine residues. The Mascot 
searched results were exported as .DAT format and then imported into the Scaffold 
software (Version 4.0.4, Proteome Software) for curation, label-free quantification 
analysis, and visualization. Scaffold’s normalized spectral counting was employed to 
compare relative protein abundance between HC-04 cell samples grown in enriched 
MEM+F12 and HC-04 grown in basic medium in each experiment as the basis for 
normalization of the spectral counts for all other LC-MS/MS data in that experiment. 
Overall, protein false discovery rates of less than 1% and peptide false discovery rates 
of less than 1% were obtained with Scaffold filters, and each protein has ≥ 2 unique 
peptides.  
 
RNA-seq. For RNA-seq analyses, HC-04 or HepG2 were grown in T75 flasks in the 
appropriate media for 24 hours. Cells were then washed twice in ice-cold PBS. Cells 
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were suspended in TRIzol to collect RNA. RNA was prepared following the 
manufacturer’s protocol (216). RNA-seq was performed on an Illumina HiSeq3000 with 
2x100 cycles based on the manufacturer’s guidelines (216).  
 
Total RNA with an OD 260/280 ratio ranging from 1.2-2.2 was used to determine the 
RNA concentration on a Qubit 2.0 Fluorometer (ThermoFisher). RNA quality was 
assessed using the Agilent 2100 Bioanalyzer. Total RNA with 28S/18S > 1 and RNA 
integrity number (RIN) ≥ 7 was used for RNA-seq library construction.  
 
Approximately 500 ng of protein-free and intact total RNA was used for library 
construction using the reagents provided in the NEBNext Ultra II RNA Library Prep 
following the manufacturer's protocol. First, 2 µl of diluted RNA was spiked with ERCC 
from the kit. Next, mRNA isolation was performed using the NEBNext Poly(A) mRNA 
Magnetic Isolation module (New England Biolabs). Then RNA was fragmented in a 
solution containing divalent cations, with incubation at 94°C. Next, first strand cDNA 
synthesis using reverse transcriptase and random primers was done. Synthesis of 
double stranded cDNA was done using the second strand master mix provided in the kit, 
followed by end-repair and dA-tailing. At this point, Illumina adaptors were ligated to the 
sample. Finally, the library was enriched by 11 cycles of amplification and purified by 
Agencourt AMPure beads (Beckman Coulter). Barcoded libraries were sized on the 
bioanalyzer and quantitated by QUBIT. Quantitative PCR was used to validate the 
library's functionality, using the KAPA Library Quantification kit (Kapa Biosystem) and 
monitoring with the BioRad Touch Real-Time PCR Detection System. Individual libraries 




Sequencing was performed on the Illumina HiSeq3000 instrument using the clustering 
and sequencing reagents provided by Illumina. Paired-end, 2x100 cycles runs require 
the combination of reagents from the 150 cycles and the 50 cycles kits. Sequencing 
reactions were set up using 5 μl of library (2.5 nM). Libraries were first denatured with 5 
μl 0.1 N NaOH for 8 minutes at room temperature. This was followed by neutralization 
with 5 µl of 200 mM Tris (pH 7.5) and mixing with 35 µl of the ExAmp reagents 
(contained in the PE-410-1001 clustering kit) according to the manufacturer’s protocol. 
Samples were clustered in the cBot clustering station using the “HiSeq 3000/4000 HD 
Exclusion Amp v1.0” protocol. Runs were set by choosing the ‘Generate FASTQ only’ 
workflow in the HiSeq Control Software v3.3.76 in the computer station that runs the 
HiSeq3000 sequencing machine (Illumina). Under these run conditions, the cluster pass-
filter was 70-75%, with a yield of 300-325 million pass-filter reads per lane. The %≥Q30 
score was typically above 95%. The reads that passed Illumina quality control filtering 
were used as raw data for further bioinformatics analysis. 
 
The RNA library construction and HiSeq 3000 sequencing run were performed at the 
Interdisciplinary Center for Biotechnology Research (ICBR) Gene Expression & 
Genotyping Core, University of Florida (UF). 
 
Reads were trimmed using Trimmomatic 0.36 (217). All leading and trailing bases with 
quality below 3 were trimmed. Reads were scanned from the 5’ end towards the 3’ end 
using a sliding window of size 4 and were cut when the average quality within the 
window dropped below 15. Reads shorter than 40 bases after trimming were discarded. 





Reads were aligned against the GRCh38 reference genome with gene annotations from 
GENCODE release 26 (both obtained April 6, 2017) using STAR 2.5.3a (218). Gene 
expression estimates were computed with the “--quantMode GeneCounts” flag, giving 
the unambiguous, unique number of reads for each gene. The GeneCounts mode is 
equivalent to running hoses-count with the union overlap resolution mode and discarding 
ambiguous reads. 
 
Differentially expressed genes were identified using DESeq2 1.28.0 (219). We compared 
all possible pairs of the three different cell lines within the same media with default 
parameters provided by DESeq2. A linear model was fit to each gene with cell line as the 
dependent variable and all gene expression estimates as independent variables. 
For each gene set, we performed a statistical enrichment test to test whether the fold 
changes within the gene set were significantly different from the distribution of fold 
changes over all genes. A p-value was computed using a two-sided Mann-Whitney U 
test. 
 
In silico analyses. For analysis of pathways and protein relationships, protein UniProt 
ID's were uploaded to DAVID Bioinformatics Resource 6.7 (National Institute of Allergy 
and Infectious Disease, NIH).  
 
MitoTracker staining. HC-04 cells were seeded on collagen-coated glass coverslips in 
24-well plates at 50,000 cells per well in either enhanced MEM+F12 medium or basic 
medium. Cells were grown for 48 hours at 37°C under standard ‘normoxic’ (5% CO2) 
conditions, then media was removed and replaced with media containing 100 nM 
MitoTracker Red CMXRos. Cells were incubated with MitoTracker for 30 minutes at 
37°C. The MitoTracker was then removed, cells were washed twice with 500 µl PBS and 
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mounted to coverslips for immediate visualization. A Zeiss Axioskop2 microscope with a 
63x objective was used for visualization. Image capture was performed using a Jenoptik 







Optimization of in vitro culture conditions to mimic the in vivo liver microenvironment for 
P. falciparum sporozoite invasion 
To increase the infection rate of P. falciparum sporozoites in the HC-04 cell line, we 
drew from published methods using primary hepatocytes (302; 303) to explore our 
prevailing hypothesis that changing culture conditions to more closely mimic in vivo liver 
conditions would increase the rate of invasion of P. falciparum in the HC-04 human 
hepatocyte cell line. We further reasoned that by understanding the proteomic changes 
that occur in HC-04 upon the alteration of growth conditions, we may gain insight into the 
changes the cells undergo in response.  
 
The original HC-04 growth media for sporozoite invasion was described as equal 
volumes minimum essential medium (MEM) and F-12 supplemented with 10% heat-
inactivated fetal bovine serum (HIFBS), 200 units/ml penicillin, and 200 µg/ml 
streptomycin; in this media, an invasion efficiency of 0.13% was achieved with P. 
falciparum sporozoites (157). Subsequently, the protocol was altered to a “culture 
medium” containing equal volumes MEM and F-12 supplemented with 10% HIFBS, 15 
mM HEPES, 20 mM sodium bicarbonate, 15 µM phenol red, 200 units/ml penicillin, and 
200 µg/ml streptomycin used at a pH of 7.4-8.0 (referred to from hereon as enhanced 
MEM+F12) (318). We previously observed that the concentration of components in 
medium has profound effects on cell biology (156), and thus, we expanded our 
previously published mass spectrometry analysis of HC-04 responses to alterations in 
media composition and culture conditions (158) to analyze the global HC-04 response to 
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alterations in media composition while also monitoring morphological changes by 
fluorescence microscopy.  
 
We first approached the goal of mimicking the in vivo liver conditions by addressing the 
glucose concentration of the media. Notably, the glucose concentration of enhanced 
MEM+F12 is approximately 8 mM, much higher than the typical 4-5.5 mM blood glucose 
level in humans (319). We decreased the glucose concentration to mimic in vivo levels 
and to counter-act what has been described as the “Warburg effect” (320). Like many 
cancer cell lines grown in aerobic conditions with high glucose concentrations, we 
hypothesized that, relative to in vivo hepatocytes, HC-04 cells had up-regulated 
glycolysis and down-regulated oxidative phosphorylation, a result of a feedback 
mechanism that limits mitochondrial respiration, also known as the “Crabtree effect” 
(321). Therefore, to push the cells back towards oxidative phosphorylation, we limited 
the amount of glucose available. HC-04 cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) without glucose, supplementing with 1 mM sodium pyruvate, 
1% fetal bovine serum, 200 units/ml penicillin, and 200 µg/ml streptomycin (hereafter 
referred to as basic medium or BM). We then used label-free quantitative proteomics to 
compare the relative abundance of proteins identified in HC-04 cells grown in the 
enhanced MEM+F12 vs. BM (Figure 6.1B). We found that, consistent with our 
hypothesis, cells grown without glucose had up-regulated proteins involved in oxidative 
phosphorylation and down-regulated those involved in glycolysis (Figure 6.1C-E). We 
also noted that many of the proteins that were highly enriched upon growth in BM were 
proteins found in the mitochondria. We performed mitochondrial staining to visualize the 
effects of the change in media on the mitochondria and noted a diffused staining pattern 
of mitochondria in HC-04 grown in enhanced MEM+F12 as opposed to the punctate 
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mitochondrial staining of HC-04 grown in BM, suggesting differences in mitochondrial 
activity (Figure 6.2).  
 
This change in medium from the enhanced MEM+F12 to BM caused the cells to adopt a 
slightly different morphology with increased spreading and granularity, decreased cell 
density (Figure 6.1A, arrows), and importantly, an increase in the number of HC-04 cells 
that were successfully invaded by sporozoites (Figure 6.3A-C). Additionally, we 
monitored cell growth following supplementation of the BM with amino acids (L-arginine, 
L-cysteine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, 
L-threonine, L-tryptophan, L-tyrosine, and L-valine) and/or a lipid mixture (arachidonic, 
linoleic, linolenic, myristic, oleic, palmitic, and stearic acids; cholesterol; Tween-80; 
tocopherol acetate; and pluronic F-68) to provide the cells with more building blocks and 
membrane material to overcome any growth deficit resulting from lower glucose levels. 
The addition of amino acids had little effect on the invasion rate, while the addition of the 
lipid mixture produced slightly higher invasion efficiency than BM alone, as well as 
greater variability in the invasion rate (Figure 6.3C). Glucose replacement immediately 
following the addition of the sporozoites, to provide the parasite with glucose it may need 
for energy production and development (322), did not increase invasion efficiency 
(Figure 6.3C). 
 
We also considered that the partial pressure of oxygen in the liver (30-75 mmHg) (323) 
is significantly lower than that usually encountered by cells in culture (110-130 mmHg) 
(302), and that hypoxic conditions for primary hepatocytes can increase infectivity with 
the murine parasites P. berghei and P. yoelii (302). We grew HC-04 cells in a hypoxic 
chamber with a 5% oxygen-air mixture and observed a moderate increase in invasion 
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efficiency over normoxic conditions, but an undesirable increase in variability of infection 
(Figure 6.3D). 
 
The HC-04.J7 clone exhibits enhanced susceptibility to sporozoite invasion 
Given the morphological differences between individual cells (Figure 6.1A) and the high 
variability in infection rates under different conditions, especially under hypoxic 
conditions (Figure 6.3D), we hypothesized that HC-04 is actually a mixed population of 
cells. Interestingly, the HC-04 cell line had never been cloned (160). If the cell line were 
homogeneous, we would have anticipated a more uniform response to the various 
culture conditions that were tested. We further hypothesized that our increased infection 
rate using the parent HC-04 in basic medium represents only a subset of favorable host 
cells for invasion by sporozoites in the mixed population. Therefore, we performed 
limited dilution sub-cloning of HC-04, giving rise to 10 sub-clones. We anticipated that 
many cultures established from a single cell would be lost following several rounds of 
passage. Of the 10 clones produced, 5 survived and continued to grow throughout the 
scale-up process from 96-well plates to T75 flasks (clones 2, 3, 5, 7 and 8) (Figure 6.4). 
Initial infection studies with the five remaining clones suggested that more of the 
sporozoites that had entered clone 7 cells (HC-04.J7) were “rounding up” or initiating LS 
development after 24 hours of incubation. Using BM only, we compared the mean 
infection rate of 1.01% (range: 0.78-1.2%) in a newly thawed stock of parental “mixed” 
population of HC-04 in an independent laboratory (Figure 6.3E) with HC-04.J7, and we 
observed a moderately enhanced mean infection rate of 3.3% (range: 2.5%-5.1%) in the 
latter (Figure 6.3F). The results for HC-04.J7 essentially mirrored the best infection rates 
observed for the parental HC-04 (Figure 6.3C), and the lower infection rate observed for 
the newly thawed line is reproducible (Figure 6.3E), suggesting the HC-04.J7 represents 
the more optimal subline of this cell. Even after being cryopreserved and shipped from 
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one lab to another, the HC-04.J7 maintain their increased ability to be invaded by P. 
falciparum sporozoites (Figure 6.3E).  
 
Comparative proteomics of HepG2, HC-04, and HC-04.J7 identified glypican-3 as a 
potential receptor for P. falciparum sporozoites 
Based on the knowledge that HepG2 does not support P. falciparum sporozoite 
invasion, but that HC-04 does and that HC-04.J7 displays an enhanced ability to 
facilitate sporozoite invasion, we hypothesized that there must be a key difference 
between HepG2 and HC-04 and the HC-04.J7 sub-clone. While there were no clear 
morphological differences between HC-04.J7 and the other HC-04 sub-clones or the 
parental line (Figure 6.4), we hypothesized that a cell surface receptor difference would 
be a key contributing factor to the marked difference in invasion. To test this hypothesis, 
we performed a targeted proteomic analysis of the three cell lines with an emphasis on 
membrane-associated molecules. While focusing on proteins that displayed statistically 
significant differences in expression between HepG2 and HC-04.J7, we further narrowed 
our search by focusing on proteins that are found on the cell membrane and that have 
putative receptor function (Figure 6.5A-B). This led us to six proteins that we considered 
as potential receptors for sporozoite invasion: integrin alpha-2, glypican-3, B-cell 
receptor-associated protein 29, transferrin receptor protein 1, integrin alpha-5, and 
transient receptor potential cation channel subfamily member 2 (Figure 6.5B).  
 
Comparative RNA-seq of HepG2, HC-04, and HC-04.J7 
To gain a more global perspective on the baseline differences in gene expression 
between the uninfected invasion-resistant HepG2 cell line and the uninfected invasion-
susceptible HC-04 and HC-014-J7 lines, we performed a global RNA-seq analysis. We 
identified several classes of transcripts that showed significantly different levels of 
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expression in HepG2 and the HC-04s. Many of these classes were involved in cellular 
metabolism, such as glucose uptake and purine metabolism, most of which are down-
regulated in HC-04.J7 (Figure 6.5C). In addition to cellular metabolism transcripts, we 
noted many transcripts involved in the apoptosis pathway and the unfolded protein 
response that displayed significant differences in expression from HepG2 to the HC-04s 
(Figure 6.5C). As expected, the differences between HC-04 and HC-04.J7 were not as 
notable as the differences between either HC-04 line and HepG2 (Figure 6.5C).  
 
Antibody-mediated inhibition of invasion 
As a proof-of-concept for the utility of our culture system as a template for testing 
potential vaccine candidates and other LS inhibitors, we performed a liver invasion 
inhibition assay using HC-04.J7 and the monoclonal antibody 2A10, which recognizes 
the NANP repeat on the P. falciparum circumsporozoite protein (324; 325). As expected, 
we observed a dose-dependent inhibition of sporozoite invasion, with 2 µg/ml of 2A10 
conferring 70% protection (Table 6.1). 
 
Additionally, we tested the ability of an anti-glypican-3 antibody to inhibit invasion of 
sporozoites in HC-04 and HC-04.J7 cells. Glypican-3 (GPC3) was identified as a 
molecule of interest in our multi-omics comparison that is present in HC-04/ HC-04.J7 
and absent in HepG2 (Figures 6.5B, 6.6A-B), and previous work has shown HSPGs like 
GPC3 play a role in sporozoite invasion (122). GPC3 is a glycosylphosphatidylinositol 
(GPI)-linked heparan sulfate proteoglycan that is present on several cell types (326). We 
hypothesized that GPC3 could play a role in sporozoite invasion due to the presence of 
the heparan sulfate chains that have been demonstrated to be involved in sporozoite 
interactions with the liver (122; 121; 327; 310). The ability of the anti-GPC3 antibody to 
block P. falciparum sporozoite invasion of HC-04 or HC-04.J7 was compared to an 
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isotype control. While anti-GPC3 had a minimal effect on invasion efficiency in HC-04 
cells (P > 0.05), it had a marked inhibitory effect on sporozoite invasion in HC-04.J7 cells 
(Figure 6.5D). However, we noted that blocking efficacy was not complete, with 
sporozoite invasion occurring in the blocked HC-04.J7 at levels comparable the HC-04 
parental line (+/- antibody). This minimum infection susceptibility is likely conferred in 
part through the presence of other known sporozoite receptor proteins, such as EphA2 








Our novel culture system provides a simple, yet elegant model for studying hepatocytes 
and liver disease. With primary human hepatocytes being expensive and difficult to 
obtain, a model utilizing an immortalized cell line is ideal. Additionally, this system allows 
us to cultivate a more in-depth understanding of what is required to make a hepatocyte 
susceptible to invasion by P. falciparum sporozoites.  
 
The development of an in vitro culture system for the study of the P. falciparum LS has 
long been a challenge for the field. The platform described herein demonstrates the 
potential of the HC-04.J7 to meet that challenge by avoiding the need for primary human 
tissue and allowing the implementation of a monoculture system. Achieving >2% invasion 
by two independent laboratories, both at Johns Hopkins and at the Walter Reed Army 
Institute of Research, makes it feasible to better study the invasion mechanism and isolate 
greater numbers of infected cells for various downstream molecular analyses.  
 
Our study also emphasizes the importance of balancing cell proliferation with the 
prevention of over-growth to allow for optimal invasion. The inverse correlation found 
between HC-04 cell density and sporozoite invasion (Figure 6.7) highlights the importance 
of controlling HC-04 growth in the system. Over-growth of cells leads to exhaustion of the 
media and a decrease in nutrient uptake by the cells (328; 329), which could have a 
negative impact on sporozoite invasion. We envision that bioengineering approaches that 
allow for HC-04.J7 huddling and polarization, while preventing over-growth, are likely to 




While we did observe slight increases in invasion with the incorporation of lipids, likely due 
to the parasite’s need for lipids to create membranes as it begins to multiply, or the use of 
hypoxia, both methods increased the variability of the invasion rate notably (Figure 6.3C-
D). Our goal was to develop an in vitro culture model to provide consistent invasion rates, 
so we elected not to include lipids or hypoxia in the final method used for antibody blocking 
assays. We believe that the increased variability observed with both culture conditions is 
due in large part to the inherent variability within the system. The hydrophobicity of the 
lipid mixture makes it difficult to dissolve in media, leading to inconsistent final 
concentrations of lipids. Similarly, the hypoxia chamber used for hypoxic culture has a 
difficult air-tight seal to maintain, allowing different levels of oxygen to enter the chamber. 
These slight changes could have also influenced the invasion rates we observed. 
Additional effort to develop or employ more efficient hypoxic chambers and consistent lipid 
mixtures is needed to explore potential improvements in P. falciparum invasion of HC-
04.J7. 
 
By comparing the HC-04 cell lines to the invasion-resistant HepG2 line, we identified some 
key components required for successful invasion (Figure 6.8). Based on our data, we 
suggest that the ideal host cell is one that up-regulates its metabolic capabilities while 
down-regulating its apoptotic tendencies. Contrary to what we expected, many of the 
previously identified cell surface receptors required for P. falciparum sporozoite invasion 
of hepatocytes were not identified in our HC-04.J7 cell line. While SCARB1 (206), 
Syndecan 2 (122), and EphA2 (207) displayed significant transcript reads in the RNA-seq 
data, their protein expression was very low or even undetectable. LRP1 (310) and CD81 
(205) displayed low transcript read numbers and very low or undetectable protein 
expression. This suggests that there may be redundancy among the receptors, as has 
been previously shown with CD81 and SCARB1 for P. berghei (313), and that some 
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receptors may function under different conditions. With the creation of this novel HC-04.J7 
line that allows a reasonable level of sporozoite invasion and can support development of 
liver stage exoerythrocytic forms (data not shown; performed at the Walter Reed Army 
Institute of Research), potential receptor molecules could be transfected in to further 
evaluate their effects and roles in sporozoite invasion. 
 
Using our multi-omics approach, we were also able to identify another receptor that is 
involved in sporozoite invasion. Glypican-3 (GPC3) is a glycosyl-phosphatidylinositol 
(GPI) anchored HSPG. Under normal conditions, GPC3 is expressed during fetal 
development, and its expression is silenced in adult tissues (330; 331). Loss of function 
mutations in GPC3 result in Simpson-Golabi-Behmel Syndrome in humans, a disease 
marked by pre- and postnatal cellular overgrowth (332; 333), suggesting that GPC3 plays 
a role in the inhibition of cellular proliferation. Through studies of GPC3’s role in cancers, 
it has been found that GPC3 affects Wnt signaling by influencing the activity of Wnt, 
Hedgehog, and bone morpho-genetic proteins (334; 335; 336), potentially leading to its 
inhibitory effects on proliferation. GPC3 has also been found to be strongly upregulated in 
clinical hepatocellular carcinomas (337), such as the HC-04 cell line, but not the HepG2 
line currently used for P. falciparum invasion studies. Previous evaluation of GPC3 with 
respect to Plasmodium sporozoite invasion has shown that it is up-regulated at the 
transcript level in HepG2-A16 cells, a HepG2 sub-line that is susceptible to P. falciparum 
sporozoite invasion but does not support further parasite development (338), upon 
infection with irradiated sporozoites (326). Additionally, GPC3 is known to interact with the 
previously-identified sporozoite receptor CD81 (339). This led to our hypothesis that GPC3 




In HC-04.J7 cells treated with anti-GPC3 antibodies, P. falciparum sporozoite invasion 
was significantly inhibited; however, it was not completely blocked. This suggests that 
GPC3 is involved as a part of a complex of proteins to act as a receptor for sporozoite 
invasion, and that GPC3 alone is not sufficient to control invasion. 
 
Beyond the application of the developed method to the study of P. falciparum liver 
invasion, this study demonstrates the utility of mimicking in vivo conditions to restore 
more organ-like features of cell lines. Many immortalized cell lines undergo a balance of 
the Warburg and Crabtree effects in energy metabolism and often adopt other properties 
very different from those of their parent tissue. By mimicking in vivo conditions, these 
cells can recover some of their more natural properties, evident in a shift away from 
glycolysis in HC-04 cells grown in basic medium, without glucose. In line with this 
phenomenon, we noted marked increases in protein expression for those proteins 
involved in the citrate cycle and the oxidative phosphorylation process (Figure 6.1B-D). 
Additionally, mitochondrial staining showed significant differences between the cells 
grown with and without glucose (Figure 6.2). Without glucose, the mitochondria appear 
much more defined; in the cells grown with glucose, MitoTracker staining is diffused 
throughout the cytoplasm. The more punctate staining of mitochondria in cells grown 
without glucose suggests that these cells may have more active mitochondria, which is 
consistent with the observation that they utilize the citrate cycle and oxidative 
phosphorylation process more heavily.  
 
Overall, this approach offers a novel, straightforward infection platform for the study of 
the P. falciparum liver stage and inhibition thereof that could be applied to the study of 
other Plasmodium species like P. vivax. By mimicking key characteristics of in vivo liver 
biology, we have moved closer to producing an environment in which the hepatocytes 
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and parasites can engage more naturally. This approach also allows for in-depth 
analysis of the cells that are more susceptible to invasion, allowing for the identification 




Figure 6.1 Global proteomic analysis of HC-04 cells grown in different culture media 
  
Figure 6.1. A. Morphological difference between HC-04 cells grown in the original 
enhanced MEM+F12 (culture media, CM) versus basic media. Arrows denote 
increased spreading and granularity in the cells grown in BM. Scale bars =16 µm. B. 
Volcano plot of quantifiable proteome comparing HC-04 protein levels when grown in 
CM and basic media. C-E. Volcano plots of the subset of proteins that fall within the 




Figure 6.2 Mitochondrial staining of HC-04 cells grown in basic and enhanced MEM+F12 
media 
  
Figure 6.2. HC-04 cells were grown for 48 hours in basic or enhanced MEM+F12 
media and stained with MitoTracker. A. HC-04 grown in enhanced MEM+F12. B. 
HC-04 grown in basic media. Scale bar ≈ 200 µm. The mitochondrial staining 
showed significant differences between the cells grown with and without glucose. 
Without glucose, the mitochondria appear much more defined; in the cells grown 
with glucose, mitochondrial staining is simply diffuse throughout the cytoplasm. The 
more punctate staining of mitochondria in cells grown without glucose suggests that 
these cells may have more functional mitochondrial units, which is consistent with 
the observation that they utilize the citrate cycle and oxidative phosphorylation 
process more heavily. 
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Figure 6.3 Enhanced invasion efficiency of Plasmodium falciparum in glucose-free 
(Basic) medium 
  
Figure 6.3. A-B. Inside-outside staining of P. falciparum sporozoites in HC-04 cells. P. falciparum 
NF54 sporozoites were allowed to invade the cells for 24 hours. Red staining denotes sporozoites 
inside cells, while yellow staining denotes sporozoites outside cells. Insets show the phase contrast 
view of the same field. A. HC-04 cells were grown in the originally published enhanced MEM+F12 mix 
that supported the invasion of P. falciparum in 0.13% of the cells (157). B. HC-04 cells were grown in 
glucose-free media (basic medium). C-D. The invasion efficiency of P. falciparum NF54 sporozoites in 
HC-04 (parental) cells. Invasion events were counted after 24 hours. C. HC-04 cells were grown 
under normoxic conditions (5% CO2); D. HC-04 cells were grown in 5% oxygen. AA: amino acids 
(arginine, cysteine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, 
tryptophan, tyrosine, valine). Lipid (arachidonic, linoleic, linolenic, myristic, oleic, palmitic, stearic, 
cholesterol, Tween-80, tocopherol acetate, and Pluronic F-68). Glc: glucose was added to the media 
at the time of sporozoite addition. Scale bars = 200 µm. No statistically significant differences were 
observed between media compositions. E-F. HC-04.J7 sub-clone invasion by sporozoites is 
compared to that of the parental HC-04. E. The mixed, parental HC-04 cell line grown in basic 
medium was infected with P. falciparum NF54 sporozoites in three biological replicate (R1-R3) 
assays. F. In parallel, the sub-clone HC-04.J7 cells grown in basic medium were infected with P. 
falciparum NF54 sporozoites in three biological replicate (R1-R3) assays. Sporozoites used for (E-F) 




Figure 6.4 Tight junction and cytoskeletal staining of HC-04 clones from limited dilution 
sub-cloning grown in enhanced MEM+F12 medium and basic medium 
  
Figure 6.4. HC-04 cells (parental or sub-clones 2, 3, 5, and 8) were grown for 24 
hours in basic or enhanced MEM+F12 medium and stained with ZO-1 and DAPI 
to show tight junction formation or stained with β-tubulin, actin, and DAPI to show 
the cytoskeleton. Sub-clones showed slightly different staining and morphology 
from the parental line and from other sub-clones. Scale bar=300 µm. Clone 2 did 
not survive well in basic medium, so cytoskeletal staining was not performed. 
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Figure 6.5. A. Volcano plot of the quantifiable surface-enriched proteome comparing 
HC-04.J7 protein levels to HepG2 protein levels when both cell lines are grown in 
IMDM. B. Proteins with a fold change greater than 1.5 and a p-value<0.05 that are 
also extracellular membrane proteins with reported receptor function when HC-04.J7 
and HepG2 normalized spectral counts are compared. C. Heatmap displaying the 
relative transcript reads of various transcripts when HC-04.J7 and HepG2 are 
compared (left), HC-04 and HepG2 are compared (center), and HC-04.J7 and HC-04 
are compared (right). D. Anti-GPC3 antibodies were used to block HC-04 or HC-
04.J7 during sporozoite invasion assays. Two independent experiments are shown 




Figure 6.6 GPC3 and EphA2 immunofluorescence assays in HC-04.J7 and HepG2 
  
Figure 6.6. A-B. HC-04.J7 cells stained with GPC3 (A) or EphA2 (B). C-D. HepG2 






Figure 6.7 Correlation between HC-04 cell density and sporozoite invasion percentage 
  Figure 6.7. HC-04 were grown for 24 hours in enhanced MEM+F12 
(with or without hepatocyte growth factor (HGF) under normoxic or 
hypoxic (hyp) conditions) or modified basic media (supplemented 
with 10% HIFBS, amino acids, and lipids), then infected with P. 
falciparum sporozoites for 24 hours. The total number of cells and 





Figure 6.8 The ideal hepatocyte for sporozoite invasion and receptor expression 
   
Figure 6.8. The schematic details pathways and processes that we expect to see in 
an ideal hepatocyte for P. falciparum sporozoite invasion. The table denotes 




Table 6.1. Demonstration of the utility of the HC-04.J7 monoculture model in 
evaluating the monoclonal antibody 2A10, which recognizes the circumsporozoite 
protein of P. falciparum. The monoclonal antibody 1D9 was used as an isotype 
matched control antibody. An ANOVA with corrections for multiple comparisons was 
used for statistical analysis. This is a representative experiment from two 
independent biological assays. 
 


















The use of immortalized Kupffer cells as a model system 
 
Primary Kupffer cells are difficult to work with, as they are terminally-differentiated cells 
that do not survive well in culture and are expensive and difficult to harvest. Additionally, 
any work with human primary Kupffer cells requires liver biopsy samples, which many 
labs cannot access. For studies of Kupffer cell biology, immunology, and interaction with 
other cell types, it is ideal to have a model that does not rely on these primary cells. The 
cell line RKC1 was developed by the Murr lab and seems to retain many of the features 
of primary Kupffer cells (221). However, upon further analysis of these cells and 
comparison with primary Kupffer cells, we found some important differences of note 
(215).  
 
While under naïve conditions the RKC1 cell line and primary rat Kupffer cells expressed 
many of the same proteins and showed similar expression levels (Figures 3.1, 3.5), upon 
immune activation with LPS they diverged significantly (Figure 3.5). Primary Kupffer cells 
displayed higher expression of most proteins involved in immune activation pathways 
(Tables 3.2-3.8). This highlights a key difference between RKC1 and primary Kupffer 
cells; RKC1 do not respond as strongly as their primary counterparts to immune 
activation. Considering these observations, we determined that while RKC1 can serve 
as a suitable model for select Kupffer cell biological processes and cellular interactions 
under naïve, steady state conditions, they are not a suitable replacement in the context 
of immunological studies.  
 
In the future it may be possible to further optimize the RKC1 system to serve as a better 
stand-in for primary Kupffer cells. We have noted in our own work that altering growth 
conditions can have profound impacts on cellular function (Chapter 6), which suggests 
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that under different growth conditions RKC1 may behave more like primary Kupffer cells. 
This could involve changing the growth media in which cells are grown, changing the 
oxygen content of their air (Chapter 6), or developing a more 3-D organoid culture set up 
that positions the cells in a more appropriate liver-like context with hepatocytes and 
stellate cells. Providing a more “scaffolded” environment with other liver cells around to 
provide more signaling cues may help direct RKC1 activity appropriately. This organoid 
approach has worked well with both embryonic and adult stem cells to provide cells the 
signaling context required for appropriate cellular function (340), such as the 
maintenance of cellular polarity and signaling capabilities (341), and could be applied in 
the future to other cell types. The use of organoids to study host-pathogen interactions 
has been growing significantly in recent years. While liver organoids have not yet been 
used in host-pathogen studies, intestinal organoid models have been successfully used 
for nearly a decade (341) and liver organoids have been successfully created (342; 343) 
 
Sporozoite-Kupffer cell interactions 
 
The intricacies of Plasmodium sporozoite and mammalian Kupffer cell interactions have 
long remained a puzzle in the malaria community. Our work highlights some key findings 
that shed light on this interaction. While evidence suggested that Kupffer cells are 
immunologically silent and undergo cell death following interaction with sporozoites (195; 
196), our results showed a very different phenotype. In our work, Kupffer cells 
responded to sporozoite exposure with a rapid, non-specific, and short-lived cytokine 
secretion (Figures 4.1, 4.2). This response was rapid; evident within just 10 minutes 
following sporozoite exposure, but quickly waned over time (Figure 4.2). Furthermore, 
this response required the presence of viable sporozoites and did not occur in the 
presence of fixed, killed sporozoites or lysed sporozoites (Figures 4.3, 4.4). This 
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suggests that the sporozoite is actively affecting the Kupffer cell to cause this cytokine 
secretion; this could be occurring either directly through cell-cell interactions or by the 
action of parasite-derived soluble factors. Additionally, our work supports the hypothesis 
that Kupffer cells do not in fact undergo cell death, but survive this interaction with 
sporozoites (Figure 4.8).  
 
Our work also suggests that there is an interaction between the P. berghei macrophage 
migration inhibitory factor (PbMIF) and Kupffer cells (Figure 5.2). While our co-
immunoprecipitation strategies were unable to identify any bona fide interacting proteins, 
evidence that PbMIF is required for late liver stage development (204) and that PbMIF 
binds to Kupffer cells (Figure 5.2) still suggests that an interaction is likely. We 
hypothesize that the purpose of this interaction is to alter the Kupffer cell’s cytokine 
release profile, based on the canonical function of MIF proteins (281), but at present the 
pathway remains elusive.  
 
The data generated in our Kupffer cell studies open several avenues for further research 
to deepen understanding of the interaction of sporozoites and Kupffer cells.  
 
The identity and function of Kupffer cell proteins involved in sporozoite entry/exit remain 
in question. A Kupffer cell protein essential for sporozoite traversal of the liver sinusoidal 
barrier has been previously identified as the triggering receptor expressed on myeloid 
cells 2 (TREM2) (344). It would be of interest to identify what sporozoite proteins interact 
with TREM2 to shed more light on how the sporozoite traversal of Kupffer cells occurs. 
 
Additionally, global Kupffer cell signaling responses to sporozoite exposure remain 
largely unknown. While our analysis focused on the downstream cytokine secretion 
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response, it would also be informative to understand more upstream processes by 
looking at RNA and protein levels and changes over time after sporozoite exposure to 
identify potentially druggable targets for disease prevention.  
 
In addition to understanding cellular processes within the Kupffer cell itself, 
understanding the full liver’s response to sporozoites would provide additional insight 
into the infection process. To investigate this, the effects of Kupffer cell cytokine 
secretions on other cells of the liver could be evaluated. Using the supernatant collected 
in our previous Kupffer cell-sporozoite interacting cultures, the resulting cytokines could 
be applied to stellate cells or hepatocytes to monitor the effects on these cell types. This 
would provide more insight into how physiologically relevant the Kupffer cell cytokine 
secretion levels are and what type of global liver response they illicit.  
 
Model for sporozoite invasion of hepatocytes 
 
Developing an in vitro culture system for the study of sporozoite invasion of and 
development in hepatocytes has been an important goal in the malaria field for studies of 
both P. falciparum and P. vivax. The identification of the HC-04 line as being supportive 
of infection was the first step towards this goal (157). However, major issues with low 
invasion rate (157) and cell overgrowth (Figure 6.7) made the model less than ideal. By 
altering culture conditions to more accurately mimic the in vivo liver environment, we 
have achieved on average over 2% invasion of P. falciparum sporozoites in the HC-04 
sub-clone J7, HC-04.J7 (Figure 6.3C, D, F).  
 
While developing this model, we also sought to answer the question of what makes a 
hepatocyte a suitable host cell for Plasmodium invasion. By performing global 
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transcriptomics, along with membrane-targeted proteomics, we found that the more 
susceptible hepatocytes up-regulated the citric acid cycle and oxidative phosphorylation 
(Figure 6.1C, D). We also noted that they had more pronounced mitochondria, 
potentially suggesting higher mitochondrial function (Figure 6.2). Our transcriptomic 
analysis also emphasized the importance of metabolic function by revealing that several 
key metabolic pathways are differentially expressed in our invasion-susceptible HC-04 
compared to our invasion-resistant HepG2 cells (Figure 6.5C). Furthermore, based on 
our analysis of proteins present in HC-04 but absent in HepG2 and subsequent invasion 
blocking assays with anti-glypican-3 antibodies, we identified glypican-3 as a receptor for 
sporozoite invasion of hepatocytes (Figure 6.5D). However, blocking glypican-3 did not 
result in complete elimination of sporozoite invasion, suggesting that glypican-3 acts as 
a member of a complex of proteins that are involved in sporozoite invasion. 
 
The major next steps for this model will be to test its ability to support P. vivax invasion 
and development and to use it for the study of P. falciparum invasion and development. 
We have already established this model’s ability to be used to test potential vaccine 
candidates (Table 6.1), making this a viable option for future use. Additionally, much 
remains undiscovered about the invasion process and subsequent intracellular 
development of the human malaria parasites. Studies of this stage have historically 
focused on the murine parasites in which in vivo studies are possible.  
 
With the current 2-3% invasion rate for P. falciparum sporozoites in the HC-04.J7 line, 
individual cells that have been invaded can now be isolated from the population through 
cell sorting using fluorescent parasites (345; 346). This allows the exciting new prospect 
of using single-cell analysis techniques to understand more than ever before about the 
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cellular changes occurring in both the hepatocyte and the sporozoite as development 
occurs.  
 
The HC-04.J7 sub-clone was produced by a simple limited dilution sub-cloning 
technique that is unbiased and does not select for any particular feature. If further sub-
cloning was performed that included cell sorting to select for cells that express high 
levels of glypican-3 or EphA2 or other sporozoite receptor molecules, there is great 
potential to further increase the invasion rate in these cells. Additionally, the HC-04.J7 
line serves as an ideal platform for further transgenic modification of the cells to 
introduce other known sporozoite receptors that are currently not expressed in HC-04.J7 
(Figure 6.8). With the increasing utility of the CRISPR-Cas9 to perform genetic screens 
(347; 348), HC-04.J7 and the invasion model detailed here can serve as the springboard 
for novel gain of function and loss of function screens to identify additional molecules 
that are involved in the sporozoite invasion and/or development processes.  
 
The liver stage of Plasmodium 
 
Overall, our work highlights major strides forward in the study of the Plasmodium liver 
stage. Understanding what happens when sporozoites cross the liver sinusoidal barrier 
and subsequently invade and develop in hepatocytes is crucial to understanding the 
parasite’s life cycle and identifying targetable steps that can be used in the fight against 
malaria. While our work fills some of these gaps by identifying a model for primary 
Kupffer cells under naïve conditions, profiling the cytokine secretion response from and 
cellular fate of Kupffer cells upon exposure to sporozoites, and developing a model for in 
vitro study of the liver stage of P. falciparum, there are still many questions unanswered. 
From a malaria-eradication stand-point, a couple major avenues of work present 
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themselves. Future work to further characterize the Kupffer cell’s intracellular response 
to sporozoites will be of great importance to understand this cell’s ability to be leveraged 
to prevent invasion. Additionally, future experiments to gain a more complete 
understanding of what makes a hepatocyte susceptible to invasion will prove immensely 
useful for the development of interventions to prevent invasion.  
 
Though much work remains, the field is inching ever closer to that goal of malaria 
eradication. I am hopeful that one day, that goal will be achieved, and that this work will 
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